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“Il ne saurait exister pour la science des vérités acquises.  
Le savant n'est pas l'homme qui fournit les vraies réponses;  
c'est celui qui pose les vraies questions.” 
Claude Lévi-Strauss 
 
“The scientist is not a person who gives the right answers,  
he is the one who asks the right questions.” 
Claude Lévi-Strauss 
 
Summary		
Histone deacetylases (Hdacs) belong to a family of 18 enzymes which removes acetylation 
marks on lysine residues of histone and non-histone proteins (Reichert et al., 2012). Hdacs were 
shown to play an important roles in cancer and are attractive pharmacological targets for cancer 
therapy (Haery et al., 2015). HDAC inhibitors (HDACis) have potent antitumor activity in 
hematological and solid malignancies, mainly by inducing apoptosis, inhibiting cell cycle 
progression and cellular differentiation (Falkenberg and Johnstone, 2014; West and Johnstone, 
2014). Previous works on classI Hdac1 and Hdac2, as well as classII Hdac6, showed that they 
play important roles in several cancer settings, including B cell malignancies (Haery et al., 2015; 
Seidel et al., 2015). However, Hdac1 and Hdac2 (Santoro et al., 2013), but also Hdac6 (Seidel et 
al., 2015), were shown to have contradicting tumor promoting and tumor suppressive roles in 
cancer. Despite improved knowledge in Hdac cancer research, the exact role of Hdac1, Hdac2, 
and Hdac6 in cancer remain largely unexplored. During my PhD thesis I investigated the 
functional role of Hdac1, Hdac2, and Hdac6 in the Eµ-myc model of B cell lymphoma.  
The first, and main part of my thesis work is the study of the functional role of classII Hdac1 and 
Hdac2 in the Eµ-myc mouse model of B cell lymphoma. We found, that Hdac1 and Hdac2 have 
a pro-oncogenic roles in both, Eµ-myc tumorigenesis and tumor maintenance. In this study, we 
reveal for the first time in the Eµ-myc model, that Hdac1 and Hdac2 promote tumorigenesis in a 
gene dose-dependent manner, with a dominant function of Hdac1. Our findings raise the 
prospect of using selective HDAC1 (and HDAC2) inhibitors in clinics for the treatment of BL 
and other B cell lymphomas with Myc deregulation. The results of this work are presented in the 
form of a publication manuscript: “Histone deacetylase 1 plays a predominant role in Eµ-myc 
driven B cell lymphoma” (Pillonel et al., Accepted for publication in Scientific Reports).  
The second part of my thesis adresses the functional role of Hdac1 and Hdac2 in B cell 
development. This work was done in collaboration with R.M. Heideman. We could confirm our 
previous findings that Hdac1 and Hdac2 regulate B cell development in a gene dose-dependent 
manner, with a dominant function of Hdac1. We show, that Hdac1Δ/Δ;Hdac2Δ/+ mice have 
abnormal early B cell development. Further preliminary findings provide an insight into the role 
of Hdac1 and Hdac2 in B cell development, and suggests possible defects in V(D)J 
recombination.  
In the last part of my thesis, I focus on the cytoplasmic classII Hdac6. We dissected the role of 
Hdac6 in Eµ-myc driven B cell lymphoma. We found, that Hdac6 overexpression accelerates 
lymphomagenesis, whereas Hdac6 knockout in the germ line may delay tumor development in 
Eµ-myc mice.  
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Introduction		
1. Lysine	acetylation	and	its	enzymes	
Lysine acetylation (Lys-Ac) is a reversible posttranslational modification that occurs on the ε-
amino group of lysine (Lys) residues (Waterborg, 2002). Lys-Ac was discovered on histone 
proteins almost half a century ago (Allfrey et al., 1964; Gershey et al., 1968). Subsequent 
research, resulted in the discovery that Lys-Ac residues are conserved in diverse organisms from 
bacteria to humans, where thousands of eukaryotic proteins, including histones, but also non-
histone proteins, were found (Choudhary et al., 2009; Kim et al., 2006; Zhao et al., 2010). By 
now it is clear that Lys-Ac is a key posttranslational modification (PTM) that potentially rivals 
phosphorylation and ubiquitination (Kouzarides, 2000; Norris et al., 2009). Acetylation occurs 
on numerous key Lys residues, including histone H3 (Lys9, Lys14, Lys18 and Lys23 and histone 
H4 (Lys5, Lys8, Lys12, and Lys16) (Kelly and Cowley, 2013; Kouzarides, 2007). Acetylation is a 
highly dynamic process regulated by the opposing action of two classes of enzymes, histone 
acetyltransferases (HATs) and histone deacetylases (HDACs) (Inche and La Thangue, 2006). 
Besides targeting histones in the nucleus, HATs and HDACs also acetylate and deacetylate many 
nonhistone proteins in the cytoplasm, and thereby regulate their function, localization and 
stability (Choudhary et al., 2009; Glozak et al., 2005; Kim et al., 2006; Kouzarides, 2000). 
Hence, these enzymes are also referred as lysine acetyltransferases (KATs) and lysine 
deacetylases (KDACs). These enzymes play crucial roles in various cellular processes and are 
intimately linked to human health and diseases. Hence, these proteins are also key drug targets 
(Aka et al., 2011). I discuss these different enzymes with the emphasis on HDACs and their 
impact on development and cancer in the following sections.  
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1.1. Histone	acetyltransferases	(HATs)	
Histone acetyltransferases (HATs) transfer acetyl moiety from acetyl-CoA to the ε-amino group 
of lysine (Lys) residues. HAT proteins are the catalytic core of several large protein coactivator 
complexes. They function by acetylating Lys residues on core histones of the promoter of genes 
and thereby activate gene expression (Haery et al., 2015). In addition, HATs also acetylate non-
histone proteins, and thereby modulate their protein stability, intracellular localization and DNA 
binding capacity (Friedmann and Marmorstein, 2013).  
 
1.2. Histone	deacetylases	(HDACs)	
Histone deacetylases (HDACs) have opposing effects to HATs. They remove acetylation marks 
on Lys residues of target proteins. The first HDAC, HDAC1 was identified in 1990 (Itazaki et 
al., 1990). Since then, 18 mammalian HDACs enzymes were discovered. HDACs modify the 
epigenome through regulation of chromatin acetylation by removing acetylation marks on 
histones. Most HDACs are part of large repressor complexes and generally act as transcriptional 
corepressors. HDACs regulate gene expression by targeting histone proteins (Dawson and 
Kouzarides, 2012). However, HDACs also deacetylate non-histone proteins and thereby impact 
on an increasing number of other cellular processes, including apoptosis, autophagy, and 
metabolism (Buchwald et al., 2009; Glozak et al., 2005; Xu et al., 2007). Hence, it is not 
surprising that aberrant deacetylation of histone and nonhistone proteins are implicated in 
numerous human diseases, including cancer (Hagelkruys et al., 2011; Peng and Seto, 2011).  
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Classification	of	HDACs	
The family of mammalian HDACs comprises 18 genes, which are subdivided into four families 
(class I-IV) based on sequence similarity, cofactor dependency and their homology to their 
respective yeast orthologs (Figure 1) (de Ruijter et al., 2003; Gregoretti et al., 2004; Grozinger 
and Schreiber, 2002; Witt et al., 2009; Yang and Seto, 2007): Class I, II, and IV are “classical” 
HDACs consisting of 11 family members. These enzymes all have a conserved Zn2+-dependent 
deacetylase domain. Class I HDACs comprises HDAC1, 2, 3, and 8, and which are similar to 
yeast Rpd3. Class II HDACs are sub grouped in Class IIa containing HDAC4, 5, 7, and 9 and 
class IIb containing HDAC6 and 10, which are similar to yeast Hda1. Class IV has only 
HDAC11 as member, which shares characteristics of both class I and class II HDACs (Gao et al., 
2002). Class III HDACs comprises seven members called Sirtuins (SIRT1 to SIRT7) by analogy 
with yeast silent information regulator 2 (SIR2) (Yang and Seto, 2008). These proteins are 
structurally and mechanistically distinct from “classical” HDACs and have a conserved 
nicotinamide-adenine dinucleotide (NAD)-dependent deacetylase activity. Sirtuins require for 
their activity NAD+ as coenzyme. (Min et al., 2001; Smith et al., 2008).  
 
Introduction	 	 		
11 
 
  
Figure 1: Classification of human HDACs. ClassI to classIV. ClassI HDAC1 and HDAC2 and classIIb HDAC6 
are highlighted. Protein domains of HDAC isoforms are presented. Post-translational modifications on lysine (K), 
threonine (T), serine (S) or tyrosine (Y) amino acids are shown for HDAC6. The numbers specify the number of 
amino acids are indicated to the right. (Figure modified from (Seidel et al., 2015)).  
 
HDAC1	and	HDAC2	
Mammalian class I HDAC1 and HDAC2, are ubiquitously expressed in different tissues. They 
are almost exclusively localized in the nucleus due to the presence of a nuclear localization 
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signal (NLS). In the nucleus these enzymes mediate histone deacetylation (Haberland et al., 
2009b). HDAC1 and HDAC2 are the biochemically predominant HDACs in the nucleus. 
Together, they account for approximately 50% of the total HDAC activity level in T cells and 
embryonic stem (ES) cells (Dovey et al., 2013).  
HDAC1 and HDAC2 cannot bind DNA directly and are most likely inactive in the absence of 
interacting partners (Zhang et al., 1999). HDAC1 and HDAC2, together with HDAC3, are 
catalytic subunits of large multiprotein transcriptional co-repressor complexes (Grozinger and 
Schreiber, 2002; Yang and Seto, 2008). For example, HDAC1 and HDAC2 are found in several 
co-repressor complexes, including Sin3, NuRD (nucleosome remodeling and deacetylation), 
CoREST (co-repressor for element-1-silencing transcription factor), and SMRT (silencing 
mediator of retinoid and thyroid repressors)/NCoR (nuclear receptor co-repressor) (Kelly and 
Cowley, 2013). Through removing acetyl groups on histones, these HDAC1 and HDAC2 
containing complexes mediate chromosomal compaction and gene repression (Bannister and 
Kouzarides, 2011; Yang and Seto, 2008). These complexes mediate HDAC localization, 
substrate specificity, act as scaffolds to recruit DNA-binding proteins and provide cofactors 
required for HDAC function (Haery et al., 2015). Currently, the molecular specificities of 
different isoforms of HDAC1 and HDAC2 containing complexes are still indefinite. Increasing 
body of evidence indicates a heterogeneity in their composition (Kelly and Cowley, 2013). Some 
evidence suggests that the composition of these complexes might also be cell-type specific. For 
instance, in T cells the Sin3A complex contains predominantly HDAC1 (Dovey et al., 2013).  
HDAC1 and HDAC2 are two paralogs that originate from a gene duplication. These two genes 
share 86% identity in amino acid sequence. Hence, it is not surprising, that to a large degree, 
these two enzymes have redundant functions (Haberland et al., 2009b). Indeed, numerous studies 
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in different tissues and cell types, including B cells, clearly demonstrate that mouse HDAC1 and 
HDAC2 have redundant functions (Chen et al., 2011; Dovey et al., 2013; Haberland et al., 2010; 
Jacob et al., 2011; LeBoeuf et al., 2010; Ma et al., 2012; Montgomery et al., 2007; Montgomery 
et al., 2009; Wilting et al., 2010; Yamaguchi et al., 2010). Nevertheless, some enzyme 
specificities have been determined. For example, HDAC1 and HDAC2 are not redundant during 
mouse embryogenesis, since the two paralogs cannot compensate for each other (Lagger et al., 
2002; Trivedi et al., 2007; Zupkovitz et al., 2010).  
 
HDAC6	
HDAC6 is a member of class IIb HDAC family. Interestingly, it is the only HDAC family 
member with two catalytic domains and unique functions among HDACs (Seidel et al., 2015). 
HDAC6 is an unusual histone deacetylase, which is not known to be part of an HDAC-
containing repression complex (Matthias et al., 2008). HDAC6 predominantly localizes in the 
cytoplasm, where it deacetylates non histone proteins (Boyault et al., 2007). Interestingly, in 
undifferentiated cells, like embryonic stem cells (ESCs) neural stem cells (NSCs), and some 
cancer cell lines, HDAC6 is mainly localized in the nucleus. Upon differentiation HDAC6 
relocalizes into the cytoplasm (Chen et al., 2013).  
HDAC6 plays important roles in protein trafficking and degradation, cellular shape and polarity, 
migration, directional movement and angiogenesis (Aldana-Masangkay and Sakamoto, 2011; 
Seidel et al., 2015). To control these processes, HDAC6 regulates cytoskeleton dynamics by 
regulating microtubule stability and dynamics. Deacetylation of the α-tubulin subunit by HDAC6 
is associated with depolymerisation of microtubules (Hubbert et al., 2002). HDAC6 also 
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deacetylates cortactin, which then enhances F-actin polymerization to promote cell migration 
(Zhang et al., 2007; Zhang et al., 2009).  
HDAC6 was shown to play a role in the elimination of misfolded proteins. Misfolded proteins 
are either degraded via the ubiquitin-proteasome pathway or through the aggresome. HDAC6 
regulates both processes (Seidel et al., 2015; Simms-Waldrip et al., 2008). HDAC6 acts as an 
adaptor protein for proteasome-independent degradation. Together with motor proteins like 
dynein, HDAC6 mediates the transport of misfolded proteins along microtubules to the 
microtubule organizing center (MTOC). At the MTOC aggresomes are formed around misfolded 
proteins, which are then transported to the lysosome for degradation (Aldana-Masangkay and 
Sakamoto, 2011; Hubbert et al., 2002; Lee et al., 2010). In addition, HDAC6 regulates 
proteasome-dependent protein degradation. HDAC6 has been shown to functions as a stress 
sensor by deacetylating heat shock protein-90 (Hsp90), an abundant cellular chaperone (Bali et 
al., 2005; Kovacs et al., 2005; Yang et al., 2008). Deacetylation of Hsp90 induces its chaperone 
activity and prevents degradation of its client proteins (Aldana-Masangkay and Sakamoto, 2011). 
Under nonstress conditions, protein degradation occurs through the proteasome. Chaperone 
valosin-containing protein/ATPase (VCP/p97) form a basal complex with heat shock factor 
(HSF)1 and HSP90 and HDAC6. This leads to disassembly of the ubiquitinated 
aggregate/HDAC6 complex so that the ubiquitinated proteins can be degraded through the 
proteasome instead of the aggresome. Under stress, when the number of misfolded proteins 
increases, HDAC6 binds these ubiquitinated protein aggregates and the basal complex 
disassembles (Aldana-Masangkay and Sakamoto, 2011; Boyault et al., 2006). Furthermore, 
HDAC6 together with HSP90 and Rac1 contribute to the regulation of endo- and exocytosis 
(Gao et al., 2007; Seidel et al., 2015).  
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HDAC6 is also involved in regulation of apoptosis. HDAC6 inhibits apoptosis by deacetylating 
Ku70, which then causes sequestration of the proapoptotic BAX (Bcl-2-associated X protein) 
protein (Subramanian et al., 2011). But HDAC6 was also shown to have other roles. For 
instance, HDAC6 was shown to impact on the PI3K/AKT and the MAPK/ERK signaling 
pathways and thereby playing a critical role in oncogenic transformation (Lee et al., 2008). 
Furthermore, HDAC6 can also contribute to transcriptional repression in some cells where it is 
located in the nucleus, by interacting with different co-repressors like SUMOylated p300 or 
HDAC11 (Gao et al., 2002; Girdwood et al., 2003; Seidel et al., 2015).  
HDAC6 loss-of-function studies revealed that HDAC6 germline knockout (KO) mice develop 
normally and remain viable and fertile, despite having hyperacetylated tubulin in most tissues 
(Zhang et al., 2008). Of note these mice also have normal lymphoid development (Zhang et al., 
2008). Hence, HDAC6 seems to be dispensable in normal mouse development to adulthood, 
suggesting that the main function of HDAC6 could be found under stress or pathologic 
conditions. Indeed, HDAC6 plays a crucial role in cancer, but also to several other diseases 
including neurodegeneration (Simoes-Pires et al., 2013), HIV (Valenzuela-Fernandez et al., 
2005) and other viral (Banerjee et al., 2014) or bacterial infections (Seidel et al., 2015) and 
pathological autoimmune response (Seidel et al., 2015).  
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2. Regulation	of	gene	expression	by	HDACs	
HDACs can regulate transcription in two different ways: First, by altering the pattern of histone 
acetylation. Thereby, these enzymes modulate chromatin structure and its accessibility to the 
transcriptional regulatory proteins (Brownell et al., 1996; Taunton et al., 1996). Second, these 
enzymes mediate deacetylation of nonhistone proteins including TFs that directly regulate 
transcription (Glozak et al., 2005). I describe the role of HDACs in regulating acetylation on 
histone and nonhistone proteins and its functional consequences, concentrating mostly on 
transcription in the following sections. 
 
2.1. Chromatin	structure	and	epigenetic	gene	regulation	
Chromatin	modifications	and	epigenetics		
Epigenetics is heritable non-DNA sequence-based gene-expression alterations. Epigenetic was 
first described in 1942 by C. Waddington (Waddington, 1942). Subsequent studies in the early 
1960s demonstrated that histones are post translationally modified (Allfrey et al., 1964). 
Subsequent studies identified a large number of different histone PTMs (Bannister and 
Kouzarides, 2011). Histone acetylation, together with other PTMs, including histone 
methylation, phosphorylation, ubiquitination, and sumoylation, are key epigenetic regulatory 
mechanism (Bannister and Kouzarides, 2011). The diverse and complex pattern of distinct PTMs 
on histones act to form a “histone code” (Jenuwein and Allis, 2001; Strahl and Allis, 2000). This 
histone code is established by “writers” (e.g. HATs) that add, and “erasers” (e.g. HDACs) that 
remove the respective PTM (Figure 2). Other proteins, called “readers” then recognize these 
modifications and decipher the code. Such readers are e.g. bromodomain-containing proteins 
(BRDs) like HATs and chromatin remodeling complexes that can recognize and bind acetylated 
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marks (Mujtaba et al., 2007; Strahl and Allis, 2000). Alternatively, also tandem plant 
homeodomain (PHD) finger containing proteins can bind acetylated lysine (Zeng et al., 2010).  
The function of these chromatin marks is more complex than initially thought (Berger, 2007). In 
addition to the important number of histone PTMs, another level of complexity exists due to 
cross-talk between different modifications (Kouzarides, 2007). For example, cooperation, 
dependence, or competition among other, may occur between modifications (Bannister and 
Kouzarides, 2011). Histone PTMs function via two main mechanisms: i) by directly influencing 
the overall structure of chromatin, either over short or long distances, or ii) by regulating either 
positively or negatively the binding of effector molecules (Bannister and Kouzarides, 2011). In 
addition, the epigenetic network has many layers of complexity, including DNA methylation, 
histone modifications, chromatin remodeling and microRNAs (Bernstein et al., 2007; Esteller, 
2006). Hence, histone modifications not only regulate chromatin structure but also recruit 
chromatin remodeling enzymes (Bannister and Kouzarides, 2011). Thereby, these modifications 
influence transcription but also many other DNA processes such as repair, replication, and 
recombination (Bannister and Kouzarides, 2011). Histone PTMs including acetylation play 
fundamental roles in most biological processes that are involved in the manipulation and 
expression of DNA (Bannister and Kouzarides, 2011). Aberrations in epigenetic mechanisms 
underlie several diseases including cancer metabolic and neurodegenerative disorders (Inche and 
La Thangue, 2006; Portela and Esteller, 2010).  
 
Chromatin	structure	
Chromatin is composed of nucleosomes consisting of an octamer of core histones (H2A, H2B, 
H3 and H4) with 147 base pairs (bp) DNA wrapped around (Marino-Ramirez et al., 2005). 
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Histone proteins have flexible histone tails that are exposed to reversible PTMs, which can both 
positively and negatively regulate gene transcription (Bannister and Kouzarides, 2011). 
Chromatin is a highly complex and dynamic structure that acts as scaffold for DNA. It consists 
of DNA, histone and other proteins. Chromatin can be found in two conformational states: i) 
heterochromatin, a compacted, transcriptional inactive state and ii) euchromatin, an open, 
transcriptionally active state (Bannister and Kouzarides, 2011; Ellis et al., 2009a). The 
remodeling of chromatin underlie gene transcription, DNA replication and repair as well as 
apoptosis and other regulatory processes acting at the level of DNA (Ellis et al., 2009a; Inche 
and La Thangue, 2006; Wang et al., 2007).  
 
Impact	of	histone	acetylation	on	chromatin	and	nucleosome	remodeling	
Lys acetylation on histone proteins neutralizes the positive charge of Lys residues and thereby 
weakens the interactions between positively charged histone proteins and negatively charged 
DNA, resulting in an open chromatin conformation (Olzscha et al., 2015). Acetylation and 
deacetylation of histone proteins by HATs and HDACs, respectively, alters the chromatin 
structure and mediates changes in gene expression (Waterborg, 2002). In general, histone 
acetylation by HATs leads to an open, less compact chromatin state which is accessible to TFs 
facilitating gene transcription. Conversely, histone deacetylation by HDACs leads to 
condensation or closed chromatin state which prevents access to TFs leading to transcriptional 
repression (Figure 2) (Jenuwein and Allis, 2001; Johnstone, 2002).  
 
Introduction	 	 		
19 
 
 
Figure 2: HATs and HDACs in regulation of gene expression. Histone acetylation on Lys residues at amino-
terminal tails of core histones proteins is catalyzed by HAT and deacetylation by HDAC. Acetylation of 
nucleosomes inhibits the folding of nucleosome arrays into secondary and tertiary chromatin structures, and favors 
gene expression. Hypo-acetylated nucleosomes are condensed, which prevents the gene expression (Figure adapted 
from (Verdin and Ott, 2015).  
 
2.2. Epigenetic	gene	regulation	by	HDACs	
HDACs deacetylate histone proteins and restore the positive charge on lysine residues. This 
stabilizes the local chromatin architecture and generally represses transcription (Bannister and 
Kouzarides, 2011). Conversely, hyperacetylation of histones by HATs leads to de-compaction of 
chromatin and exposes DNA allowing TF binding and initiation of transcription (Figure 2) (Li et 
al., 2007; Verdin and Ott, 2015).  
Class I HDACs (1, 2, 3, and 8) have the most decisive roles in regulating gene expression. They 
regulate gene expression as catalytic core of multiprotein complexes with transcriptional co-
repressors like Sin3 or SMART (Yang and Seto, 2008). These complexes contain multiple 
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DNA/chromatin recognition motifs. In combination with other DNA-binding proteins like DNA 
methyltransferases (DMTs), TFs or nuclear receptors recruit HDAC1 and HDAC2 at specific 
DNA sites (Olzscha et al., 2015).  
 
2.3. Non-epigenetic	gene	regulation	by	HDACs	
HDACs also regulate gene transcription in an non-epigenetic manner by deacetylating 
nonhistone proteins including TFs. Acetylation of TFs can affect their function in four different 
ways: 1) by increasing protein stability by blocking the site of ubiquitination which prevents 
proteasome degradation; 2) by blocking the DNA-binding domain and decrease the ability of 
TFs to bind DNA; 3) by increasing or decreasing protein-protein interaction with TF regulators; 
and 4) by serving as docking domain for bromodomain of HATs, which can increase their 
transcriptional activity (Haery et al., 2015; Yang and Gregoire, 2005).  
Surprisingly, HDAC1 and 2 might also promote gene expression. Numerous KO studies in yeast 
and mice demonstrated that a significant fraction of genes are down-regulated upon ablation of 
these enzymes (Bernstein et al., 2000; Montgomery et al., 2007; Yamaguchi et al., 2010; 
Zupkovitz et al., 2006). This may be explained by indirect effects on increasing expression of 
transcriptional repressors upon ablation of HDAC1 and HDAC2. Nevertheless, growing 
evidence indicates that these HDACs might be directly involved in gene activation. Genome 
wide chromatin immunoprecipitation (ChIP) and ChIP-seq (ChIP combined with high-
throughput sequencing) experiments mapped several HDACs, including HDAC1 and 2 to 
transcriptionally active loci (Kidder and Palmer, 2012; Kurdistani et al., 2002; Wang et al., 
2009). Hence, HDAC1 and 2 can mediate both gene repression and gene activation (Kelly and 
Cowley, 2013).  
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3. Role	of	HDAC1	and	HDAC2	in	B	lymphocyte	development	
Most of the knowledge regarding the function of HDACs in development comes from loss-of-
function studies in animal models. Numerous studies using mouse models with tissue-specific 
conditional deletion were performed to investigate the function of these enzymes in different 
tissues. These studies demonstrated that ablation of either HDAC1 or HDAC2 had no effect on 
the development of heart (Montgomery et al., 2007), epidermis (LeBoeuf et al., 2010), 
adipocytes (Haberland et al., 2010), oocytes (Ma et al., 2012), neuronal precursors (Montgomery 
et al., 2009), neural crest cells (Montgomery et al., 2007), MEFs (Wilting et al., 2010; 
Yamaguchi et al., 2010), T cells (Dovey et al., 2013) and B cells (Yamaguchi et al., 2010). 
Interestingly, ablation of both HDAC1 and HDAC2 results in a strong phenotype in these 
systems, demonstrating that HDAC1 and HDAC2 have redundant functions. I will discuss in 
further details the role of HDAC1 and HDAC2 in B cell development in the following sections.  
 
3.1. B	lymphocyte	development	-	overview	
B lymphocytes, like T lymphocytes and all other blood cell types, are derived from HSCs found 
in the fetal liver before birth and in the postnatal BM (Kondo et al., 1997; Lai and Kondo, 2008; 
Mandel and Grosschedl, 2010). These earliest pluripotent progenitor cells have self-renewal 
potential and are characterized by the absence of lineage markers (Lin-) as well as c-kit and Sca-
1 expression (Spangrude et al., 1988). HSCs differentiate into multipotent progenitors (MPPs). 
During the process of differentiation, HSCs gradually lose self-renewing potential. MPPs have 
lost the ability to self-renew, but retain the capability to differentiate into separate lymphoid and 
myeloid lineages (Morrison et al., 1997). The first restriction step towards progenitor cell types, 
concomitant with gradual loss in pluripotency, is made when MPPs differentiate into common 
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myeloid progenitors (CMPs) and lymphoid multipotent progenitors (LMPPs) containing early 
lymphoid progenitor (ELPs) (Igarashi et al., 2002; Lai and Kondo, 2008; Medina et al., 2001). 
CMPs give rise to megakaryocyte/erythrocyte progenitors (MEPs) and granulocyte/macrophage 
progenitors (GMPs) (Parra, 2009). ELPs give rise to common lymphoid progenitors (CLPs), 
which in turn branch into B, T, natural killer (NK) lymphocytes, and dendritic cells (DCs) 
(Cobaleda and Busslinger, 2008; Kondo et al., 1997; Nutt and Kee, 2007). The first clearly 
identifiable B cell-specific progenitors in the BM that arise from CLPs are variously termed pre-
pro B cells, CLP-2 or hereinafter referred as ProB cells (Nutt and Kee, 2007). B cells are then 
generated by further differentiation steps passing through early B cell precursors proB cells 
(B220+;c-kit+; CD19-; CD25-; IgM-), preBI cells (B220+;c-kit+; CD19+; CD25-; IgM-), PreBII 
cells (large and small) (B220+;c-kit-; CD19+; CD25+; IgM-), immature B cells (B220+;c-kit-; 
CD19+; CD25+/-; IgM+), expressing the characteristic indicated cell surface markers (Figure 3) 
(Matthias and Rolink, 2005). Immature B cells are produced in the BM and migrate to the spleen 
where are they found as transitional B cells (T1-3). Transitional B cells are then negatively 
selected and develop eventually into naïve B cells. These naïve B cells then differentiate into the 
terminally differentiated plasma cells and memory B cells (germinal-center B cells) (B220+;c-kit-
; CD19+; CD25-; IgM+; IgD+) (Ikawa, 2014; Lopez-Granados, 2011; Matthias and Rolink, 2005).  
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Figure 3: Schematic representation of early B-cell differentiation in the BM. The different developmental stages 
are shown. Surface cell markers used to discriminate them are indicated below: (+) expressed, (-) not expressed. 
Curved arrows indicate for proliferation activities: intermediate in pro-BI and pre-BI and high in large pre-BII; small 
pre-BII and immature and mature B cells are not proliferating. V(D)J rearrangement status of the different Ig gene 
alleles during B cell differentiation is shown. The kind of membrane bound immunoglobulin is indicated. (Figure 
adapted from (Yamaguchi et al., 2010)).  
 
3.2. Ig	recombination	and	B	cell	maturation	
A key step during B development is the generation of diverse repertoire of high affinity B cell 
receptors (BCR) which is needed for adaptive immune response by B cells. The BCRs consist of 
an immunoglobulin (Ig) heavy chain (IgH) and Ig light chain (IgL). The extremely diversified 
primary BCR repertoire is generated by V(D)J recombination. This process involves 
recombination activating genes (RAG) 1 and 2 proteins that bind recombination signal sequences 
(RSS) (Lopez-Granados, 2011). Once the IgH chain has been rearranged in large PreBII cells, it 
assembles at the surface of the cell with the surrogate Ig light chain to form a functional pre-B-
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cell receptor (pre-BCR) (Figure 3) (Matthias and Rolink, 2005). Signaling through the pre-BCR 
mediates allelic exclusion, a mechanism by which only one of the IgH allele undergoes 
recombination (Mostoslavsky et al., 1999). This stimulates proliferation and clonal expansion of 
such large preBII cells (Matthias and Rolink, 2005). Efficient signaling through the pre-BCR is 
required for rearrangement of the IgL locus. Successful rearrangement of the IgL will allow the 
expression of the BCR. At this immature B cell stage, cells are tested for autoreactivity. 
Autoreactive B cells undergo a secondary Ig gene rearrangement known as receptor editing 
otherwise eliminated or inactivated (Nemazee and Weigert, 2000). After having successfully 
passed this check-point immature B cells exit the BM and circulate to the spleen. There these 
transitional B cells are negatively selected and then differentiate to mature B cells (Matthias and 
Rolink, 2005). B cells undergo Ig class switch DNA recombination (CSR), resulting in an 
isotype switch from IgM/IgD to IgG, IgE, or IgA, and also undergo somatic hypermutation 
(SHM), a mutation process that introduces single nucleotide substitutions into the variable region 
of Ig genes. Thereby, these antigen specific B cells further improve their affinity to antigens (Zan 
and Casali, 2015). Finally, these B cells can differentiate to memory B cells or long-lived plasma 
cells for the immune memory (Zan and Casali, 2015). 
 
3.3. Epigenetic	control	of	B	cell	development	and	Ig	recombination	
B cell development requires appropriate regulation of dynamic TF networks. Lineage 
commitment requires activation of lineage-specific gene-expression programs and repression of 
lineage-inappropriate-gene programs (Kioussis and Georgopoulos, 2007; Mandel and 
Grosschedl, 2010; Nutt and Kee, 2007). Several TFs were shown to induce B cell lineage 
specification and determination: PU.1, Ikaros, E2A, EBF1, and Pax5 could be considered as the 
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most important TFs in this process (Busslinger, 2004; Matthias and Rolink, 2005; Nutt and Kee, 
2007). Increasing body of evidence demonstrates that B cell development is also regulated by 
epigenetic mechanisms (Ikawa, 2014; Lopez-Granados, 2011; Parra, 2009). This regulation may 
act by interplay of transcription factors and epigenetics. Gene expression programs during B cell 
development are activated by recruitment of lineage-specific TFs, but also by chromatin 
remodeling upon epigenetic changes. Several changes in histone modifications and DNA 
methylation have been reported at lineage specific loci in HSCs and MPPs (Attema et al., 2007; 
Lopez-Granados, 2011). Interestingly, progression through lymphocyte differentiation from 
HSCs to lymphoid lineages is associated with loss of the well-studied epigenetic marks, histone 
3 acetylation (H3Ac) and histone 4 acetylation (H4Ac). This indicates a closed chromatin 
structure at lineage non-associated genes (Attema et al., 2007; Maes et al., 2008). Hence, this 
suggests that lymphoid-specific genes are already "primed" for expression before lineage 
commitment and that this permissive chromatin structure is progressively lost during 
differentiation (Maes et al., 2008). However, this model was recently challenged by Choukrallah 
et al., in our lab, demonstrating that enhancer repertoires are reshaped independently of early 
priming and heterochromatin dynamics during B cell differentiation (Choukrallah et al., 2015).  
Another example of epigenetic regulation during B lymphocyte development involves regulation 
of V(D)J recombination in the Ig gene locus (Li et al., 2013; Schatz and Ji, 2011; Su and 
Tarakhovsky, 2005). H3Ac and H4Ac were shown to be enriched in the IgH locus during V(D)J 
recombination. This requires an accessible open chromatin conformation allowing RAG1 and 
RAG2 proteins to access and cleave DNA at the RSS (Busslinger, 2004; Chowdhury and Sen, 
2001; Johnson et al., 2003; McMurry and Krangel, 2000; Morshead et al., 2003).  
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3.4. HDAC1	and	HDAC2	in	B	cell	development	
Yamaguchi et al., generated in our lab HDAC1 and HDAC2 B cell-specific KO mice to dissect 
the role of individual HDACs in B cell development and showed that in B cells, HDAC1 and 
HDAC2 have redundant functions. Conditional deletion of either HDAC1 or HDAC2 alone in 
early B cell stages has no obvious effect (Yamaguchi et al., 2010). Conversely, combined loss of 
HDAC1 and HDAC2 results in a block in B cell development and cell cycle arrest. Hence, 
HDAC1 and HDAC2 play a key role in B cell development. In resting mature B cells, combined 
deletion of HDAC1 and 2 has no effect on cell survival or function. However, HDAC1 and 
HDAC2 double KO cells fail to proliferate in response to lipopolysaccharide (LPS) and IL-4 
(Yamaguchi et al., 2010).  
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4. The	biology	of	HDACs	in	cancer	
Initially, cancer has been regarded as consequence of alterations in DNA sequence including 
mutations, deletions, amplifications and rearrangements affecting oncogenes or tumor suppressor 
genes. A compelling body of evidence indicates that epigenetic alterations also contribute to 
cancer initiation and progression. In contrast to genetic alterations, epigenetic changes are 
reversible, and therefore attractive targets for cancer therapy. Chromatin modification proteins, 
like HATs and HDACs, were shown to be good targets. One prominent example of such epi-
drugs with potent anticancer activity are HDACis (Hagelkruys et al., 2011; Rodriguez-Paredes 
and Esteller, 2011). In the following sections, I briefly introduce B cell malignancies with the 
focus on lymphomas with c-myc deregulation. I will discuss as well the role of HDACs in 
tumorigenesis, their contribution to the hallmarks of cancer and their involvement in B cell 
malignancies. Finally, I will discuss the use of HDACis in the treatment of these diseases.  
 
4.1. B	cell	lymphomas	with	c-myc	deregulation	
The c-myc oncogene is described as one of the most frequently deregulated proteins in cancer 
and is estimated to be activated in 20% of all human cancers (Nesbit et al., 1999). Deregulated c-
myc expression in cancer correlates with high proliferation, reprogrammed cellular metabolism 
and poor prognosis (Dang, 2012; Van Dang and McMahon, 2010).  
 
The	c-myc	oncogene	
c-Myc is the most studied member of the Myc protein family of transcription factors (Dang, 
2012; Luscher and Vervoorts, 2012). c-Myc forms a heterodimer with its partners Max (Myc 
associated x) and Mad (Max dimerization protein). In most cases c-Myc acts by binding E-boxes 
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(CACGTG) and recruiting transcriptional coactivators to regulatory promoter elements in target 
genes (Conacci-Sorrell et al., 2014; Dang, 2012). c-Myc also represses genes by recruiting 
HDACs and by binding and inhibiting Miz-1, a transcriptional activator (Eilers and Eisenman, 
2008; Kurland and Tansey, 2008).  
c-Myc can activate or repress transcription of numerous genes and thereby regulating multiple 
cellular processes (Eilers and Eisenman, 2008). The c-Myc protein is important in the regulation 
of cellular growth and differentiation. c-myc is transcriptionally up-regulated during proliferation 
and repressed during differentiation (Zou et al., 1997). It is involved in many biological 
functions, including regulation of cell proliferation, differentiation, cell cycle progression and 
apoptosis (Figure 4) in many cellular types, including B lymphocytes (Meyer and Penn, 2008; 
Pelengaris et al., 2002). c-Myc promotes during cell cycle the G0/G1-S transition by activating 
genes that encode proteins of the cyclin/cyclin-dependent kinase complexes and by repressing 
cell cycle inhibitors such as p21 or p27 in numerous cell types (Bernard and Eilers, 2006).  
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Figure 4: Biological functions of c-Myc in health and disease. c-Myc regulates proliferation, cell-cycle, 
apoptosis, cell differentiation, cell metabolism, angiogenesis, cell adhesion and motility. Deregulation of Myc may 
result in apoptosis, uncontrolled cell proliferation, genomic instability, escape from immune surveillance, 
immortalization and growth factor independence (Cai et al., 2015).  
 
c-Myc was initially described as a general transcription factor that amplifies gene expression 
without any specificity (Levens, 2013; Lin et al., 2012; Nie et al., 2012). Subsequent studies 
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reported, that overexpressed c-Myc binds to almost all active promoters within a cell, although 
with different binding affinities (Guccione et al., 2006; Lin et al., 2012; Sabo et al., 2014), and 
modulates the expression of distinct subsets of genes (“selective amplification”) (Dang, 2014; 
Guccione et al., 2006; Sabo et al., 2014; Van Dang and McMahon, 2010; Walz et al., 2014).  
The c-Myc transcriptional network also regulates the expression of large number of non-coding 
RNA, including microRNAs (miRNAs) that bind mRNA, and typically inhibit translation (Bui 
and Mendell, 2010). These miRNAs regulated by c-Myc were shown to act as oncogenes (Chang 
et al., 2008) or tumor suppressor genes (Cai et al., 2015). Interestingly, c-Myc represses several 
miRNAs involved in tumor suppression by recruiting HDACs. These miRNAs regulate 
important functions in tumorigenesis such as apoptosis, proliferation, or cell differentiation (Cai 
et al., 2015; Ott et al., 2013). In addition c-Myc was recently shown to act on long-non-coding 
RNAs (lncRNAs) which typically form functional secondary and higher order structures 
comprising protein-protein or protein-nucleic acid complexes (Weinberg et al., 2015). 
Interestingly, c-Myc may also repress transcription by recruiting HDACs to promoter containing 
E-boxes (Ott et al., 2013; Zhang et al., 2012). 
In cancers induced by genetic deregulation of c-myc expression, loss of checkpoint components, 
such as p53, allows c-Myc to drive malignant transformation (Klapproth and Wirth, 2010). 
Deregulation of c-Myc results in apoptosis, genomic instability, uncontrolled cell proliferation, 
escape from immune surveillance, immortalization and independence of growth factor (Figure 4) 
(Cai et al., 2015).  
The relevant oncogenic role of c-Myc has encouraged scientist to search for therapeutic 
strategies. However, targeting c-Myc pharmacologically appears to be difficult due to its lack of 
a simple enzymatic function that mediates its activity (Vita and Henriksson, 2006). The 
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breakthrough came in 2011, with the discovery that c-myc transcription depends on the 
regulatory function of BRD4, and the two inhibitors JQ1 and iBET (Delmore et al., 2011; Mertz 
et al., 2011). This discovery opened the way for new potential therapeutic opportunities. BRD4 is 
a member of the bromodomain and extraterminal (BET) protein family that can bind specific 
acetylated lysine residues on histone tails (Albihn et al., 2010; Delmore et al., 2011). Two small 
molecule inhibitors, JQ1 and iBET, displace BRD4 from acetylated lysine. Thereby, these 
inhibitors downregulate c-myc and modulate its transcriptional program. They were shown to 
have marked anti-proliferative cell effects and to inhibit tumor growth (Ott et al., 2013).  
 
B	lymphocyte	malignancies-overview	
Lymphomas are solid tumors of the immune system. They represent approximately 5% of all 
cancers and are the most common hematological malignancy in the United States (Groves et al., 
2000). They can be divided in two major groups: 10% of all lymphomas are Hodgkin’s 
lymphoma (HL), and the remaining 90% are referred to as non-Hodgkin lymphomas (NHL) 
(Shankland et al., 2012; Siegel et al., 2015). NHL is a large heterogeneous group of malignancies 
that derive from a monoclonal proliferation of B or T lymphocytes and less commonly natural 
killer (NK) cells. The vast majority of all NHL (85–90 %) derive from B lymphocytes and the 
rest arise from T lymphocytes or NK lymphocytes. The two most common types are diffuse large 
B-cell lymphoma (DLBCL) and follicular lymphoma (FL), (Chiu and Hou, 2015). NHL can 
develop at various stages of differentiation, and can occur in almost any tissue (Chiu and Hou, 
2015; Shankland et al., 2012). NHL are distinguished between precursor and mature neoplasms 
corresponding to stages of differentiation. NHL ranges from the most indolent follicular 
lymphoma (FL) to the most aggressive DLBCL and Burkitt’s lymphomas (BL) (Shankland et al., 
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2012). These malignancies are presently classified according to the fourth edition of the World 
Health Organization (WHO) classification of tumors of hematopoietic and lymphoid tissues 
(Campo et al., 2011).  
The c-myc oncogene is dysregulated in most hematopoietic malignancies (Dang, 2012). Almost 
all lymphomas with deregulated c-myc are of B cell origin. The most prominent abnormality are 
chromosomal translocations involving c-myc found in BL and DLBCL.  
 
The	Eµ-myc	mouse	model		
The transgenic (tg) Eµ-myc mouse was developed as a preclinical model for studying c-myc-
induced tumorigenesis (Adams et al., 1985). In these Eµ-myc mice the c-myc gene (from a 
murine plasmacytoma) was placed under the ectopic control of the lymphoid-specific IgH locus 
enhancer (Eµ). Hence, these mice carrying the tg, overexpress the c-myc oncogene in the B cell 
lineage and develop tumors at several stages of B cell development. Tg expression causes 
hyperproliferation of B-lymphocytes (Harris et al., 1988). These mice rapidly and invariably 
develop clonal tumors with both pre-B and B cell phenotypes (Adams et al., 1985; Harris et al., 
1988), causing massive enlargement of lymph nodes (LN). Blood and lymphoid organs such as 
spleen (SP), lymph nodes (LNs) and thymus predominantly contain lymphoblastic cells. The 
pathological diagnosis of these tumors is multicentric lymphosarcoma (disseminated lymphoma) 
with associated leukemia (Adams et al., 1985).  
The Eµ-myc mouse model has been successfully used to perform genetic manipulation by cross-
breeding and retroviral transduction to produce “compound mutant” lymphomas. These are 
useful tools for in vitro and in vivo studies to identify molecular pathways important for a given 
drug, like HDACis, to have an anticancer effect (Lindemann et al., 2007; Schmitt et al., 2000).  
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4.2. Role	of	acetylation	in	cancer		
It is now clear that epigenetic changes have important impact on tumor initiation and progression 
(Bannister and Kouzarides, 2011; Esteller, 2008). Aberrant histone modifications or dysregulated 
activity of associated enzymes may lead to cancer through at least two different mechanisms: i) 
by altering gene expression of oncogenes and/or tumor suppressor genes, and ii) by affecting 
genome integrity and/or chromosome segregation (Bannister and Kouzarides, 2011).  
Acetylation has been associated to both hematological and solid malignancies (Esteller, 2008; 
Wang et al., 2007). Overexpression of HDACs or inactivating mutations and gene deletions of 
HATs are commonly found in B and T cell malignancies. Decreased global histone and TF 
acetylation appears to correlates with tumor cell proliferation and survival, whereas increased 
acetylation is associated with tumor growth arrest and cell death (Haery et al., 2015).  
 
HATs	and	cancer-overview	
Altered activity of HATs has been identified in various cancers and can occur due to genetic 
mutations, chromosomal translocations or aberrant recruitment and localization (Olzscha et al., 
2015). One example of HATs involved in chromosomal rearrangement is the MOZ-TIF2 fusion 
which is associated with acute myeloid leukemia (AML) (Carapeti et al., 1998; Liang et al., 
1998). It involves the HAT protein MOZ (Champagne et al., 2001) and the nuclear receptor 
coactivator TIF2 (Torchia et al., 1997). Deregulation of HATs, including CBP and p300, has 
been shown to impact on genome integrity and stability during replication in B cell lymphoma 
(Pasqualucci et al., 2011).  
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HDACs	and	cancer-overview	
In cancer, several normal cellular functions are deregulated. Several of these processes, including 
proliferation, apoptosis, autophagy, DNA repair and cell motility have been shown to be 
regulated at least in part by HDACs (Hagelkruys et al., 2011; Peng and Seto, 2011). In cancer, 
several HDACs have been shown to be deregulated (usually overexpressed) or misstargeted, but 
are generally not known to be mutated (Olzscha et al., 2015). For instance HDAC1 and HDAC2 
have been reported to be overexpressed in many tumor types, including in B cell lymphomas 
(Haery et al., 2015). In addition, HDAC function can also become deregulated and ultimately 
lead to cancer in the context of chromosomal translocations which result in aberrant fusion 
proteins that bind and missregulate these HDACs. One prominent example is acute 
promyelocytic leukemia (APL) where the retinoic acid receptor (RAR) gene is fused to the 
promyelocytic leukemia (PLM) gene, resulting in the RARα-PML fusion protein (Ellis et al., 
2009a).  
 
4.3. Impact	of	HDACs	on	the	hallmarks	of	cancer	
The hallmarks of cancer, described by Hanahan and Weinberg (Figure 5) (Hanahan and 
Weinberg, 2000, 2011), are known to be regulated by epigenetic mechanisms, including histone 
acetylation (Hagelkruys et al., 2011). In the following sections, I discuss the major impacts of 
HDACs on some crucial hallmarks for cancer development (Figure 6).  
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Figure5: The hallmarks of cancer. Illustration of the six hallmark capabilities proposed by Hanahan and Weinberg 
(Hanahan and Weinberg, 2011).  
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Figure 6: Impact of HDACs on the hallmarks of cancer. HDAC induce proliferation, angiogenesis and 
metastasis, whereas they block apoptosis and differentiation. The impact of individual HDAC 
isoforms are indicated (Hagelkruys et al., 2011).  
 
HDACs	and	proliferation	
The ability of cancer cells to sustain chronic proliferation is the most fundamental and the first of 
the six cancer hallmarks (Hanahan and Weinberg, 2000, 2011). HDAC1, 2, 3, and 4 were shown 
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to be implicated in proliferation of cancer cells (Glaser et al., 2003; Haberland et al., 2009a; 
Mottet et al., 2009; Senese et al., 2007; Wilson et al., 2008). These HDACs affect cell cycle, and 
lead to G1 or G2/M cell cycle arrest and a delay in S-phase progression (Hagelkruys et al., 
2011). Ablation of HDAC1, 2, 3, or 4 has been shown to have an impact on proliferation by 
increasing the levels of cyclin-dependent kinase inhibitors (CKI) including p21WAF/CIP1, p27KIP1, 
and p57KIP2 preventing cell cycle progression in different cellular systems including primary and 
transformed cells (Lagger et al., 2002; Mottet et al., 2009; Senese et al., 2007; Wilson et al., 
2008; Wilson et al., 2006; Yamaguchi et al., 2010; Zupkovitz et al., 2010). In addition to the 
regulation of cell cycle regulatory genes, HDACs also affect cell cycle progression by impacting 
on histone acetylation and thereby affecting the chromatin structure during mitosis (Krebs et al., 
2000).  
HDAC1 is mainly considered as positive regulator of proliferation. Mice lacking HDAC1 have 
proliferation defects and are embryonically lethal (Lagger et al., 2002). Consistently, ablation of 
HDAC1 in embryonic stem (ES) cells also leads to proliferation defects (Zupkovitz et al., 2010). 
However, the impact of HDAC1 on proliferation depends on the cell type and probably on its 
corresponding HDAC1 target genes. For example, loss of HDAC1 was linked to enhanced 
proliferation of T cells (Grausenburger et al., 2010) and epithelial cells (Lagger et al., 2010).  
Ablation of both HDAC1 and HDAC2 in tumor cells have been reported to block tumor cell 
growth, by inducing nuclear bridging and fragmentation and eventually cell death (Haberland et 
al., 2009a). In fact, combined deletion of both HDAC1 and HDAC2, strongly impacts on 
proliferation with dramatic defects in cell cycle progression in several systems, including 
fibroblasts, hematopoietic cells, B and T cells, cardiomyocytes, neural and epidermal cells 
(Dovey et al., 2013; LeBoeuf et al., 2010; Montgomery et al., 2007; Montgomery et al., 2009; 
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Wilting et al., 2010; Yamaguchi et al., 2010). HDAC6 as well as Sirtuin 1 (SIRT1) have also 
been shown to be implicated in proliferation of cancer cells (Hagelkruys et al., 2011; Lee et al., 
2008).  
 
Impact	of	HDACs	in	resistance	to	apoptosis	
Evasion of apoptotic cell death is a hallmark of most and perhaps all cancer types (Hanahan and 
Weinberg, 2000, 2011). Apoptosis is a natural barrier to cancer development, and is triggered in 
response to numerous physiological stresses. Such apoptosis-inducing stresses are among others 
DNA damage, signaling imbalance resulting from oncogene action of e.g. c-Myc, insufficiency 
of survival factors, or hypoxia (Evan and Littlewood, 1998; Lowe et al., 2004). Apoptosis is a 
programmed cell death, which is orchestrated in a precise series of steps leading to the complete 
degradation of the cell, through selected destruction of subcellular structures and organelles and 
the genome (Adams and Cory, 2007; Hanahan and Weinberg, 2011).  
In tumorigenesis, HDACs act as regulators in the process of apoptosis. (Hagelkruys et al., 2011). 
The apoptotic machinery is composed of sensor proteins, detecting abnormalities, and effector 
proteins mediating cell death through two major apoptotic programs, the extrinsic and the 
intrinsic. Both apoptotic pathways are affected by HDACs. They can both be induced by 
HDACis treatment (Beumer and Tawbi, 2010; Hagelkruys et al., 2011). In tumor cells, HDACis 
trigger increased expression of sensor protein receptors and their ligands from the extrinsic 
apoptotic pathway (Xu et al., 2007). Interestingly, HDAC1 and HDAC2 were shown to be the 
major targets for this HDACi-mediated extrinsic apoptosis induction (Inoue et al., 2006).  
The apoptotic trigger is controlled by pro- and anti-apoptotic members of the Bcl-2 family of 
regulatory proteins. These proteins are either pro-apoptotic (Bax, Bak, Bid, Bim) or anti-
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apoptotic (Bcl-2, Bcl-XL, Bcl-W). Bcl-2 and Bcl-xl inhibit apoptosis largely by suppressing the 
two pro-apoptotic proteins Bax and Bak (Hanahan and Weinberg, 2000). Inhibition of HDACs 
by HDACis causes a decrease in expression of such antiapoptotic factors and an increase of 
proapoptotic Bcl-3 family members (Beumer and Tawbi, 2010). Furthermore, also specific 
HDAC1 knockdown in some cancer cells can activate such pro-apoptotic genes and thereby 
increase apoptosis (Senese et al., 2007). These pro- and anti-apoptotic proteins control 
mitochondrial death signaling through cytochrome C release, which then activates a cascade of 
caspase proteases that execute the cell death program (Hanahan and Weinberg, 2000). HDAC1 
knockdown was shown to induce the release of Caspase-3 and thereby guide initiation of 
apoptosis (Senese et al., 2007).  
Alterations in components of the apoptotic machinery have dramatic effects on tumor 
progression. This provides a rationale for the inactivation of apoptosis during tumor development 
(Hanahan and Weinberg, 2000). The apoptotic program can be circumvented e.g. by 
overexpression of anti-apoptotic oncogenes like Bcl-2. Differently, OE of oncogenes like c-myc 
triggers apoptosis, unless counterbalanced by anti-apoptotic factors (Junttila and Evan, 2009; 
Lowe et al., 2004). Furthermore, also tumor suppressors like p53 can cause apoptosis by 
upregulation of pro-apoptotic Bax in response to DNA damage and need to be counteracted for 
malignant transformation to occur (Dang et al., 2005). Resistance to apoptosis can be acquired 
by cancer cells through mutations in p53 that functionally inactivate this tumor suppressor. This 
was reported to occur in more than 50% of human cancers (Hanahan and Weinberg, 2000; 
Harris, 1996; Junttila and Evan, 2009). Interestingly, HDAC1 can deacetylate p53, which is 
destabilized and degraded, and thereby repress p53-dependent transcription (Ito et al., 2002; Luo 
et al., 2000; Tang et al., 2008).  
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Angiogenesis	and	HDACs	
Angiogenesis, a process of generation of new blood vessels from preexisting vasculature is 
another hallmark of cancer (Hanahan and Weinberg, 2000, 2011). Vascularization of all tissues, 
including tumors is needed to access to oxygen and nutrients, as well as removing carbon dioxide 
and metabolic waste products. Tumor-associated neovasculature is critical for progression and 
metastasis of solid tumors. Already early during tumorigenesis, an “angiogenic switch” occurs, 
which causes normally quiescent vasculature to sprout new blood vessels. This helps to sustain 
expansion of neoplastic growth (Bergers and Benjamin, 2003; Hanahan and Folkman, 1996; 
Raica et al., 2009).  
Under physiological conditions, angiogenesis is tightly regulated by angiogenic regulators that 
bind to stimulatory or inhibitory cell surface receptors on vascular endothelial cells (Baeriswyl 
and Christofori, 2009). The best known angiogenesis inducer is the vasculature endothelial 
growth factor (VEGF). Such angiogenic factors that promote neovascularization can be 
upregulated upon hypoxia or in some tumors upon oncogene signaling mediated by e.g. c-Myc 
and RAS oncogenes (Carmeliet, 2005; Hanahan and Weinberg, 2011).  
The primary trigger of angiogenesis is hypoxia within the tumor microenvironment. This induces 
hypoxia-inducible factor 1α (HIF-1α), a key regulator of angiogenesis (Ellis et al., 2009c). 
Importantly, the stability of HIF-1α is regulated partly by acetylation. Under normoxic 
conditions HIF-1α undergoes acetylation, and is degraded by the ubiquitin-proteasome pathway. 
Whereas under hypoxic conditions, HIF-1α is stabilized and leads to transcriptional induction of 
its target genes, including VEGF, and thereby mediate angiogenesis (Ke and Costa, 2006).  
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HDACs were reported to regulate angiogenesis. Several HDACis, including trichostatin A 
(TSA), were shown to have antiangiogenesis properties by inhibiting HIF-1α (Kim et al., 2001). 
Interestingly, expression of HDAC 1, 2, and 3 has been shown to increase in response to hypoxia. 
More importantly, HDAC1 OE leads to increased level of HIF-1α and VEGF (Kim et al., 2001). 
HDAC1, 3, 4, and 6 have been shown to interact with HIF-1α and enhance its stability and 
activity under hypoxic conditions, suggesting important roles of these enzymes in HIF-1α 
mediated neovascularisation in tumors (Kim et al., 2007; Qian et al., 2006). Interestingly, 
HDAC6 has been shown to repress the expression of the metalloproteinase ADAMTS1 which is 
responsible for sequestration of VEGF and release of TSP-1/2 (Chou and Chen, 2008). In 
summary, class I and II HDACs play a crucial role in angiogenesis and are attractive targets for 
antiangiogenic therapy (Hagelkruys et al., 2011).  
 
Impact	of	HDACs	on	invasion	and	metastasis	
In most types of human cancer, some cells acquire the potential to escape the primary tumor 
mass and colonize new distant sites. This process called invasion and metastasis is associated to 
higher pathological grades of malignancy and is the main cause of human cancer death (Hanahan 
and Weinberg, 2011).  
Interestingly, HDAC6 has been shown to regulate cell motility and epithelial-mesenchymal 
transition (EMT) (Shan et al., 2008). EMT is the biological process that allows a stationary 
epithelial cell to undergo multiple phenotypic changes, including the loss of cell-cell adhesion, to 
acquire mesenchymal characteristics with enhanced migratory capacity and invasiveness (Polyak 
and Weinberg, 2009; Thiery et al., 2009).  
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HDAC6 is a microtubule-associated deacetylase that deacetylates alpha-tubulin and thereby 
positively impacts on cell migration (Hubbert et al., 2002). In addition to its role in microtubule-
dependent cell motility, HDAC6 also modulates cell migration by deacetylation of cortactin 
(Zhang et al., 2007). In addition, HDAC6 deacetylates HSP90 alpha that regulates client 
oncoproteins involved in invasion and metastasis (Yang et al., 2008).  
Metastatic cells have altered cell shape and lose the attachment to the extracellular matrix. 
Cancer cells can acquire invasiveness and metastatic ability by activating extracellular proteases, 
altering the binding specificity of cell adhesion molecules (CAM) and integrins (Hanahan and 
Weinberg, 2000). The most prominently altered CAM is E-cadherin, a key suppressor of 
invasion and metastasis (Berx and van Roy, 2009). E-cadherin expression is repressed by 
SNAIL/SLUG TFs. Interestingly, SNAIL1 interacts with HDAC1 and HDAC2 to repress E-
cadherin in tumor cells (Peinado et al., 2007; von Burstin et al., 2009).  
Furthermore, several metastasis repressors were shown to be induced in response to HDACis. 
Hence, HDACs have a promoting role in tumor metastasis (Hagelkruys et al., 2011). Despite 
considerable advances in this field, the complex process of metastatic dissemination and the role 
of HDACs in this process is not completely understood yet (Hagelkruys et al., 2011; Hanahan 
and Weinberg, 2011).  
 
4.4. Role	of	HDACs	in	B	cell	malignancies	
HDAC	dysregulation	in	hematological	malignancies	
Altered expression and function of various HDACs is a common feature of a wide range of 
human cancers, including in B cell, T cell, and other hematological malignancies but also solid 
tumors (Haery et al., 2015). HDACs can be deregulated in their expression or abnormally 
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recruited in tumor cells (Mercurio et al., 2010). However, OE is the most prevalent alteration of 
HDAC function in tumors (Hagelkruys et al., 2011). Many studies provide compelling evidence 
that deregulated HDAC expression plays a key role in cancer. Elevated levels of different 
HDACs in cancer cells are often linked to more aggressive disease and poor prognosis 
(Hagelkruys et al., 2011).  
In hematological malignancies, where chromosomal translocations are the main cause, HDACs 
can be aberrantly recruited to promoters through association with such oncogenic DNA-binding 
fusion proteins. One prominent example is the fusion protein PML-RAR, which causes APL. In 
this disease co-repressor complexes containing HDAC3 are recruited and decrease transcription 
of PML-RAR target genes (Atsumi et al., 2006). Another cause of hematological malignancies is 
OE of repressive TFs which interacts with HDACs. In DLBCL for example, the TF Bcl6 is 
overexpressed and recruits HDAC2 causing repression of genes regulating cell growth 
(Pasqualucci et al., 2003).  
 
HDAC1	and	HDAC2	involvement	in	lymphoma	and	leukemia	
HDAC1 and HDAC2 have been reported to be overexpressed in several B and T cell lymphomas 
and leukemias (Haery et al., 2015), including ALL (Gruhn et al., 2013; Moreno et al., 2010; Van 
Damme et al., 2012); HL (Adams et al., 2010); DLBCL (Marquard et al., 2009). Even though 
both HDAC1 and HDAC2 are highly expressed in classical HL, only HDAC1 expression 
correlated with a worse outcome (Adams et al., 2010). However, HDAC2 expression was found 
to be higher in aggressive compared to indolent CTCL (Marquard et al., 2008). Hence, the 
precise role of HDAC1 and HDAC2 in the different cancer types remains elusive. HDAC1 and 
HDAC2 were shown to have tumor promoting but also tumor suppressive functions. For 
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example, Santoro et al. performed transient depletion of mammalian HDAC1 or HDAC2 using 
small interfering RNA (Santoro et al., 2013), and demonstrated that HDAC1 has a dual role in 
APL: oncosuppressor in tumorigenesis, oncogene in tumor maintenance. Similar observations 
were made in a skin tumor model (Winter et al., 2013). Another study demonstrated that HDAC1 
and HDAC2 have a dosage-dependent oncosuppressor role in thymocytes (Heideman et al., 
2013). However, more mechanistic studies and genetic based evidences using different cancel 
models are needed.  
 
HDAC6	in	B	cell	malignancies	
HDAC6 expression is also deregulated in several lymphoid malignancies. HDAC6 has been 
reported to be both overexpressed or underexpressed in different lymphoid malignancies. For 
example, HDAC6 OE was shown in ALL (Bradbury et al., 2005; Moreno et al., 2010; Van 
Damme et al., 2012), AML (Bradbury et al., 2005), CLL (Van Damme et al., 2012; Wang et al., 
2011) and CTCL (Marquard et al., 2008). Surprisingly, HDAC6 was found to be both, 
overexpressed (Marquard et al., 2009; Zhang et al., 2004) and underexpressed (Gloghini et al., 
2009) in DLBCL.  
Furthermore, HDAC6 was shown to have oncogenic or tumor suppressor roles, depending on the 
cancer type and stage (Seidel et al., 2015). HDAC6 was shown to have oncogenic roles in AML 
(Bradbury et al., 2005). HDAC6 was also found to be overexpressed in advanced stage of ALL 
(Bradbury et al., 2005). However, HDAC6 may also play a role as tumor suppressor. OE of 
HDAC6 correlates with a good prognosis in DLBCL (Marquard et al., 2009), CLL (Van Damme 
et al., 2012) and CTCL (Marquard et al., 2008) and HDAC6 underexpression was found to be 
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correlated with a poor prognosis in CLL (Van Damme et al., 2012). Hence, the exact role of 
HDAC6 in the different cancer types remains elusive.  
 
4.5. HDAC	 inhibitors	 (HDACis)	 in	 treatment	 of	 lymphoid	
malignancies	
Unlike DNA mutations, changes in the epigenome associated with cancer are potentially 
reversible. This enables the use of “epigenetic drugs” like HDACis in the treatment of several 
cancers (Sharma et al., 2010). The first indication that HDACis might be useful in cancer 
treatment came from studies done almost three decades ago showing that the first specific 
HDACi trichostatin A (TSA) has anti-proliferative activity in transformed cells in vitro (Yoshida 
and Beppu, 1988). Subsequently, various other compounds that inhibit HDAC activity were 
found. Several studies discovered that HDACs are overexpressed in various cancer types and cell 
lines (Haery et al., 2015). Hence, these enzymes represent an interesting pharmacological target 
for cancer therapy. Indeed, targeting HDACs using HDACis has demonstrated activity in 
hematological and solid malignancies (Falkenberg and Johnstone, 2014; West and Johnstone, 
2014). HDACis represent now the most extensively studied family of epigenetic modulators 
(Seidel et al., 2012). In the following sections, I discuss the different types of HDACis and their 
use in research and clinics in the context of lymphoid cancers.  
 
Mode	of	action	of	HDACis	
HDACis modulate gene expression and cellular function via various molecular pathways. The 
major effects of HDAC inhibition by HDACis are 1) induction of apoptosis; 2) inhibition of cell 
cycle progression; 3) cellular differentiation; 4) suppression of angiogenesis and 5) enhancement 
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of antitumor immunity (Falkenberg and Johnstone, 2014). Thereby, HDACis impact on almost 
all hallmarks of cancer to control crucial functions in lymphomagenesis (see above).  
The most prominent effect of HDAC inhibition is its effect on cell cycle regulation and control. 
HDACis block cell proliferation and cause apoptosis in hematologic and solid tumors cells by 
causing cell cycle arrest. HDACis affect the cell cycle mainly by regulating the expression of 
several cell cycle proteins including cyclins A and D (Sandor et al., 2000) and cyclin-dependent 
kinase inhibitors p21waf1/cip1, p27Kip1 and p57Kip2 (Gui et al., 2004; Ocker and Schneider-Stock, 
2007; Peart et al., 2003; Richon et al., 2000; Sambucetti et al., 1999). Thereby, HDACis induce 
cell cycle arrest at the G1/S or G2/M checkpoints (Bolden et al., 2006).  
HDACis impact on survival pathways and induce death in tumor cells. HDACis regulate genome 
stability and repair, by preventing chromosome compaction and facilitating an accumulation of 
irreparable DNA breaks. Thereby, HDACis may induce apoptosis and impact on cell survival 
(Bhaskara et al., 2010; Miller et al., 2010; Robert et al., 2011). HDACis can induce both 
extrinsic and intrinsic apoptotic pathways. In addition, HDACis also induce tumor cell death 
through non-apoptotic mechanisms like autophagy (Shao et al., 2010; Zain and O'Connor, 2010).  
HDACis induce their effect by impacting on gene expression. HDACis induce histone 
hyperacetylation and mediate chromatin remodeling and thereby increase gene transcription 
(Figure 2). This is primarily occurring through inhibition of classI HDAC1, 2 and 3. HDACs 
have pleotropic effects and regulate the expression of numerous genes involved in multiple 
cellular processes (Falkenberg and Johnstone, 2014).  
The therapeutic activity of HDACis is likely based on a combined effect on histone and 
nonhistone proteins (Johnstone and Licht, 2003). For example, through inhibiting HDAC6, 
HDACis act through hyperacetylation of nonhistone proteins like Hsp90 or TFs and thereby 
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increase or decrease their activity. For example, HDACi mediates degradation of HSP90 client 
oncoproteins, including BCR-ABL and ERBB2. This has been proposed as a major effector of 
HDACi mechanism of action (Bolden et al., 2006).  
Importantly, it is expected that the effects of HDACis vary between different types of tumor 
cells, but also within a tumor type and even within a given tumor, due to the inter-and intra-
tumor heterogeneity (Haery et al., 2015).  
 
Classification	of	HDACis		
Currently, numerous HDACis are used in clinics as therapeutic agents (Table 1). These inhibitors 
are chemically diverse and inhibit HDAC activity in a wide range of concentrations from low 
nM to high mM (Batty et al., 2009; Johnstone and Licht, 2003; Zain and O'Connor, 2010). 
HDACis can be classified into 3 main classes according to their chemical structure and 
specificity (Bradner et al., 2010): 1) hydroxamic acids, 2) cyclic tetrapeptides, 3) benzamides. 
The most predominant HDACi family is hydroxamic acids. The currently clinically most 
successful inhibitor of this family is SAHA (suberoxylanilide hydroxamic acid) (Vorinostat, 
Zolinza; Merck). SAHA inhibits class I HDACs as well as HDAC6 at low nanomolar 
concentrations (Richon et al., 2009). Two other prominent hydroxamate HDACis are belinostat 
(PXD101, Beleodaq) that inhibits class I, II and IV HDACs and panobinostat (LBH589, 
Farydak) that inhibits only class I and II HDACs (Marks, 2010). Another hydroxamate is 
tubacin, a HDAC6 specific inhibitor (Butler et al., 2010), and trichostatin A (TSA) (Mai and 
Altucci, 2009). The prominent member of cyclic peptide HDACis is the depsipeptide romidepsin 
(FK228, Isodax; Celgene). It inhibits with high specificity class I HDACs but almost not 
HDAC6 (Batty et al., 2009; Furumai et al., 2002). Another group of HDACis are the benzamide 
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family inhibitors. These HDACis are class I selective and inhibit HDAC1, 2, and 3. It comprises 
among others entinostat (MS-275) and mocetinostat (MGCD-0103). Entinostat has highest 
efficacy against HDAC1 and mocetinostat mainly inhibits HDAC1 and HDAC2 (Mottamal et al., 
2015).  
 
 
Table 1: Summary of HDACi compounds. Classified according to the HDACi classes. Target of HDACis and 
clinical trial stage are indicated (modified from ((Haery et al., 2015) 
 
HDACi	in	clinical	settings	
HDACis have become promising targets for therapeutic intervention (Table 1). They are 
particularly active in hematologic malignancies and they gained since 2001 a widespread use in 
the clinic for the treatment such diseases (Falkenberg and Johnstone, 2014; Mercurio et al., 2010; 
Rasheed et al., 2008; West and Johnstone, 2014). Currently, four HDACis, varinostat, 
romidepsin, belinostat, and panobinostat, are Food and Drug Administration (FDA)-approved for 
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the following hematological malignancies: Cutaneous T cell lymphoma (CTCL), Peripheral T 
cell lymphoma (PTCL) and multiple myeloma (Ghobrial et al., 2013; Rasheed et al., 2008; 
Richardson et al., 2013; San-Miguel et al., 2013). Even though these HDACis are relatively well 
tolerated by patients, in some cases they were shown to have side effects like thrombocytopenia, 
cardiac toxicity, thrombosis and pulmonary embolism (Zain and O'Connor, 2010).  
These FDA approved HDACis, and the majority of available HDACis, are broad-based pan-
HDACis that target Zn2+-dependent HDACs, including class I and/or II HDACs including 
HDAC1, 2, 3, and 6 (Bantscheff et al., 2011). Due to the unselectivity of these pan-HDACis it is 
unclear which HDACs isoforms are crucial for tumor cell growth and/or survival. It still remains 
unclear whether selective HDAC inhibition might have comparable therapeutic benefit and 
whether they could limit toxicity observed with broad-spectrum inhibitors (Dawson and 
Kouzarides, 2012; Ononye et al., 2012). Therefore, isoform-selective HDACis have been 
developed (Balasubramanian et al., 2009). Currently there are very few HDAC isoform selective 
inhibitors available. Tubacin, a hydroxamate HDAC6 specific inhibitor, is one of these. Several 
other HDACis are currently in progress, mostly as oncology agents (Bolden et al., 2006; Khan et 
al., 2008; Moradei et al., 2008).  
However, despite the very promising results in hematological malignancies, the use of HDACis 
in solid tumors have shown only limited clinical benefit and unfavorable side-effects 
(Slingerland et al., 2014). Nevertheless, many preclinical data and clinical trials appear 
promising for the use of HDACis in combination with other chemotherapeutics in the treatment 
of different types of lymphoma, leukemia and multiple myeloma, but also solid tumors (Dhanak 
and Jackson, 2014; Haery et al., 2015; Mai and Altucci, 2009; Olzscha et al., 2015; Slingerland 
et al., 2014). Some of the most promising drug combinations are HDACis with BCL6 inhibitors 
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or nicotinamide to co-target the BCL6-p53 pathway, or with proteasome inhibitors like 
bortezomib (Paoluzzi et al., 2010; Zain and O'Connor, 2010). Hence, development of future 
therapeutic strategies involves now rational drug combinations to achieve synergistic effects.  
 
HDACi	in	B	cell	lymphoma	research	
Currently, there are no HDACis approved specifically for the treatment of B cell lymphoma. 
However, increasing amount of pre-clinical data support a beneficial effect of select HDACis for 
their use in B cell malignancies. One of the first reports of the efficacy of HDACis in the 
treatment of B cell malignancies was published 10 years ago, demonstrating that the weak 
HDACi valproic acid induced a complete remission in a patient with refractory DLBCL (Zain et 
al., 2007). Subsequently, during the last decade, several other more potent HDACis have been 
tested for the treatment of B cell NHL (Haery et al., 2015). These studies demonstrated that 
several compounds including vorinostat have therapeutic activity in B cell malignancies. 
Currently, numerous HDACis are in development for various lymphoid malignancies (reviewed 
by (Haery et al., 2015)).  
Pre-clinical research with the Eµ-myc B cell lymphoma model demonstrated the activity of 
several currently available HDACis: Broad-spectrum HDACis like varinostat, romidepsin and 
panobinostat were shown to have therapeutic efficacy in Eµ-myc lymphoma (Ellis et al., 2009b; 
Lindemann et al., 2007; Newbold et al., 2008; Newbold et al., 2013; Newbold et al., 2014). 
However, it is not known whether single HDAC1 or HDAC2 isoform-selective inhibitors would 
offer similar or better anti-tumor efficacy. However, there are currently no available HDAC1-
specific and only few HDAC2-specific inhibitors (Wagner et al., 2015), but there are several 
compounds capable of inhibiting both HDAC1 and HDAC2 (Mottamal et al., 2015). One 
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HDAC1 and HDAC2 isoform selective inhibitor, RGFP233 was shown to induce apoptosis in 
Eµ-myc tumor cells in vitro (Matthews et al., 2015). Another, Cpd-60 (“Compound 60”) was 
shown to inhibit growth of primary B-ALL cells in vitro and in vivo (Methot et al., 2008; 
Schroeder et al., 2013; Stubbs et al., 2015), but has not been tested in Eµ-myc cells. Although 
several of HDACis were shown to have an in vitro and/or in vivo therapeutic efficacy in pre-
clinical model like Eµ-myc, it is possible that different drugs may have different mechanistic, 
biological, and therapeutic activities.  
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5. Conclusion
Huge efforts were made in understanding the relevance of HDACs in health and disease. 
Particular progress was made in cancer research, were HDAC deregulation was shown to be 
strongly implicated. HDACs were shown to contribute to the hallmarks of cancer by inducing 
proliferation, angiogenesis and metastasis, as well as by blocking apoptosis. HDACis were 
shown to have effective broad-spectrum antitumor effects impacting on these hallmarks of 
cancer. However, the exact mechanism by which HDACis induce tumor cell death, remains 
unclear. Furthermore, the knowledge of the relevant HDACs isoforms in the different cancer 
settings in not comprehensive.  
Research focusing on HDAC1, HDAC2 and HDAC6 has shown that these enzymes are 
implicated in many cancer types, including lymphoid malignancies. Most of these malignancies 
have dysregulation of the c-myc oncogene, which correlates with high proliferation and poor 
prognosis. The most prominent B cell lymphomas associated with recurrent c-myc rearrangement 
are BL and DLBCL. One prominent preclinical mouse model to study BL is the Eµ-myc model B 
cell lymphoma.  
Several efforts were made in the last decades to elucidate the role of HDAC1, HDAC2 and 
HDAC6 isoforms in different cancer settings. However, these isoforms were shown to have 
contradicting tumor promoting but also tumor suppressive functions, depending on the cancer 
type and cancer stage. Much more work remains to clarify the role of these HDACs in cancers. 
Future studies will focus on identifying the relevant HDAC isoforms in the different cancer types 
and the discovery of selective HDACis.  
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Aim	of	this	thesis	
In the lab of Prof. Dr. Patrick Matthias we focus our research on histone deacetylases (Hdacs) 
and their role in normal physiology or pathological settings such as cancer. Previous work on 
classI Hdac1 and Hdac2, as well as classII Hdac6, showed that they play important roles in 
several cancer settings, including B cell malignancies (Haery et al., 2015; Seidel et al., 2015). 
However, Hdac1 and Hdac2 (Santoro et al., 2013), but also Hdac6 (Seidel et al., 2015), were 
shown to have contradicting tumor promoting and tumor suppressive roles in cancer. Despite 
improved knowledge in Hdac cancer research, the exact role of Hdac1, Hdac2, and Hdac6 in 
cancer remains largely unexplored. The aim of my PhD thesis is to better understand the 
functional role of Hdac1, Hdac2, and Hdac6 in the Eµ-myc model of B cell lymphoma.  
In the first, and main part of my thesis I studied the functional role of classII Hdac1 and Hdac2 in 
the Eµ-myc mouse model of B cell lymphoma. I performed this work I collaboration with Prof. 
Dr. Alexandar Tzankov, an experienced hematopathologist from the university hospital Basel. 
The result of this work is presented in the form of a publication manuscript: “Histone deacetylase 
(Hdac) 1 plays a predominant role in Eµ-myc driven B cell lymphoma” (Pillonel et al., Accepted 
for publication in Scientific Reports).  
In the second part of my thesis, I started a collaboration with R.M. Heideman, a postdoctoral 
research fellow in the lab. Together, we started to explore the role of Hdac1 and Hdac2 in B cell 
development. The work from this side project is presented in the result section of my thesis: 
“Analysis of the functional role of Hdac1 and Hdac2 in B cell development”. 
In the last part of my thesis I investigated the function of the cytoplasmic classII Hdac6 in the 
Eµ-myc model: “Dissecting the role of histone deacetylase 6 in Eµ-myc driven B cell 
lymphoma”. The results from this work are presented in the result section of my thesis.  
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In parallel, I also participated in the revision work of the manuscript from Camille Du Roure, a 
previous postdoc in the lab: “Hematopoietic Overexpression of FOG1 Does Not Affect B-Cells 
but Reduces the Number of Circulating Eosinophils” (Du Roure et al., 2014). This published 
work is presented in the appendix of my thesis. Furthermore, I also participated in the revision 
work of the manuscript from another previous lab member, Nina Reichert: “Hdac1 and 2 repress 
lineage inappropriate expression of Flt3 and Ptprf in B cells via Pax5 and Grg4” (unpublished 
work). Since this work is not yet submitted, I only show the abstract in the appendix of my 
thesis.  
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Results	Part	1	(Pillonel	et	al.	Accepted	for	publication	in	Sci	Rep.)	
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Results	Part1:	Histone	deacetylase	1	plays	a	predominant	pro-oncogenic	
role	 in	 Eµ-myc	 driven	 B	 cell	 lymphoma	 (Pillonel	 et	 al.	 Accepted	 for	
publication	in	Scientific	Reports)	
Vincent Pillonel1, 2, Nina Reichert1, Chun Cao1, Marinus R. Heideman1, Teppei 
Yamaguchi1, Gabriele Matthias1, Alexandar Tzankov3 & Patrick Matthias1, 2,*
1Friedrich Miescher Institute for Biomedical Research, Novartis Research Foundation, 4058 
Basel, Switzerland.  
2Faculty of Sciences, University of Basel, 4031 Basel, Switzerland. 
3Pathology Institute, University Hospital Basel, 4031 Basel, Switzerland.  
*Correspondence and requests for materials should be addressed to P.M. (email:
patrick.matthias@fmi.ch; Tel.: +41 61 697 66 61; Fax.: +41 61 697 39 76) 
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Manuscript	Text			Abstract	
 
The two histone deacetylases (Hdacs), Hdac1 and Hdac2, are erasers of acetylation marks on 
histone tails, and are important regulators of gene expression that were shown to play important 
roles in hematological malignancies. However, several recent studies reported opposing tumor-
suppressive or tumor-promoting roles for Hdac1 and Hdac2. Here, we investigated the functional 
role of Hdac1 and Hdac2 using the Eµ-myc mouse model of B cell lymphoma. We demonstrate 
that Hdac1 and Hdac2 have a pro-oncogenic role in both Eµ-myc tumorigenesis and tumor 
maintenance. Hdac1 and Hdac2 promote tumorigenesis in a gene dose-dependent manner, with a 
predominant function of Hdac1. Our data show that Hdac1 and Hdac2 impact on Eµ-myc B cell 
proliferation and apoptosis and suggest that a critical level of Hdac activity may be required for 
Eµ-myc tumorigenesis and proper B cell development. This provides the rationale for utilization 
of selective Hdac1 and Hdac2 inhibitors in the treatment of hematological malignancies.  
 Introduction	
 
Histone deacetylases (Hdacs) belong to a family of 18 enzymes that removes acetylation marks 
on lysine residues of histone and non-histone proteins [1]. Hdacs modify the epigenome through 
deacetylation of histone proteins, thereby inducing chromatin condensation leading to 
transcriptional repression [2, 3]. They also act on an increase number of non-histone substrates, 
nuclear or cytoplasmic, and therefore impact on multiple cellular functions [4, 5]. Human Hdacs 
(HDACs) have been reported to have altered function and expression (usually overexpressed) in 
a wide range of human cancers [6-9] and have been considered attractive pharmacological 
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targets for cancer therapy. HDAC inhibitors (HDACis) have potent antitumor activity in 
hematological and solid malignancies, mainly by inducing apoptosis, inhibiting cell cycle 
progression and cellular differentiation [10, 11]. Currently, four pan-HDACis, (targeting class I 
and/or class II HDACs [12]) are approved for the treatment of T cell lymphoma and multiple 
myeloma [13-16] and several others are in clinical trials for various cancers, including B cell 
malignancies (reviewed by [9]). However, it is unclear which HDAC isoforms are crucial for 
tumor cell growth and/or survival, and whether selective HDAC inhibition might have 
comparable therapeutic benefit with less toxicity compared with broad-spectrum HDACis [2, 
17].  
Although the two class I Hdacs, Hdac1 and Hdac2, have been shown to be implicated in 
proliferation of cancer cells and to play an important role in hematological malignancies [9, 18-
23], their exact functions in the different cancer types remains elusive. Hdac1 has been shown to 
have opposing tumor-suppressive as well as tumor-promoting functions in tumorigenesis and in 
tumor maintenance, respectively [24]. Numerous studies in different cell types, including B cells, 
demonstrated that these two enzymes have largely redundant functions during normal 
development and malignant transformation [25-32]. Some studies reported a dose-dependent 
function of Hdac1 and Hdac2 in some cell types, including T cells and epidermal cells [33, 34].  
In view of these observations, we assessed the functional role of Hdac1 and Hdac2 in the 
development and progression of Eµ-myc driven B cell lymphomas. Eµ-myc transgenic (tg) mice 
overexpress the c-myc oncogene in B lymphocytes and develop multicentric lymphomas 
associated with leukemia [35-37]. We investigated the impact of B lymphocyte-specific deletions 
of combination of Hdac1 and Hdac2 alleles using targeted conditional deletion with the mb1-cre 
recombinase [30] in Eµ-myc mice. Here, we show that Hdac1 and Hdac2 have tumor-promoting 
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roles in both Eµ-myc tumorigenesis and tumor maintenance. This study reveals that Hdac1 and 
Hdac2 have a gene dose-dependent pro-oncogenic role in Eµ-myc tumorigenesis, with a 
predominant role of Hdac1.  
 Results	
 
Hdac1 and 2 have no tumor suppressor functions in B cells.     Previous studies reported that 
T cell-[32, 33] and epidermal cell-[34] specific ablation of Hdac1 and Hdac2 alleles 
unexpectidely leads to spontaneous tumor formation. Therefore, we first investigated whether 
ablation of Hdac1 and Hdac2 in B cells also induces tumor development. For this we generated 
B cell-specific deletions of different combinations of Hdac1 and Hdac2 alleles in vivo 
(Supplementary Figure 1A) and monitored mice for tumor development over a period of 300 
days by the Kaplan-Meyer (KPLM) method. Interestingly, in contrast to previous observation in 
T cells, ablation of Hdac1 and/or Hdac2 in B cells did not lead to spontaneous tumor 
development (Figure 1A). Eµ-myc tg mice were used as controls and developed tumors as 
expected (Figure 1A; Supplementary Figure 2D). We then performed histopathological analysis 
from the mice lacking Hdac1 and/or Hdac2 to verify the absence of malignant phenotypes. 
Consistent with the absence of visible and palpable tumors in the KPLM analysis, we did not 
detect any pathological signs in Hdac1 and/or Hdac2 KO mice at 8, 20, and even 40 weeks in the 
spleen, lymph nodes, or thymus (Figure 1B). Taken together, our results indicate that Hdac1 and 
Hdac2 do not have a tumor suppressor function in B cells.  
 
Eµ-myc tumorigenesis is Hdac1 and Hdac2 gene dose-dependent.      We next investigated the 
effect of Hdac1 and Hdac2 ablation in the Eµ-myc cancer background, and in particular whether 
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they have tumor suppressive or tumor promoting functions during Eµ-myc tumorigenesis. We 
previously reported that concomitant ablation of Hdac1 and Hdac2 in non-transformed B cells 
induced a cell cycle block and apoptosis [30]. We therefore hypothesized that similar ablation of 
Hdac1 and Hdac2 might also have this effect in malignant Eµ-myc tg B cells which overexpress 
the strong c-myc oncogene. We crossed mice with B cell-specific deletions of different 
combinations of Hdac1 and Hdac2 alleles with Eµ-myc mice in order to obtain mice having the 
Eµ-myc tg in different backgrounds with respect to Hdac1 and Hdac2 (Supplementary Figure 
2A). Eµ-myc mice overexpressed the c-myc oncogene in all B lymphocytes, as expected 
(Supplementary Figure 2B-C), and developed multicentric lymphomas (Supplementary Figure 
2D), as previously reported [35-37]. We then monitored tumor-free survival by KPLM analysis 
in mice having different combinations of Hdac1 and Hdac2 alleles. Interestingly, we observed 
that mono-allelic expression of Hdac2 in Hdac1-deficient Eµ-myc B cells (Hdac1Δ/Δ;Hdac2Δ/+) 
resulted in delayed tumor development, whereas complete Hdac1 and Hdac2 deletion 
(Hdac1Δ/Δ;Hdac2Δ/Δ) prevented tumorigenesis altogether (Figure 2A). We observed a gradual 
decrease in tumor incidence and concomitant gradual increase in mean overall survival upon 
deletion of combinations of Hdac1 and Hdac2 alleles (Figure 2B). Importantly, these findings 
demonstrate that Hdac1 and Hdac2 have pro-oncogenic roles in tumorigenesis of Eµ-myc mice, 
in contrast to other cancer models such as acute promyelocytic leukemia (APL) [24]. These 
findings further indicate that Eµ-myc tumorigenesis is Hdac1 and Hdac2 gene dose-dependent. 
We observed that a critical level of Hdac1 and Hdac2 is required for tumorigenesis. Moreover, 
Hdac1 and Hdac2 are not completely redundant; we observed that Hdac1 functions as the 
dominant protein (Figure 2 A-B).  
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Complete Hdac1 and Hdac2 ablation prevents Eµ-myc tumorigenesis.     The foregoing 
findings demonstrate that complete Hdac1 and Hdac2 deletion (Hdac1Δ/Δ;Hdac2Δ/Δ) prevents 
tumorigenesis (Figure 2). To determine how the lack of Hdac1 and Hdac2 in B cells impacts Eµ-
myc tumorigenesis, we analysed 8-week old mice by first measuring spleen weight, since Eµ-myc 
mice typically have splenomegaly. We found that only complete ablation of both enzymes 
(Hdac1Δ/Δ;Hdac2Δ/Δ), but not ablation of either Hdac1 (Hdac1Δ/Δ;Hdac2+/+) or Hdac2 
(Hdac1+/+;Hdac2Δ/Δ) alone, prevented spleen enlargement (Figure 3A). We next performed 
histopathological analysis from spleen (Figure 3B). As expected, some Eµ-myc mice displayed 
high grade non-Hodgkin’s lymphomas (HG-NHL, roughly corresponding to Burkitt’s lymphoma 
in humans), as described previously [35, 38]. Importantly, no Hdac1Δ/Δ;Hdac2Δ/Δ Eµ-myc mice 
had HG-NHL in spleen and lymph nodes, whereas ablation of either Hdac1 or Hdac2 alone did 
not prevent HG-NHL development (Figure 3B, table). We next measured circulating peripheral 
blood lymphocytes (PBL) using an automated blood cell analyzer. Eµ-myc mice had 
significantly elevated PBL compared to control wild-type mice (Figure 3C). Interestingly, we 
observed that Hdac1Δ/Δ;Hdac2Δ/Δ Eµ-myc mice had significantly lower PBL counts, compared to 
control Hdac1+/+;Hdac2+/+ Eµ-myc mice, and hence reduced leukemia burdens (Figure 3C). 
Ablation of Hdac1 (Hdac1Δ/Δ;Hdac2+/+), but not Hdac2 (Hdac1+/+;Hdac2Δ/Δ) in Eµ-myc mice, 
significantly reduced PBL counts at 8 weeks (Figure 3C). However, this phenotype is transient, 
since we did not see any effect in PBL counts in older (10 and 20 week old) Hdac1Δ/Δ;Hdac2+/+ 
Eµ-myc mice (Supplementary Figure 4). Hence, we conclude that ablation of Hdac1 
(Hdac1Δ/Δ;Hdac2+/+) alone has no major impact on Eµ-myc tumorigenesis. Finally, we 
performed an analysis of the bone marrow (BM) of Eµ-myc mice by flow cytometry. We 
performed immunofluorescence stainings with B cell-surface-marker-specific antibodies 
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including B220, IgM, CD19 and CD25 to identify the different B cell populations in the BM 
(Figure 3D). Eµ-myc mice displayed blasts at the Pro/PreB cell stage that dominates the BM, as 
previously reported [39]. Consistent with the data outlined above, ablation of Hdac1 
(Hdac1Δ/Δ;Hdac2+/+) or Hdac2 (Hdac1+/+;Hdac2Δ/Δ) alone had no effect (Figure 3 E-F). 
However, ablation of both Hdac1 and Hdac2 (Hdac1Δ/Δ;Hdac2Δ/Δ) prevented the appearance of 
such Eµ-myc-induced B cell blasts at the Pro/PreB stage (B220+; IgM-; Figure 3E), more 
specifically at the PreBII cell stage (B220+;CD19+;CD25+; Figure 3F). Altogether, these results 
indicate that ablation of Hdac1 and Hdac2 (Hdac1Δ/Δ;Hdac2Δ/Δ) prevents Eµ-myc tumorigenesis. 
However, quantification of flow cytometric analysis revealed that Hdac1Δ/Δ;Hdac2Δ/Δ Eµ-myc 
mice had significantly reduced B cell numbers and almost no PreBII cells (Figure 3G). These 
findings suggest that the effect of complete Hdac1 and Hdac2 ablation on tumorigenesis could 
be due to a B cell developmental defect at the PreBII cell stage.  
 
Conditional ablation of Hdac1 and Hdac2 in Eµ-myc tumor cells delays tumor appearance 
in vivo.     In order to discriminate between indirect B cell developmental defects and direct 
effects of Hdac1 and Hdac2 ablation, we investigating the role of Hdac1 and Hdac2 in existing 
tumor cells. Therefore, we performed conditional targeted deletion of Hdac1 and Hdac2 in Eµ-
myc tumor cells using an in vivo transplantation approach (Figure 4A). Briefly, syngeneic 
recipient mice were injected with Eµ-myc lymphoma cells carrying floxed Hdac1 and Hdac2 
alleles as well as hormone-inducible cre (Hdac1F/F;Hdac2F/F; Actin-cre ER tg; Eµ-myc tg) and 
subsequently treated with 4-hydroxytamoxifen (4-OHT) to induce deletion of Hdac1 and Hdac2 
specifically in transplanted tumor cells. We then performed KPLM tumor-free survival analysis 
and observed that mice treated with 4-OHT had significantly delayed tumor appearance 
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compared to control mice treated with vehicle (Figure 4B). Thus, Hdac1 and Hdac2 have a pro-
oncogenic role in the Eµ-myc dependent tumor progression. This transplantation assay clearly 
demonstrates that conditional ablation of both Hdac1 and Hdac2 directly impacts on existing 
tumor cells and delays tumor appearance.   
 
Hdac1Δ/Δ;Hdac2Δ/+ delays Eµ-myc tumorigenesis.     As shown above, Eµ-myc tumor 
development was significantly delayed in mice having a single allele of Hdac2 and no Hdac1 
(Hdac1Δ/Δ;Hdac2Δ/+), while this was not the case in mice with a single allele of Hdac1 and no 
Hdac2 (Hdac1Δ/+;Hdac2Δ/Δ; Figure 2). We analysed 8-week old lymphoma-free Eµ-myc mice 
and first performed flow cytometry analysis of the BM. Interestingly, Hdac1Δ/Δ;Hdac2Δ/+ ;Eµ-
myc mice had significantly reduced blasts at Pro/PreB cell stages (Figure 5A, upper panels) and 
displayed a strongly reduced number of B cells and Pro/PreB cells in the BM (Figure 5B, upper 
panels). Furthermore, we found that these mice had several fold increased PreBI cell numbers 
and similarly decreased PreBII cell numbers (Figure 5A, lower panels). Quantification revealed 
significant changes (Figure 5B, lower panels). We next measured circulating PBL, and observed 
that Hdac1Δ/Δ;Hdac2Δ/+ Eµ-myc mice had significantly lowered PBL counts compared to control 
Eµ-myc mice with normal levels of Hdac1 and Hdac2 (Figure 5C). Hence, Hdac1Δ/Δ;Hdac2Δ/+ 
Eµ-myc mice have reduced leukemia. Taken together, these results indicate that reduction of 
Hdac2 in absence of Hdac1 (Hdac1Δ/Δ;Hdac2Δ/+) impacts Eµ-myc tumorigenesis by reducing the 
Eµ-myc-induced blasts in the BM, resulting in reduced circulating tumor cells and eventually 
delays Eµ-myc tumorigenesis (Figure 2).  
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Hdac1 has a predominant role in non-malignant B cells.     In order to test whether the impact 
of Hdac1 and Hdac2 on B cells is restricted to the Eµ-myc background, we examined mice with 
B cell-specific deletions of different combinations of Hdac1 and Hdac2 alleles but no Eµ-myc tg 
(Supplementary Figure 1A). We first examined the effect of Hdac1 and Hdac2 ablation in the 
BM by flow cytometry. We observed that Hdac1Δ/Δ;Hdac2Δ/+ but not Hdac1Δ/+;Hdac2Δ/Δ mice 
had less B cells, whereas Hdac1Δ/Δ;Hdac2Δ/Δ mice had a complete block in B cell development 
(Figure 6A). Quantification of the flow cytometry analysis revealed that Hdac1Δ/Δ;Hdac2Δ/+, but 
not Hdac1Δ/+;Hdac2Δ/Δ mice, have higher numbers of PreBI cells and reduced PreBII cell 
numbers compared to control Hdac1+/+;Hdac2+/+ mice (Figure 6B). Of note, B cells development 
was not blocked in Hdac1Δ/Δ;Hdac2Δ/+ mice since these mice still had PreBII cells (Figure 6C) 
that could develop throughout all B cells stages and eventually fill the complete pool of mature B 
cells in the spleen (Supplementary Figure 6). In comparison, mice lacking both Hdac1 and 
Hdac2 (Hdac1Δ/Δ;Hdac2Δ/Δ) had almost no PreBII cells (Figure 6C), as shown previously [30].  
We next determined the effect of Hdac1 and Hdac2 ablation on the global Hdac-activity in BM 
B cells. Interestingly, we observed that progressive ablation of Hdac1 and Hdac2 alleles 
generated a B cell-specific gradient of Hdac-activity, with Hdac1 having a greater contribution: 
Hdac1+/+;Hdac2+/+ = Hdac1+/+;Hdac2Δ/Δ > Hdac1+/Δ;Hdac2Δ/Δ ≥ Hdac1Δ/Δ;Hdac2+/+ ≥ 
Hdac1Δ/Δ;Hdac2+/Δ (Figure 6D). Further assessment by immunoblotting of Hdac1 and Hdac2 
protein levels in isolated B cells confirmed that these mice had efficient deletion of Hdac1 and 
Hdac2 (Figure 6E). Ablation of Hdac1 resulted in increased Hdac2 protein levels, as shown 
previously [30], while ablation of Hdac2 did not result in increased Hdac1 proteins levels. These 
results suggest compensatory regulation of Hdac1 and Hdac2 protein levels in B cells, with a 
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predominant compensation of Hdac2 upon loss of the other paralog (Figure 6E). Taken together, 
these data demonstrate that Hdac1 also has a predominant role in non-malignant B cells.  
 
Hdac1Δ/Δ;Hdac2Δ/+ impact on proliferation and apoptosis.     We previously showed that 
simultaneous ablation of Hdac1 and Hdac2 (Hdac1Δ/Δ;Hdac2Δ/Δ) in non-transformed B cells 
induced cell cycle arrest and subsequent apoptosis [30]. These findings prompted us to 
hypothesize that proliferation and apoptosis might also be affected in Eµ-myc B cells lacking 
Hdac1 and Hdac2. Therefore, we first investigated the impact of Hdac1 and Hdac2 ablation on 
proliferation of Eµ-myc B cells, by in vivo BrdU labelling experiments. We found that 
Hdac1Δ/Δ;Hdac2Δ/+ Eµ-myc mice had decreased B cell proliferation, as evidenced by reduced 
BrdU incorporation (Figure 7A). Quantification of B220+;BrdU+ cells revealed a significant 
decrease (Figure 7B). We next investigated whether apoptosis was induced in Hdac1Δ/Δ;Hdac2Δ/+ 
Eµ-myc B cells, using AnnexinV apoptosis assay by flow cytometry, and indeed observed that 
Hdac1Δ/Δ;Hdac2Δ/+ Eµ-myc B cells underwent apoptosis at higher frequencies than control 
Hdac1+/+;Hdac2+/+ Eµ-myc B cells (Figure 7C). Quantification of these data revealed a 
significant decrease in viable cells (AnnV-;DAPI-), concomitant with a significant increase in 
apoptotic (AnnV+;DAPI-) and dead cells (AnnV+;DAPI+; Figure 7D). In summary, B cells with 
only one allele of Hdac2 have decreased proliferation and undergo apoptosis more frequently. 
Taken together, our data demonstrate that Hdac1Δ/Δ;Hdac2Δ/+ reduces Eµ-myc tumorigenesis by 
decreasing proliferation and inducing apoptosis.  
 Discussion	
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In this study, we used targeted conditional deletion of Hdac1 and Hdac2, to investigate the 
functional role of these enzymes in the Eµ-myc murine B cell lymphoma model. Our data reveal 
a predominant role of Hdac1 in both Eµ-myc tg B cells and non-malignant B cells. We 
demonstrate that Hdac1 and Hdac2 have a gene dose-dependent pro-oncogenic role in Eµ-myc 
tumorigenesis with a predominant role of Hdac1. Our results highlight the tumor-promoting role 
of Hdac1 and Hdac2 in both Eµ-myc tumorigenesis and tumor maintenance.  
In accordance with our previous study with young B cell-specific Hdac1 and/or Hdac2 KO mice 
[30], we show here that Hdac1 and Hdac2 do not have a tumor suppressor function in B 
lymphocytes of old mice (Figure 1). Indeed, we found that ablation of Hdac1 and/or Hdac2 in 
non-malignant B cells did not lead to spontaneous tumor development, in contrast to T cells [32, 
33], and epidermal cells [34], in which Hdac1 and Hdac2 were reported to act as tumor 
suppressors. One plausible interpretation of this apparent discrepancy between our data and these 
previous studies could be a cell type-specific role of Hdac1 and Hdac2.  
We further investigated the function of Hdac1 and Hdac2 in the Eµ-myc murine B cell 
lymphoma model. In accordance with previous reports using HDACis in B lymphoid cancer 
models [9-11], we demonstrated using genetic ablation that Hdac1 and Hdac2 have pro-
oncogenic roles during Eµ-myc tumorigenesis (Figure 2). Interestingly, these findings differ from 
previous studies using a skin tumor model [34], or APL [24], in which Hdac1 (but not Hdac2) 
was reported to act as a tumor suppressor during tumorigenesis. This divergence supports the 
idea that tumor type- or oncogene-specific effects may be decisive. Moreover, we previously 
observed that Hdac1 and Hdac2 have partly different target preferences [30], suggesting that they 
might regulate different set of genes in a cell type-specific manner. 
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We further show that complete deletion of both Hdac1 and Hdac2 (Hdac1Δ/Δ;Hdac2Δ/Δ) prevents 
Eµ-myc tumorigenesis, whereas ablation of either Hdac1 (Hdac1Δ/Δ;Hdac2+/+) or Hdac2 
(Hdac1+/+;Hdac2Δ/Δ) had no effect (Figure 2). In line with this, we found that absence of these 
two Hdacs prevents Eµ-myc splenomegaly, HG-NHL occurrence, reduces leukemia, and stops B 
cell blasts accumulation, which otherwise dominates the BM of Eµ-myc mice (Figure 3). Thus, 
ablation of Hdac1 and Hdac2 prevents tumorigenesis already in the BM by preventing Eµ-myc-
induced blasts at early B cell stage. This is in agreement with our earlier report in non-
transformed B cells, where ablation of Hdac1 and Hdac2 (Hdac1Δ/Δ;Hdac2Δ/Δ) using Mb1-cre 
induced a cell cycle block and apoptosis at the PreBII cell stage [30]. However, the non-
inducible Mb1-Cre system does not allow proper discrimination between indirect B cell 
developmental defects and direct effects of Hdac1 and Hdac2 ablation in Hdac1Δ/Δ;Hdac2Δ/Δ Eµ-
myc mice. We therefore used two different approaches to investigate the direct effect of Hdac1 
and Hdac2: i) the use of mice with only one allele of Hdac2 (Hdac1Δ/Δ;Hdac2Δ/+), which do not 
have this block in B cell development to study the tumorigenesis and ii) a transplantation 
approach allowing conditional deletion of Hdac1 and Hdac2 (using inducible CreERT) in 
existing tumor cells and test the effect of Hdac1 and Hdac2 ablation on tumor maintenance. Our 
transplantation experiment (Figure 4) clearly demonstrates that conditional ablation of both 
Hdac1 and Hdac2 has a direct impact on existing tumor cells, since we observed significantly 
delayed tumor appearance. Interestingly, we observed that Hdac1 and Hdac2 are not deleted in 
tumors arising in 4-OHT treated transplanted mice (Supplementary Figure 5), suggesting that the 
delayed tumor growth observed represents cells that have escaped deletion of Hdac1 and Hdac2. 
From these findings we conclude that the partial effect we observed after 4-OHT treatment of 
transplanted recipient mice (Figure 4) can be explained by incomplete elimination of Hdac1 and 
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Hdac2 using the tamoxifen inducible CreERT system. Our findings demonstrate that loss of 
Hdac1 and Hdac2 has a direct impact on Eµ-myc tg B cells and demonstrate a critical pro-
oncogenic role of Hdac1 and Hdac2 in Eµ-myc tumor progression.  
Eµ-myc mice with a single allele of Hdac2 and no Hdac1 (Hdac1Δ/Δ;Hdac2Δ/+), but not with a 
single allele of Hdac1 in absence of Hdac2 (Hdac1+/Δ;Hdac2Δ/Δ), exhibited delayed tumor 
development (Figure 2). This demonstrates that Eµ-myc tumorigenesis is Hdac1 and Hdac2 gene 
dose-dependent, and identifies a predominant role of Hdac1. We further observed that Hdac1 has 
a predominant role also in non-malignant B cells (Figure 6). Hdac1Δ/Δ;Hdac2Δ/+ mice, but not 
Hdac1+/Δ;Hdac2Δ/Δ mice, had a reduction in PreBII cell numbers (Figure 6C). Furthermore, 
ablation of Hdac1 resulted in a strong increase of Hdac2 protein levels, as previously observed 
[30]. Interestingly, this increase in Hdac2 levels was not sufficient to compensate for the absence 
of Hdac1, indicating partially redundant functions and highlighting the predominant role of 
Hdac1. Furthermore, we observed that Hdac1Δ/Δ;Hdac2Δ/+ B cells had significantly reduced 
Hdac activity compared to Hdac1+/Δ;Hdac2Δ/Δ B cells. These data demonstrate the predominant 
role of Hdac1, and suggest that a critical level of Hdac activity may be required for Eµ-myc 
tumorigenesis.  
Similar to Hdac1Δ/Δ;Hdac2Δ/Δ, we found that Hdac1Δ/Δ;Hdac2Δ/+ impacted Eμ-myc tumorigenesis 
by reducing the Eμ-myc-induced blasts at the early preBII cell stage in the BM, resulting in 
reduced circulating tumor cells (Figure5). We further investigated whether the impact of 
Hdac1Δ/Δ;Hdac2Δ/+ in Eµ-myc B cells could be due to proliferation defects and/or apoptosis. 
Strikingly, we found that Hdac1Δ/Δ;Hdac2Δ/+ decreased proliferation and increased apoptosis in 
Eµ-myc B cells (Figure 7). Taken together, these findings demonstrate that Hdac1Δ/Δ;Hdac2Δ/+ 
reduces Eµ-myc-induced blasts in the BM and delays tumorigenesis by decreasing proliferation 
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and inducing apoptosis. Hence, we conclude that Hdac1 and Hdac2 have pro-oncogenic roles in 
Eµ-myc tumorigenesis. These findings are consistent with earlier studies reporting that complete 
loss of Hdac1 and Hdac2 induces cell death in proliferating cells, including B and T cells [30, 32, 
33]. In line with this, Hdac1 and Hdac2 were shown to be the major targets for HDACi-mediated 
apoptosis induction in leukemic cell lines [40]. Furthermore, a recent study also showed that 
ablation of both Hdac1 and Hdac2 decreases proliferation and induces apoptosis in Eµ-myc 
tumor cells [23]. Hence, an effect on proliferation and apoptosis upon Hdac1 and Hdac2 ablation 
could likely explain the delayed tumor appearance in our transplantation experiment (Figure 4).  
Our results describe the pro-oncogenic roles of Hdac1 and Hdac2 in Eµ-myc tumorigenesis and 
tumor maintenance and support the clinical use of HDACis. Previous studies clearly 
demonstrated the therapeutic efficacy of pan-HDACis in Eµ-myc lymphomas [41-45]. 
Interestingly, we found that human HDAC1, but not human HDAC2, mRNA expression is 
increased in some Burkitt’s lymphoma (BL) and diffuse large B cell lymphoma (DLBCL) cancer 
cell lines and human lymphoma samples, when compared to other cancer cell lines or other 
human cancer samples, respectively (Supplementary Figure 3). Hence, these data are consistent 
with our findings outlined above, revealing a predominant role of Hdac1. Our findings 
demonstrate that Hdac1 can be considered an important factor in Eµ-myc tumorigenesis, and 
suggest that selective HDAC1 (and HDAC2) inhibitors could be effective for the treatment of 
BL, as modeled by our preclinical Eµ-myc system, and possibly other hematological 
malignancies, including some DLBCL. Accordingly, several HDAC1 and HDAC2 isoform-
selective inhibitors were recently shown to have in vitro and/or in vivo therapeutic efficacy in 
pre-clinical models such as Eµ-myc [23, 42].  
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In conclusion, our results demonstrate that Hdac1 and Hdac2 promote tumor initiation and 
progression in Eµ-myc mice and that they impact on proliferation and apoptosis. To the best of 
our knowledge, this is the first study showing a gene dose-dependent pro-oncogenic role of 
Hdac1 and Hdac2 in tumorigenesis, with a predominant role of Hdac1. Future research will 
focus on elucidating the underlying molecular mechanisms by which Hdac1 and Hdac2 regulate 
proliferation and apoptosis in malignant and non-malignant cells. Our study raises the prospect 
of using selective HDAC1 and HDAC2 inhibitors for the treatment of BL and other B cell 
lymphomas with Myc deregulation, with possibly less side effects than pan-HDACis currently 
used.  Material	and	Methods	
 
Experimental mice. All experiments were performed in accordance with Swiss federal 
guidelines for animal experimentation (Art.13a TSchG; Art. 60-62 TSchV) and approved by the 
FMI Animal committee and the local veterinary authorities (Kantonales Veterinäramt of Kanton 
Basel-Stadt, permit no. 2384-03). All efforts were made to minimize animal suffering and to 
reduce the number of animal used.  
Hdac1F/F;Hdac2F/F conditional knockout (KO) mice have been previously described and 
characterized [30]. B lymphocyte-specific deletion of Hdac1 and/or Hdac2 was obtained by 
crossing Hdac1F/F and Hdac2F/F mice with heterozygote Mb1-cre transgenic (tg) mice [30]. For 
transplantation, Actin-Cre ER mice (The Jackson Laboratory; B6.Cg-Tg(CAG-cre/Esr1)5Amc/J) 
were used to conditionally delete Hdac1 and Hdac2 using tamoxifen. Hdac1 and Hdac2 
conditional KO mice were interbred to congenic C57BL/6 heterozygote Eµ-myc tg mice (The 
Jackson Laboratory; B6.Cg-Tg (IghMyc)22Bri/J ) [35]. All mice were in C57BL/6 genetic 
backgrounds (backcrossing at least 11 generations). The mice were housed in groups of one to 
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five at 25°C with a 12:12 h light-dark cycle and received a standard laboratory diet containing 
0.8% phosphorus and 1.1% calcium (NAFAG 890, Kliba, Basel, Switzerland) and water ad 
libitum.  
 
Genotyping PCR. Polymerase chain reaction (PCR)–based genotyping was performed on tail-
derived DNA. Mice were genotyped for Hdac1 and Hdac2 conditional alleles as described 
previously [30]. The following primer sets were used: Hdac1 flox or WT (forward; 5’-
CCTGTGTCATTAGAATCTACTT, and reverse; 5’-GGTAGTTCACAGCATAGTACTT); 
Hdac1 KO (forward; 5’-GTTACGTCAATGACATCGTCCT, and reverse; 5’-
GGTAGTTCACAGCATAGTACTT); Hdac2 flox or WT (forward; 5’-
CCCTTTAGGTGTGAGTACAT, and reverse; 5’-rev: AACCTGGAGAGGACAGCAAA); 
Hdac2 KO (forward; 5’-CCACAGGGAAAAGGAAACAA, and reverse; 5’-
AACCTGGAGAGGACAGCAAA). Eµ-myc tg (forward; 5’-TCCAGGGTACATGGCGTATT; 
and reverse; 5’-TCGGCTGAACTGTGTTCTTG), based on previously published insertion site 
of c-myc [46]. Mb1-cre tg (forward; 5’-GGGAAGAAAGAGGCCATAGG; and reverse, 5’-
TCCCTCACATCCTCAGGTTC). Actin-Cre tg (forward; 5’-
GCGGTCTGGCAGTAAAAACTATC; and reverse, 5’-CAGAGACGGAAATCCATCGCTC). 
PCRs were performed using the GoTaq Flexi DNA Polymerase Kit (Promega, Cat.M8306) and 
MJ Mini Thermal Cyclers (BioRad).  
 
RNA isolation and qRT–PCR. Total RNA was isolated using an RNeasy Mini kit (Qiagen) 
followed by cDNA synthesis using Improm Reverse Transcriptase (RT) Kit (Promega) according 
to the manufacturer’s protocol. 5-10 ng of cDNA were used to perform Semiquantitative real-
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time PCR using MESA GREEN qPCR MasterMix Plus for SYBR Assay (Eurogentec) on an 
ABI PRISM7000 Sequence Detection System (Applied Biosytems). Each reported value is an 
average of three independent experiments. Relative expression levels were determined by 
normalizing to gapdh expression using the ΔΔCt method. The following primers were used: for 
c-myc (forward; 5’-TTTGTCTATTTGGGGACAGTGTT; and reverse; 5’-
CATCGTCGTGGCTGTCTG); for Gapdh (forward; 5’-GCCTCGTCCCGTAGACAAAAT; and 
reverse; 5’-TTCCCATTCTCGGCCTTGA).  
 
Kaplan-Meyer (KPLM) tumor-free survival analysis. Tumor development was monitored 
every 2-3 days by palpation of cervical, axillary, and inguinal regions for characteristic “water 
wing” appearance described for Eµ-myc tg mice [37]. Typically, moribund mice presented with 
several of the following visible features: enlarged lymph nodes, hunched posture, dyspnea, 
weight loss, ruffled coats, paralysis, and immobility. Mice were monitored over a period of 300 
days for tumor onset and sacrificed when moribund, or reaching tumor-specific endpoints 
(lymph nodes>1cm). For moribund mice without tumors, the date of euthanasia was used as the 
date of death in survival studies. Tumors were isolated, weighted, and prepared for 
histopathology or protein and RNA extraction. The survival rate was calculated using the 
Kaplan-Meier method, using R (R Project for Statistical Computing).  
 
Blood sampling and analysis. Mice were bled at 4 and 8 weeks and blood was collected in 
EDTA pre-coated tubes. Samples were analyzed utilizing a fully automated hematology analyzer 
(Sysmex XT-2000i).  
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Histopathological analysis. Biopsies were formalin-fixed (Shandon Formal-Fixx, Thermo 
Scientific) for 24h, dehydrated, paraffin-embedded, cut into 3-µm-thick sections, and stained 
with hematoxylin and eosin (Merck). Pathological analysis was performed according to the 
Bethesda proposals for classification of lymphoid neoplasms in mice [38].  
 
Cell preparation. Single cell suspensions were prepared from BMs by flushing tibia and femur 
with PBS supplemented with 3% fetal bovine serum. Single-cell suspensions from spleen and 
lymph nodes were prepared by squeezing splenocytes and lymphocytes from their capsule 
through a 40-µm nylon mesh of the cell strainer. Peripheral blood was obtained by venous 
puncture or at autopsy by cardiac puncture. Red blood cells were depleted by lysis in Gey’s 
solution prior to staining. 
 
Immunofluorescent staining and flow cytometric analysis. Flow cytometry was done 
according to standard procedures [30]. The following directly conjugated antibodies were used: 
anti-CD45R/B220-FITC (clone RA3-6B2), anti-CD25-PE (clone PC61), anti-IgM-APC (clone 
II/41), anti-IgD-BV605 (clone 11-26c.2a), were all purchase from BD Biosciences; anti-
CD117/c-kit-APC (clone 2B8, eBioscience); and anti-CD19-PE-Cy7 (clone 6D5, Biolegend). All 
flow cytometry analyses were performed using a multicolor BD LSRII Flow Cytometer (Becton 
Dickinson). Data were analyzed using Flow-Jo (Tree Star) software.  
 
B cell isolation by magnetic-activated cell sorting (MACS). Separation of B cells was 
performed using positive selection with CD19 monoclonal antibodies coupled to magnetic 
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microbeads (anti-CD19 MicroBeads) according to the manufacturer’s protocol (MACS, Miltenyi 
Biotec). Control flow cytometry from MACS separated cells revealed 95% purity.  
 
In vivo cell cycle analysis by bromodeoxyuridine (BrdU) incorporation. For in vivo BrdU 
incorporation, mice were injected intraperitoneally with 1.5 mg of BrdU solution (10 mg/mL; 
BD Bioscience) and sacrificed 24 hours later. BrdU staining was performed according to the 
manufacturer’s protocol (BD Bioscience). BM cells were analyzed by flow cytometry. 
Percentages of cells in G0/G1-, S-, and G2/M-phases of the cell cycle were determined by manual 
gating.  
 
Apoptosis assay. Apoptotic lymphocytes were determined using an antibody against AnnexinV 
conjugated to FITC (AnnexinV apoptosis detection kit, BD Biosciences) and DAPI (Sigma) 
counterstain, following the manufacturer’s protocol. Percentages of apoptotic cell (FITC+, DAPI-
) were determined by manual gating.  
 
Protein extracts and Western blot analysis. Cells were harvested in cold RIPA buffer 
containing 50mM Tris, 150 mM sodium chloride, 1% Nonidet P-40, 0.25% sodium 
deoxycholate, 1mM EDTA, 0.1% SDS and protease inhibitors (Roche). Protein concentrations 
were determined by Bradford assay, and equal amounts of protein (20 ug) were loaded on 4-12% 
NuPAGE Bis-Tris Mini Gels (life technologies) separated on SDS–PAGE followed by transfer 
onto a PVDF transfer membrane (Immobilon-P, Milipore). The following antibodies were used: 
anti-mouse actin (ab5, Neo Markers), anti-mouse Hdac1 and anti-mouse Hdac2 (provided by Dr. 
Christian Seiser, Biocenter, Vienna) [47]. Antibodies were diluted 1:1,000. 
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In vitro Hdac-activity assay. Global Hdac activity was measured with the Fluor-de-Lys Hdac 
assay kit (Enzo; BML-KI104-0050) according to the manufacturer's protocol. Fluorescence 
intensity was detected with Spectromax Gemini plate reader (Molecular Devices). 
 
Eµ-myc lymphoma transplantation. Syngeneic C57BL/6 recipient mice (The Jackson 
Laboratory; B6.SJL-Ptprca Pepcb/BoyJ) were sub-lethally irradiated (350 cGy whole-body γ-
irradiation) using a Rad-source RS2000 irradiator (1.2 Gy/min) and transplanted intra-venously 
with 2.5×105 thawed cryopreserved lymph node-derived tumor cells from Hdac1F/F;Hdac2F/F, 
Actin-creER tg, Eµ-myc tg donor mice, as previously described [36, 48]. Recipient mice were 
treated with neomycin-supplemented drinking water (2 mg/ml; sigma) 1 week before, and 2 
weeks post transplantation. 14 days post transplantation, conditional KO was induced by 
intraperitoneal injection of 4-hydroxytamoxifen (4-OHT; 5x 2mg). Control mice were injected 
with vehicle control (ethanol). Mice were monitored for tumor onset and sacrificed when they 
reached termination criteria as described above.  
 
Oncomine and CCLE database analysis. Human Hdac1 (HDAC1) and human Hdac2 
(HDAC2) mRNA expression levels were compared in human tumor samples and human cancer 
cell lines using the publicly available databases Oncomine (http://www.oncomine.org) and 
Cancer Cell Line Encyclopedia (CCLE), respectively [49, 50] [51]. 
 
Statistical analysis. Data are represented as mean ±s.e.m. (standart error measurement of mean). 
For all analyses, several independent experiments (N≥ 3) were carried out. Student’s unpaired 2-
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tailed t-tests were performed for all analyses using Microsoft Excel. Statistical significance was 
determined by p values: N.S. p >0.05, *p <0.05, **p <0.01. Statistical analysis of the KPLM 
survival curves was done using the log-rank test in R (www.r-project.org).  
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1.1. Figures			Figure	legends	
 
Figure 1: Hdac1 and Hdac2 have no tumor suppressor function in B cells. (A) KPLM 
tumor-free survival curves for 15 age-matched mice are shown with indicated genotypes. Eµ-
myc tg mice are shown as control. Mice were monitored over a period of 300 days for tumor 
onset and sacrificed when they reached termination criteria (see Material and Methods). (B) 
Table summarizing histopathological analysis from spleen and lymph nodes of Hdac1 and/or 
Hdac2 KO mice with indicated genotypes at 8, 20, and 40 weeks. n=4-10 as indicated, N.A. for 
not analyzed.  
 
Figure 2: Eµ-myc tumorigenesis is Hdac1 and Hdac2 gene dose-dependent. (A) Kaplan-
Meier tumor-free survival curves are shown for 15 age-matched mice with indicated genotypes. 
The log-rank test was used to determine the level of significance between curves in the KPLM 
plots. Significant differences between genotypes are indicated, *p < 0.05; **, p < 0.01. N.S., not 
statistically significant. (B) Tumor incidence (%; upper panel), and mean overall survival (days; 
lower panel), according to indicated Hdac1 and Hdac2 genotypes. Bar plots show values 
extracted from panel A. 
 
Figure 3: Complete Hdac1 and Hdac2 ablation prevents Eµ-myc tumorigenesis. All 
experiments were performed in 8-week-old mice. (A) Boxplot shows relative spleen weight (% 
of body weight) of mice with indicated genotypes. p-values were generated using Wilcoxon 
Signed-Rank Test (n=11). (B) Representative pictures from histopathological analysis of 
Results	 	 Pillonel	et	al.,	Accepted	for	publication	in	Sci	Rep.		
85 
 
hematoxylin and eosin stained spleen sections of Eµ-myc mice with indicated genotypes and 
healthy Hdac1+/+;Hdac2+/+ control. Original magnification of 4X and 10X as indicated (left 
panel). Pathological findings of HG-NHL were scored in spleen and lymph nodes and 
summarized (table, right panel, n=10). p-value was calculated using Student unpaired 2-tailed t 
test. (C) Blood analysis with automated blood analyzer. Percentage (%) of PBL of indicated 
genotypes (n≥10). p-value calculated with Wilcoxon Signed-Rank Test. (D-F) Eµ-myc BM cells 
from mice with indicated genotypes were stained with B cell surface marker-specific antibodies, 
including B220, IgM, CD19 and CD25, and analyzed by flow cytometry. (D) Schematic 
representation of wild-type BM profile: B220/IgM to distinguish between Pro/preB (B220+; IgM-
), immatureB (B220low;IgM+), transitional B (B220+;IgM+) and mature B (B220high;IgM+) cells 
(upper panels). CD19/CD25 to identify PreBII cell subset (B220+;CD19+; CD25+; lover panels). 
(E) Representative flow cytometry dot plots of B220/IgM staining gated on total BM 
lymphocytes. Gated regions indicate B cell subsets of interest with frequency in percent. (F) 
Representative flow cytometry dot plots showing PreBII lymphocytes subsets. (G) 
Quantification of flow cytometry analysis from (E-F; n=4-6 biological replicates). Average 
percentage of B cells (B220+) and PreBII cells represented with s.e.m. Statistical analysis was 
performed with Student unpaired 2-tailed t test. Significant differences in means between 
genotypes are indicated, *p < 0.05; **, p < 0.01. N.S., not statistically significant.  
 
Figure 4: Conditional ablation of Hdac1 and Hdac2 in Eµ-myc tumor cells delays tumor 
appearance in vivo. (A) Experimental workflow scheme for transplantation experiments. Wild-
type syngeneic recipient mice were sub-lethally irradiated (350 cGy of whole-body γ-irradiation) 
and transplanted intra-venously with lymph node-derived tumor cells from Hdac1F/F;Hdac2F/F; 
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Actin-creER tg; Eµ-myc tg mice after development of overt malignancy. Recipient mice were 
treated with neomycin-supplemented drinking water 1 week before transplantation and up to 2 
weeks post transplantation. At two weeks post transplantation, conditional KO was induced in 
one group of mice by intraperitoneal injection of 4-hydroxytamoxifen (4-OHT, 5x 2mg). Control 
mice were injected with vehicle. Mice were monitored for tumor onset and sacrificed when they 
reached termination criteria (see Material and Methods). (B) KPLM tumor-free survival curves 
of mice transplanted with tumor cells and treated with 4-OHT (n=6) or vehicle (Ctr, n=4) are 
shown. Survival is plotted as days post transplantation. The log-rank test was used to determine 
the level of significance between curves in the two groups.  
 
Figure 5: Hdac1Δ/Δ;Hdac2Δ/+ Eµ-myc mice have delayed tumorigenesis. All experiments were 
performed in 8-week-old lymphoma-free mice. (A-B) BM cells obtained from 8-week old Eµ-
myc mice with indicated genotypes were stained with B cell surface marker-specific antibodies, 
including B220, IgM, CD19 and c-kit, and analyzed by flow cytometry (representative dot plots 
are shown). (A) Representative flow cytometry dot plots gated on total BM lymphocytes. Gated 
regions indicate B cell subsets of interest with frequency in percent. Pro/preB cell subset (B220+; 
IgM-) is indicated (red gate, upper panels). Gated PreBI (B220+;c-kit+; CD19+) and PreBII 
(B220+;CD19+; c-kit-) cell populations are indicated (lower panels). (B) Quantification of flow 
cytometry analysis with s.e.m. (n=3 biological replicates). Average percentage of B cells (B220+) 
and Pro/PreB cells (upper plots), and PreBI and PreBII (lower plots). Statistical analysis was 
performed with Student unpaired 2-tailed t test. (C) Blood was analyzed with automated blood 
analyzer. Shown are box plots with frequency (%) of PBL from indicated genotypes (n=10). p-
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value calculated with the Wilcoxon Signed-Rank Test. Significant differences are indicated, *p < 
0.05; **, p < 0.01. N.S., not statistically significant.  
 
Figure 6: Hdac1 has a predominant role in non-malignant B cells. All experiments were 
performed in 8-week-old animals. (A) Representative flow cytometry dot plots of B220/IgM 
staining, gated on B220+ lymphocytes derived from BM of mice with indicated genotypes. Gated 
regions in dot plots indicate B cell subsets of interest with frequency in percent: Pro/preB 
(B220+; IgM-), ImmatureB (B220low;IgM+), Transitional B (B220+;IgM+) and mature B 
(B220high;IgM+) cells. (B) Quantification of flow cytometry analysis shown in (A). Bar plots 
represent average numbers of cells (gated 50,000 lymphocytes) from the different B lymphocyte 
subsets in the BM. (C) Quantification of flow cytometry analysis shown in (A). Average 
numbers of absolute PreBII cells. (D) Global Hdac-activity assay performed in CD19+ MACS 
sorted B cells from BM of mice with indicated genotypes. Values are shown in Relative 
Fluorescence Units (RFU) relative to control Hdac1+/+;Hdac2+/+ cells. (E) Immunoblot analysis 
of Hdac1 and Hdac2 expression, and actin as loading control from CD19+ MACS sorted splenic 
B cells derived from mice with indicated genotypes. The cropped blots originate from a single 
blot for each protein. The full-length blots are presented in Supplementary Figure 7. All graphs 
represent mean ± s.e.m. from 3 mice of each genotype. Statistical analysis with Student unpaired 
2-tailed t test, *p < 0.05; **, p < 0.01. N.S., not statistically significant. 
 
Figure 7: Hdac1Δ/Δ;Hdac2Δ/+ impact on proliferation and apoptosis. Experiments were 
performed in 8-week-old lymphoma-free mice. (A-B) Proliferation analysis by flow cytometry 
from BM B cells of mice with indicated genotypes injected with BrdU. (A) Representative flow 
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cytometry dot plots from indicated genotypes. Gated regions indicate B220+;BrdU+ cycling B 
cells with frequency in percent. (B) Quantification from flow cytometry analysis with mean and 
s.e.m. of BrdU-positive B cells is shown. (C-D) BM cells isolated from Hdac1+/+;Hdac2+/+ and 
Hdac1Δ/Δ;Hdac2Δ/+ Eµ-myc mice and stained with Annexin V, DAPI and B cell surface markers 
for flow cytometry analysis. (C) Representative flow cytometry dot plots from apoptosis assay: 
viable B cells (P5; annexinV- DAPI-), apoptotic B cells (P6; annexinV+ DAPI-) cells, and dead 
cells (P7; annexinV+ DAPI+). (D) Quantification of figure (C). Mean percentages and standard 
deviations are shown. All statistical analysis were performed with the Student unpaired 2-tailed t 
test. Significant differences in means between genotypes are indicated, *p < 0.05.  
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1.2. Supplentary	Figures	
 Supplementary	Figure	legends	
 
 
Supplementary Figure 1: B cell specific deletion of Hdac1 and Hdac2. (A) PCR genotyping 
for Hdac1 and Hdac2 wild-type (WT), flox (FL), and knockout (KO) allele and mb1-cre 
transgene (tg). PCR was performed from mouse tails and CD19+ MACS sorted splenic B cells 
from 8-week-old mice with indicated genotypes. Specific allele annotations are to the left of the 
gel. Size marker (M) is indicated.  
 
Supplementary Figure 2: Analysis of Eµ-myc tg mice lacking Hdac1 and/or Hdac2 in B 
lymphocytes. (A) Schematic representation of the breeding setup to generate Eµ-myc tg mice 
lacking Hdac1 and/or Hdac2 in B cells. Hdac1 and Hdac2 Floxed (F), WT (+) and knockout (Δ) 
alleles and transgenes (tg) are indicated. Red circle represents visibly enlarged and palpable 
lymph nodes scored in the KPLM. (B) Schematic representation illustrating the key steps of B 
cell development in the bone marrow (BM) with the expression of the different cell surface 
markers listed below. Curved arrows indicate cells in cell cycle. c-myc expression in the Eµ-myc 
tg mouse and mb1 expression in the Mb1-cre tg mouse is shown above. (C) B lymphocytes from 
isolated from 8-week-old WT and Eµ-myc tg mice were FACS sorted for indicated B cell 
developmental stages and quantitative real-time PCR (RT-qPCR) was performed for c-myc. Data 
represents means ± s.e.m. (n=3). (D) Development of pathologic diseased stage in Eµ-myc tg 
mice. Representative picture of dissected enlarged inguinal lymph nodes (LN), spleen (S), and 
thymus (T) of Eµ-myc tg Hdac1+/+;Hdac2+/+, and control WT (Hdac1+/+;Hdac2+/+) mice at 
termination criteria of 1cm LN for KPLM analysis.  
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Supplementary Figure 3: Predominant overexpression of HDAC1, but not HDAC2, in BL 
and DLBCL compared to other cancers. Search for HDAC1 and HDAC2 mRNA expression 
of human lymphomas with the focus on diffuse large B-cell lymphoma (DLBCL) and Burkitt’s 
lymphomas (BL), two myc-driven B cell lymphomas. Online, publically available databases were 
used. Cancer Cell Line Encyclopedia (CCLE) (www.broadinstitute.org) was used to screen for 
HDAC1 (A) and HDAC2 (B) mRNA expression in tumor cell lines. Extracted mRNA expression 
levels (log2 scale) are shown. Gene expression profiles of HDAC1 (C) and HDAC2 (D), 
analyzed on Oncomine microarray database. Analysis of HDAC1 and HDAC2 mRNA levels in 
lymphoma tissues vs. other cancers (Ramaswamy Multi-cancer statistic datasets).  
 
Supplementary Figure 4: Loss of Hdac1 (Hdac1Δ/Δ;Hdac2+/+) has no impact on PBL at 10 
weeks and 20 weeks in Eµ-myc mice. Mice were bled at 10 and 20 week of age and blood was 
analyzed in an automated blood analyzer, (Sysmex XT-2000). Hdac1Δ/Δ;Hdac2+/+ Eµ-myc mice 
had no significant difference in PBL counts at (A) 10 and (B) 20 weeks compared to control 
Hdac1+/+;Hdac2+/+ Eµ-myc mice. Shown are detailed analysis of different Hdac1 knockout 
animals with or without Eµ-myc at 10 and 20, weeks (n≥10). Frequency (%) of PBL of indicated. 
p-value calculated with the Wilcoxon Signed-Rank Test. Significant differences in means is 
indicated, **p < 0.01; N.S. for not statistically significant.  
 
Supplementary Figure 5: Hdac1 and Hdac2 are not deleted in tumors arising in 4-OHT 
treated transplanted mice.  (A) In vivo conditional ablation of Hdac1 and Hdac2 using the 
CreER-LoxP system inducible with tamoxifen (4-OHT) treatment in Hdac1F/F;Hdac2F/F; 
ActinCre tg mice. Recombination was not 100%, since Hdac1 (and Hdac2) floxed alleles did not 
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disappear completely. (B) Representative PCR genotyping of tumors from control (Ctr) and 
tamoxifen (4-OHT) treated transplanted mice. Control Hdac1 and Hdac2 KO PCR from 
Hdac1Δ/Δ;Hdac2Δ/Δ mice is included. PCR genotyping for Hdac1 and Hdac2 wild type (WT), 
floxed (FL) and knockout (KO) alleles are indicated to the left of each gel. PCR for Hdac1, 
Hdac2 and Eµ-myc are to the left of each gels. (C) Hdac1 and Hdac2 are expressed in tumors 
from 4-OHT treated transplanted mice. Immunohistochemistry (IHC) of tumors from Ctr and 4-
OHT treated transplanted mice (splenic sections). (D) Control IHC experiment for Hdac1, Hdac2 
and c-Myc antibodies using Hdac1Δ/Δ;Hdac2+/+ Eµ-myc mice, Hdac1+/+;Hdac2Δ/Δ Eµ-myc mice 
and Hdac1+/+;Hdac2+/+ Eµ-myc mice from serial splenic sections stained for c-Myc, Hdac1, and 
Hdac2.  
 
Supplementary Figure 6: Hdac1Δ/Δ;Hdac2Δ/+ mice have normal numbers of mature B cells 
in the spleen. (A) Spleen cells were obtained from 8-week old mice with indicated genotypes 
and stained with B cell surface marker-specific antibodies, including B220, IgM and IgD and 
analyzed by flow cytometry. Quantification of flow cytometry analysis with s.e.m. (n=3 
biological replicates). Average number of absolute B cells (B220+, IgM+, IgD+) are shown in bar 
plots. Statistical analysis was performed with Student unpaired 2-tailed t test. N.S., not 
statistically significant.  
 
Supplementary Figure 7: Full-length immunoblots of Hdac1 and Hdac2 expression. 
Immunoblots for (A) Hdac1, (B) Hdac2, and (C) actin are shown. (C) Hdac1 blot was stripped 
and reblotted for actin (see residual Hdac1 bands). Mice genotypes are indicated below. 
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Molecular size marker is shown in the first row of each gel. Protein of interest is indicated on the 
right of each gel.  
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Supplementary	methods	
 
Immunohistochemistry	(IHC)	
Immunohistochemistry experiments were performed on Ventana DiscoveryUltra instrument 
(Roche Diagnostics, Manheim) with the procedure RUO Discovery Universal. CC1 (Roche 
Diagnostics, Manheim) pre-treatment was used for anti-HDAC1, -HDAC2, and -c-Myc 
antibodies with the following incubation times: 16, 24, and 72 min respectively. Antibodies were 
incubated for one hour at 37°C except for anti-c-Myc which was incubated for 16 min. In 
addition, a blocking step (Innovex Background Buster NB306, Innovex, 12 min incubation) was 
added for anti-HDAC1 and -HDAC2 antibodies. Detection of bound anti-HDAC1, -HDAC2 and 
-c-Myc antibodies was achieved by using anti-rabbit HQ followed by anti-HQ horseradish 
peroxidase (Roche Diagnostics, Manheim) incubated for 32 min at 37°C. ChromoMap DAB kit 
(Roche Diagnostics, Manheim) was used for the detection and slides were counterstained with 
Hematoxylin II and Bluing Reagent (Roche Diagnostics, Manheim) for 8 min. Hdac1 and Hdac2 
staining were used to confirm the genotype of the lymphoma.  
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Results	Part2:	Supplementary	findings	on	the	role	of	Hdac1	and	Hdac2	in	
Eµ-myc	B	cell	lymphoma	 
2.1. Supplementary	results		
Old	Hdac1Δ/Δ;Hdac2+/+	mice	do	not	develop	spontaneous	tumors	
As previously shown, Hdac1 and Hdac2 have no tumor suppressor function in B cells (Figure 1). 
To further validate our observation, we analyzed more extensively old Hdac1Δ/Δ;Hdac2+/+ mice. 
We first assessed whether 20- and 70 week-old Hdac1Δ/Δ;Hdac2+/+ animals had any enlarged 
lymphoid organs, including SP, LN and Thymus (Thy) compared to control Hdac1+/+;Hdac2+/+ 
mice. Consistent with our previous findings (Figure 1), we observed that old Hdac1Δ/Δ;Hdac2+/+ 
mice had normal SP and LN weights at 20 weeks (Suppl. Figure 4A). Similarly, SP, LN, and 
thymus weights were normal in 70-week-old Hdac1Δ/Δ;Hdac2+/+ mice. We then determined by 
flow cytometry the percentage of large B220+ subset of cells in the BM, which is massively 
elevated in Eµ-myc mice. We observed, that 20-week-old Hdac1Δ/Δ;Hdac2+/+ mice have normal 
large B220+ cell number in the BM compared to control Hdac1+/+;Hdac2+/+ mice. These results 
are consistent with our findings described in Figure 1 and confirm that mice with B cell specific 
Hdac1Δ/Δ;Hdac2+/+ do not develop spontaneous tumors.  
 
Hdac1	and	Hdac2	have	no	tumor	suppressor	function	in	B	cells	
As previously shown (Suppl. Figure 1B), Jdp2 is not de-repressed in Hdac1 and/or Hdac2 B cell 
KOs in contrast to T cell specific KO (Heideman et al., 2013). We further assessed Jdp2 
expression in mice with only one allele of Hdac2 (Hdac1Δ/Δ;Hdac2Δ/+), since these mice were 
shown to develop spontaneous tumors with the highest frequency in T cell specific KO 
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(Heideman et al., 2013). To test this, we measured by RT-qPCR analysis the Jdp2 gene 
transcripts in 8-week-old Hdac1Δ/Δ;Hdac2Δ/+ and control Hdac1+/+;Hdac2+/+ CD19+ MACS 
sorted B lymphocytes. In contrast to T cell specific KO, but consistent with the previously shown 
microarray in B cells (Suppl. Figure 1B), we did not observe any change in Jdp2 expression in B 
cell specific Hdac1Δ/Δ;Hdac2Δ/+ cells (Suppl. Figure 5A, preliminary results). Taken together, 
our results shows, that Hdac1 and Hdac2 do not regulate this gene in B cells. This is in contrast 
to T cells where Hdac1 and Hdac2 regulate p53-dependent barrier to constrain myc-
overexpressing thymocytes from progressing into lymphomas by regulating Myc-collaborating 
genes like Jdp2 (Heideman et al., 2013). It was previously reported, that most tumors found in 
Eµ-myc mice display a disruption of the p19ARF-MDM2-p53 tumor suppressor pathway, and p53 
mutations are the most frequent event in this model (Eischen et al., 1999). Inactivation of the p53 
pathway can occur through inactivating p53 mutations, which results in high p53 levels and 
stabilized, but inactive p53 protein (Eischen et al., 1999). In T cells, Hdac1Δ/Δ;Hdac2Δ/+ results in 
spontaneous lymphomagenesis with tumors having low p53 levels due to de-repression of the 
p53 repressor Jdp2 (Heideman et al., 2013). In B cells, Hdac1Δ/Δ;Hdac2Δ/+ does not result in 
spontaneous lymphomagenesis (Figure 1) and Jdp2 is not de-repressed (Suppl. Figure 5A). 
Hence, if Hdac1Δ/Δ;Hdac2Δ/+ does not affect p53 in B cells, we would expect to have similar p53 
levels in Eµ-myc Hdac1Δ/Δ;Hdac2Δ/+ tumors vs. control Eµ-myc Hdac1+/+;Hdac2+/+ tumors. In 
contrast, if Hdac1Δ/Δ;Hdac2Δ/+ would affect p53 we would expect to see less p53 positive Eµ-
myc Hdac1Δ/Δ;Hdac2Δ/+ tumors as previously reported in T cell specific Hdac1Δ/Δ;Hdac2Δ/+ 
(Heideman et al., 2013). We therefore performed Immunohistochemistry (IHC) staining for p53 
in Eµ-myc Hdac1Δ/Δ;Hdac2Δ/+ tumors and control Eµ-myc Hdac1+/+;Hdac2+/+ tumors. We 
observed, that p53 was strongly expressed in all Eµ-myc tumor samples (Suppl. Figure 5C), 
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suggesting for stabilized/mutant p53 disrupting the p53 tumor suppressor function. Interestingly, 
Eµ-myc Hdac1Δ/Δ;Hdac2Δ/+ tumors had also high p53 expression (Suppl. Figure 5C), with 
similar intensity and frequency compared to control Eµ-myc Hdac1+/+;Hdac2+/+ tumors (Suppl. 
Figure 5D). Hence, this suggests, that p53 is mutated in Eµ-myc Hdac1Δ/Δ;Hdac2Δ/+ tumors to 
circumvent p53 induced apoptosis, thereby enabling tumorigenesis. This is consistent with our 
previous findings (Suppl. Figure 1 and Suppl. Figure 5A), and suggest that in B cells Hdac1 and 
Hdac2 do not impact on p53 via Jdp2 like in T cells (Heideman et al., 2013). Therefore, we 
propose, that in B cells, Hdac1 and Hdac2 do not impact on p53 tumor suppressor pathway via 
Jdp2 (Suppl. Figure 5B). Our data collectively show, that Hdac1 and Hdac2 do not have any 
tumor-suppressor function in B cells.  
 
Development	of	pathologic	diseased	state	in	Eµ-myc	tg	mice	
In complement to Suppl. Figure 2, we further analyzed Eµ-myc mice by histopathology from 
H&E-stained sections taken from a terminally ill Eµ-myc Hdac1+/+;Hdac2+/+ animal. We 
observed, that Eµ-myc Hdac1+/+;Hdac2+/+ mice had marked enlarged spleen (S), thymus (T), 
lymph nodes (LN) due to infiltration of neoplastic cells. The form and architecture of these 
organs was also altered (Suppl. Figure 6A). Further analysis demonstrated, that Eµ-myc 
Hdac1+/+;Hdac2+/+ mice have infiltration of tumor cells into the peripheral organs which is 
indicative of disseminated disease (Suppl. Figure 6B). SP and mandibular LN of Eµ-myc 
Hdac1+/+;Hdac2+/+ mice were enlarged and had destroyed architecture due to diffuse infiltration 
by neoplastic lymphocytes. These mice also had neoplastic cell infiltration into: liver, 
myocardium of the heart, submucosa of the urinary bladder, pelvis of the kidney, all layers of the 
small intestine, duodenum (mucosa, submucosa, muscular layer and serosa), as well as stomach 
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mucosa (Suppl. Figure 6B). These data show that our Eµ-myc mice develop multicentric 
lymphosarcomas which is consistent with the previous description of the Eµ-myc tg mouse 
(Adams et al., 1985; Harris et al., 1988; Langdon et al., 1986).  
 
Eµ-myc	mice	have	a	trend	to	slightly	increased	Hdac1	and	Hdac2	expression	levels	
In complement to Figure 2 and Suppl. Figure 2, we analyze by quantitative real-time PCR (RT-
qPCR) Hdac1 and Hdac2 expression in Eµ-myc mice. Interestingly, we found that Eµ-myc mice 
have a trend to slightly increased Hdac1 and Hdac2 expression levels in the cells of most B cell 
developmental stages (Suppl. Figure 7A).  
 
Loss	of	both,	Hdac1	and	Hdac2	(Hdac1Δ/Δ;Hdac2Δ/Δ)	reduces	leukemia	in	Eµ-myc	mice	
We showed that Hdac1Δ/Δ;Hdac2Δ/Δ reduces leukemia in Eµ-myc mice (Figure 3C). In 
complement to these data we further performed a detailed blood analysis in Eµ-myc mice 
lacking Hdac1 and/or Hdac2 at 4 and 10 (Suppl. Figure 8). We found, that Eµ-myc 
Hdac1Δ/Δ;Hdac2Δ/Δ mice had significantly lower PBL counts at 4 and 10 weeks compared to 
control Eµ-myc Hdac1+/+;Hdac2+/+ mice (Suppl. Figure 8B). Interestingly, we observed that 
Hdac1Δ/Δ;Hdac2+/+ mice had reduced PBL only at 4 but not at 10 weeks (Suppl. Figure 8B). 
These results are consistent with our observation that only ablation of both, Hdac1 and Hdac2 
prevents tumorigenesis, whereas ablation of either Hdac1 or Hdac2 had no major effects.  
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Only	ablation	of	both,	but	not	single	Hdac1	and	Hdac2,	prevents	B	cell	blast	 in	BM	of	
Eµ-myc	mice	
We previously showed, that only complete Hdac1 and Hdac2 deletion prevents tumorigenesis by 
blocking Eµ-myc induced blast in the BM (Figure 3E-G). Here, in supplement, we show the 
impact of Hdac1Δ/Δ;Hdac2Δ/Δ, Hdac1Δ/Δ;Hdac2+/+ ,and Hdac1+/+;Hdac2Δ/Δ in absence of Eµ-myc 
tg. We further analyzed for comparison Eµ-myc mice with lymphadenopathy that had reached 
endpoint criteria, and with a pathological findings of HG-NHL (indicated by asterisk). We 
measure by flow cytometry the BM B lymphocytes by B220/IgM (Suppl. Figure 9A) and PreBII 
lymphocytes subsets (B220+;CD19+;CD25+) (Suppl. Figure 9B). Quantification of these flow 
cytometry analysis revealed that only ablation of both , Hdac1 and Hdac2 (Hdac1Δ/Δ;Hdac2Δ/Δ) 
resulted in a statistically significant decrease in B lymphocytes (B220+) (Suppl. Figure 9C) and 
PreBII (B220+;CD19+; CD25+) subsets (Suppl. Figure 9D). Hence, ablation of both Hdac1 and 
Hdac2 prevents normal B cell development as we previously reported (Yamaguchi et al., 2010), 
but prevents also Eµ-myc induced blast which dominate the BM of these mice. Some rare 
Hdac1Δ/Δ;Hdac2Δ/Δ mice had tumors and showed the typical Eµ-myc induced blast (Suppl. 
Figure 9A-B). In summary, we conclude, that Hdac1Δ/Δ;Hdac2Δ/Δ prevents tumorigenesis by 
blocking Eµ-myc induced blast at PreBII B cell stage.  
 
Ablation	both,	Hdac1	and	Hdac2	(Hdac1Δ/Δ;Hdac2Δ/Δ)	is	required	to	reduce	tumor	cell	
load	
We demonstrated that Hdac1Δ/Δ;Hdac2Δ/Δ prevents tumorigenesis by blocking Eµ-myc induced B 
cell blasts at PreBII cell stage (Figure 3F). We further assessed the tumor cell load in a different 
way by quantifying the large lymphocyte subset as well as the B220low population, which are 
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characteristically highly overrepresented in Eµ-myc mice (Croxford et al., 2013; Langdon et al., 
1986). We first measure by flow cytometry large lymphocyte subsets in BM. Consistently, with 
the results previously observed, we found that Hdac1Δ/Δ;Hdac2Δ/Δ significantly reduced the 
percentage of large lymphocyte subset in BM of Eµ-myc mice (Suppl. Figure 10A). Rare Eµ-myc 
Hdac1Δ/Δ;Hdac2Δ/Δ mice, which developed end stage tumors (indicated with red asterisks), had 
almost only large lymphocytes similar to control Eµ-myc Hdac1+/+;Hdac2+/+ tumor mice. 
Malignant cells in Eµ-myc tg mice express B220 at a low level (B220low) (Croxford et al., 2013). 
Hence, we analyzed by flow cytometry B220low cells populations in in BM, SP, and LN, and 
blood (BL) of Eµ-myc Hdac1+/+;Hdac2+/+ mice compared to wild type (Hdac1+/+;Hdac2+/+) 
control animals (Suppl. Figure 10B-D). Consistent with previously published data, we observed, 
that Eµ-myc Hdac1+/+;Hdac2+/+ mice had massive increase in B220low cells population in all 
these organs (Suppl. Figure 10B). Quantification revealed a significant increase in B220low cells 
population in Eµ-myc Hdac1+/+;Hdac2+/+ compared to control Hdac1+/+;Hdac2+/+ mice (Suppl. 
Figure 10B). We next determined the effect of Hdac1 and/or Hdac2 ablation on B220low cells 
population in BM, SP, and LN. Ablation of Hdac1 (Hdac1Δ/Δ;Hdac2+/+) or Hdac2 
(Hdac1+/+;Hdac2Δ/Δ) had no effect, but ablation of both enzymes (Hdac1Δ/Δ;Hdac2Δ/Δ) massively 
reduced B220low cells population (Suppl. Figure 10D). Quantification revealed no significant 
changes in B220low cells population comparing Eµ-myc Hdac1+/+;Hdac2+/+ mice to Eµ-myc mice 
lacking either Hdac1 (Hdac1Δ/Δ;Hdac2+/+) or Hdac2 (Hdac1+/+;Hdac2Δ/Δ) (Suppl. Figure 10C). 
Collectively, these data presented here demonstrate, that ablation both, Hdac1 and Hdac2 is 
required to reduce tumor cell load.  
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Hdac1Δ/Δ;Hdac2Δ/Δ	 induced	a	B	 cell	 developmental	 block	 in	 the	BM	 that	 prevents	 Eµ-
myc	tumorigenesis	
We previously showed, that Hdac1Δ/Δ;Hdac2Δ/Δ prevents tumorigenesis by blocking Eµ-myc 
induced blast in the BM (Figure 3F-G). Here, in supplement, we analyzed the exact impact of 
Hdac1Δ/Δ;Hdac2Δ/Δ not only in Eµ-myc mice, but also in non-Eµ-myc mice, to rule out the effect 
of the Eµ-myc tg. We first performed B220/IgM flow cytometry analysis in the BM, and 
observed that Hdac1Δ/Δ;Hdac2Δ/Δ induced a B cell developmental block in both, Eµ-myc and non 
Eµ-myc tg mice (Suppl. Figure 11A). More precisely, CD19/CD25 flow cytometry revealed that 
this block occured at PreBII (CD25+;CD19+) cell stage (Suppl. Figure 11B). We further analyzed 
SP and LN by B220/IgM flow cytometry and found that Hdac1Δ/Δ;Hdac2Δ/Δ also prevented or 
massively reduced mature B cell populations (B220+;IgM+) in both, Eµ-myc mice, but also in 
non-Eµ-myc mice. Quantification of flow cytometry analysis revealed significant reduction of B 
cells and almost absence of PreBII cells in BM of Eµ-myc Hdac1Δ/Δ;Hdac2Δ/Δ mice, but also in 
Hdac1Δ/Δ;Hdac2Δ/Δ mice (Suppl. Figure 11E). Similarly, quantification SP and LN flow 
cytometry analysis revealed significant reduction and almost absence of mature B cell 
populations upon Hdac1Δ/Δ;Hdac2Δ/Δ in both Eµ-myc and non Eµ-myc mice (Suppl. Figure 11E). 
Thus we conclude, that B cell specific double KO of Hdac1 and Hdac2 (Hdac1Δ/Δ;Hdac2Δ/Δ) 
impairs B cell development in both, non-transgenic and in Eµ-myc tg mice. Hdac1Δ/Δ;Hdac2Δ/Δ 
induces a B cell developmental block in the BM that prevents Eµ-myc tumorigenesis and 
colonization of SP and LN with mature B cells.  
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Rare	Hdac1F/F;Hdac2F/F	Mb1-Cre	tg;	Eµ-myc	animals	are	not	KO	for	Hdac1	and	Hdac2	
and	develop	tumors	
We observed that rare Hdac1F/F;Hdac2F/F Mb1-Cre tg; Eµ-myc animals developed tumors. 
Histopathological analysis from H&E stained tumor sections revealed, a malignant phenotype 
(granulocytic leukemia) (Suppl. Figure 12A). The SP of these Hdac1F/F;Hdac2F/F Mb1-Cre tg; 
Eµ-myc mice had red pulp expanded with neoplastic cells (different than Hdac1+/+;Hdac2+/+ Eµ-
myc phenotype, Suppl. Figure 6). In the decalcified sternum of these mice normal BM was 
replaced by neoplastic cells and the liver was infiltrated with neoplastic cells (Suppl. Figure 
12A). Since we demonstrated, that complete ablation of Hdac1 and Hdac2 prevents 
tumorigenesis (Figure 2 and Figure 3), we hypothesized, that in Hdac1F/F;Hdac2F/F Mb1-Cre tg; 
Eµ-myc animal, Hdac1 and Hdac2 are not completely ablated. To test this hypothesis, we 
performed immunohistochemistry (IHC) analysis from serial splenic sections from 
Hdac1F/F;Hdac2F/F Mb1-cre tg Eµ-myc tumors for c-Myc, Hdac1, and Hdac2. Interestingly, we 
found that these tumors expressed high c-Myc but also Hdac1 and Hdac2 (Suppl. Figure 12B). 
Interestingly, Hdac1F/F;Hdac2F/F Mb1-Cre tg; Eµ-myc animals never had any tumors lacking 
both Hdac1 and Hdac2. Therefore, we speculate, that sporadic deletion due to inefficient cre 
expression or inefficient loxP recombination might underlie this phenotype. Taken together, our 
results indicates, that complete ablation of Hdac1 and Hdac2 is not compatible with development 
and progression of Eµ-myc tg B cells and consequently prevents tumorigenesis. In rare cases, 
Hdac1 and Hdac2 are not efficiently ablated in Hdac1F/F;Hdac2F/F Mb1-Cre tg; Eµ-myc mice 
which then eventually develop tumors.  
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Rare	Hdac1Δ/Δ;Hdac2Δ/Δ	animals	developed	interstitial	pneumonia	
We also observed that rare Hdac1F/F;Hdac2F/F Mb1-Cre tg mice unexpectedly died. We 
investigated the reason of this death by extensive histopathological analysis. We stained several 
organs, including SP, LN, thymus, liver, heart, and lung with H&E. We did not detect any 
pathological sign in any organ, except for the lung. Histopathological analysis of lung samples 
from Hdac1Δ/Δ;Hdac2Δ/Δ and control Hdac1+/+;Hdac2+/+ mice with and without Eµ-myc tg, 
revealed interstitial pneumonia (Suppl. Figure 13). Inflammation sites with infiltration of 
macrophages were clearly visible (Suppl. Figure 13A lover panels). We observed multifocal 
enlargement of alveolar septae due to infiltration of macrophages. Multifocally alveoli were 
filled with foamy exudate mixed with inflammatory cells, including macrophages, lymphocytes 
and neutrophils (Suppl. Figure 13A lover panels). We observed multifocal alveolar inflammatory 
exudate (foamy exudate) infiltrated with protein and liquid as well as massive infiltration of 
inflammatory cells including macrophages mainly (Suppl. Figure 13B). General staining for 
fungus with Grocott staining revealed fungal elements and abundant fungal cysts present within 
the alveolar foamy exudate (Suppl. Figure 13C). In summary, we observed, that rare 
Hdac1Δ/Δ;Hdac2Δ/Δ mice suffer from interstitial pneumonia due to abundant presence of fungal 
elements.  
 
In	vivo	 conditional	ablation	of	Hdac1	and	Hdac2	using	 the	CreER-LoxP	system	 in	Eµ-
myc	tumor	cells	
We showed, that Hdac1 and Hdac2 also have pro-oncogenic roles in tumor progression (Figure 
4). In supplement, we show a schematic representation of the experimental workflow for the 
transplantation experiment (Suppl. Figure 14A). We performed conditional targeted deletion of 
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Hdac1 and Hdac2 in Eµ-myc tumor cells using the tamoxifen inducible CreER-LoxP system. To 
examine whether tamoxifen efficiently induced deletion of both, Hdac1 and Hdac2, we 
performed PCR genotyping for Hdac1 and Hdac2 wild type (WT), floxed (FL) and knockout 
(KO) alleles. Interestingly, we observed, that recombination was not 100%, since Hdac1 (and 
Hdac2) FL alleles did not disappear completely (Suppl. Figure 14B). Importantly, these findings 
are consistent with the data outlined above showing that conditional ablation of Hdac1 and 
Hdac2 in Eµ-myc tumor cells only delays and do not completely prevent tumor appearance 
(Figure 4).  
 
Eµ-myc	 tg	Hdac1Δ/Δ;Hdac2Δ/+	mice	have	 less	 circulating	 leukemic	 cells	but	eventually	
develop	HG-NHL	
As previously shown, Hdac1Δ/Δ;Hdac2Δ/+ significantly delayed Eµ-myc tumor development 
(Figure 2). We further investigated the impact of Hdac1Δ/Δ;Hdac2Δ/+ on Eµ-myc induced 
splenomegaly. We therefore measured SP weights. However, no difference was observed on SP 
weight between Eµ-myc Hdac1Δ/Δ;Hdac2Δ/+ and Eµ-myc Hdac1+/+;Hdac2+/+ mice (Suppl. Figure 
15A). We further determined the impact of Hdac1Δ/Δ;Hdac2Δ/+ on circulating PBL in Eµ-myc 
mice, by analyzing the blood of lymphoma-free Eµ-myc mice using an automated blood cell 
counter. We found, that Hdac1Δ/Δ;Hdac2Δ/+ significantly lowered PBL count in Eµ-myc mice at 8 
weeks (Figure 5C). We further examined the impact of Hdac1Δ/Δ;Hdac2Δ/+ on PBL at 4 weeks, 
and found a similar significant decrease in PBL count (Suppl. Figure 15B). Furthermore, we 
quantified white blood cells (WBC) counts and observed, that Hdac1Δ/Δ;Hdac2Δ/+ significantly 
reduced WBC numbers at 4 and 8 weeks (Suppl. Figure 15C). Hence, we conclude, that 
Hdac1Δ/Δ;Hdac2Δ/+ mice reduces leukemia in Eµ-myc mice at 4 and 8 week of age. We next 
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performed histopathological analysis of Eµ-myc Hdac1Δ/Δ;Hdac2Δ/+ mice, in order to determine 
which type of tumors these mice develop. We compared Eµ-myc Hdac1Δ/Δ;Hdac2Δ/+ mice with 
lymphoma to Hdac1+/+;Hdac2+/+ control mice (Suppl. Figure 15D). All depicted peripheral 
organs, including SP, LN, liver, and thymus (Thy), were enlarged and had destroyed architecture 
du to diffuse infiltration by neoplastic lymphocytes. This state was pathologically diagnosed as 
HG-NHL characteristic for Eµ-myc tg mice. Hence, as expected, Hdac1Δ/Δ;Hdac2Δ/+ Eµ-myc 
mice develop the characteristic pathological state of Eµ-myc mice. Taken together, our results 
demonstrate, that Eµ-myc tg Hdac1Δ/Δ;Hdac2Δ/+ mice have less circulating leukemic cells but 
eventually develop HG-NHL.  
 
Hdac1Δ/Δ;Hdac2Δ/+	impacts	on	Eµ-myc	proliferation	at	the	G1	phase	of	the	cell	cycle	
We previously showed, that Hdac1Δ/Δ;Hdac2Δ/+ decreased proliferation of Eµ-myc B cells 
(Figure 7). We performed in vivo BrdU assays and found, that Eµ-myc Hdac1Δ/Δ;Hdac2Δ/+ B 
cells had massively less incorporation of BrdU compared to Eµ-myc Hdac1+/+;Hdac2+/+ B cells 
(Suppl. Figure 16A). We next investigated which phases of the cell cycle are affected in Eµ-myc 
Hdac1Δ/Δ;Hdac2Δ/+ B cells. Our preliminary data show, that Hdac1Δ/Δ;Hdac2Δ/+ impairs cell 
cycle at G1 phase (Suppl. Figure 16B).  
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2.2. Supplementary	figure	legends		
Suppl.	Figure	4:	Old	Hdac1Δ/Δ;Hdac2+/+	mice	do	not	develop	spontaneous	tumors	
(A) SP and LN organ weight analysis in old Hdac1Δ/Δ;Hdac2+/+ mice. Dot plot showing relative 
organ weights (in % of body weight) from 20-week-old Hdac1+/+;Hdac2+/+ and 
Hdac1Δ/Δ;Hdac2+/+ mice (n=4) and Eµ-myc mice with or without tumors as control (n=1). 
Horizontal bars represent median. Statistical analysis with Wilcoxon Signed-Rank Test. N.S. for 
not statistically significant. (B) SP, LN, and thymus (Thy) weight analysis in 70-week-old 
Hdac1Δ/Δ;Hdac2+/+ mice. Bar plots show relative organ weights (in % of body weight) from 70-
week-old Hdac1+/+;Hdac2+/+ (n=2), Hdac1Δ/Δ;Hdac2+/+ (n=3) and control Eµ-myc 
Hdac1+/+;Hdac2+/+ (n=1) mice. (C) Quantification of flow cytometry analysis from 20-week-old 
mice with indicated genotypes. The bar plots represents the average percentage of large B220+ 
cell. SEM are indicated for the comparison of Hdac1+/+;Hdac2+/+, and Hdac1Δ/Δ;Hdac2+/+mice 
(n=4). The statistical analysis was performed with the Student unpaired 2-tailed t test. N.S. for 
not statistically significant.  
 
Suppl.	Figure	5:	Hdac1	and	Hdac2	have	no	tumor	suppressor	function	in	B	cells	
(A) Jdp2 expression is not affected in B cell specific Hdac1Δ/Δ;Hdac2Δ/+. Jdp2 gene transcript 
abundance was measured by quantitative real-time PCR (RT-qPCR) analysis in CD19+ MACS 
sorted B lymphocytes from 8-week-old Hdac1+/+;Hdac2+/+ and Hdac1Δ/Δ;Hdac2Δ/+ mice. Data 
were normalized to Gapdh and log 2 expression values of Jdp2 mRNA are shown. Data are 
representative of a single experiment using 3 individuals of each genotype (preliminary results). 
The statistical analysis was performed with the Student unpaired 2-tailed t test. N.S. for not 
statistically significant. (B) p53 tumor suppressor pathway and the impact of Hdac1 and Hdac2 
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on p53 regulation in T cells based on previous study by Heideman et al., 2013, showing that 
Hdac1 and Hdac2 regulate p53-dependent barrier to constrain myc-overexpressing thymocytes 
from progressing into lymphomas by regulating Myc-collaborating genes like Jdp2. (C) 
Hdac1Δ/Δ;Hdac2Δ/+ Eµ-myc tumors have high p53 staining, indicating for stabilized/mutant p53. 
Representative pictures of immunohistochemistry (IHC) analysis of p53 expression in 
Hdac1+/+;Hdac2+/+ Eµ-myc and Hdac1Δ/Δ;Hdac2Δ/+ Eµ-myc tumors from spleen (SP). Healthy 
tissue from a Hdac1+/+;Hdac2+/+ mouse is shown as control with and without 1st Ab against p53 
(SP1 and SP2 respectively). (D)Incidence of p53 staining in Hdac1Δ/Δ;Hdac2Δ/+ Eµ-myc tumors 
and control Hdac1+/+;Hdac2+/+ Eµ-myc tumors is comparable. Summary of p53 staining intensity 
of Figure (C). High (++) and medium (+) staining of p53 is present is all samples (n=7).  
 
Suppl.	Figure	6:	Development	of	pathologic	diseased	state	in	Eµ-myc	tg	mice	
(A) Pathological analysis: representative organs from Hdac1+/+;Hdac2+/+ and Eµ-myc 
Hdac1+/+;Hdac2+/+ mice (H&E staining). Eµ-myc mice have marked enlarged spleen (S), thymus 
(T), lymph nodes (LN) (mesenteric) due to infiltration of neoplastic cells. The form and 
architecture of these organs is altered. Shown are transversal cut of organs at 3X magnification. 
(B) Pathological analysis of Eµ-myc mice. H&E-stained sections illustrating infiltration of tumor 
cells into the peripheral organs of the Eµ-myc mice indicative of disseminated disease. Depicted 
are representative sections taken from a terminally ill Eµ-myc Hdac1+/+;Hdac2+/+ animal and 
control Hdac1+/+;Hdac2+/+ mice. Spleen and mandibular LN of Eµ-myc Hdac1+/+;Hdac2+/+ mice 
are enlarged and have destroyed architecture due to diffuse infiltration by neoplastic 
lymphocytes (tumor cells). White pulp (W), red pulp (R). These mice also have neoplastic cell 
infiltration into: the liver, the myocardium (arrow) of the heart, the submucosa of the urinary 
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bladder, the pelvis of the kidney, all layers of the small intestine, the duodenum (mucosa, 
submucosa, muscular layer and serosa), as well as the stomach mucosa (arrow). Epithelial cell 
layer (mucosa) (E), and muscle layer (M). Infiltration of tumor cells are indicated (T). Images 
were taken and processed at Novartis NIBR. Scale bar are indicated.  
 
Suppl.	 Figure	 7:	 Eµ-myc	 mice	 have	 a	 trend	 to	 slightly	 increased	 Hdac1	 and	 Hdac2	
expression	levels	
(A) Eµ-myc mice have a trend to slightly increased Hdac1 and Hdac2 expression levels in the 
cells of most B cell developmental stages. B lymphocytes from isolated from 8-week-old WT 
(n=2) and Eµ-myc tg (n=4) mice were sorted by flow cytometry for indicated B cell 
developmental stages and quantitative real-time PCR (RT-qPCR) was performed for Hdac1 and 
Hdac2. Data represents means ± SEM.  
  
Suppl.	Figure	8:	Loss	of	both,	Hdac1	and	Hdac2	(Hdac1Δ/Δ;Hdac2Δ/Δ)	reduces	leukemia	
in	Eµ-myc	mice	
Mice were bled at 4 and 10 week of age and blood was analyzed in an automated blood analyzer, 
(Sysmex XT-2000). (A) Representative plot of the manual gating for peripheral blood 
lymphocytes (PBL) used for Sysmex blood analysis. (B) Hdac1Δ/Δ;Hdac2Δ/Δ Eµ-myc mice had 
significantly lower PBL counts at 4 and 10 weeks than control Hdac1+/+;Hdac2+/+ Eµ-myc mice. 
Hdac1Δ/Δ;Hdac2+/+ mice had reduced PBL only at 4 but not at 10 weeks. Shown are detailed 
analysis of different Hdac1 and/or Hdac2 KO animals with or without Eµ-myc tg at 4 and 10, 
weeks (n≥10). Frequency (%) of PBL of indicated. p-value calculated with the Wilcoxon Signed-
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Rank Test. Significant differences in means is indicated, **p < 0.01; N.S. for not statistically 
significant.  
Suppl.	Figure	9:	Only	ablation	of	both,	but	not	single	Hdac1	and	Hdac2,	prevents	B	cell	
blast	in	BM	of	Eµ-myc	tg	mice	
Immunofluorescence staining with B cell surface marker-specific monoclonal antibodies (B220, 
IgM, CD19 and CD25) followed by flow cytometry analysis was performed on BM. All 
experiments were performed with 8-week-old mice and from lymphoma-free Eµ-myc mice, 
unless otherwise indicated. Mice genotypes are indicated. (A-B) Representative flow cytometry 
dot plots from BM lymphocytes derived from mice with indicated genotypes and gated on total 
lymphocytes for B cells B220/IgM (A) and PreBII lymphocytes subsets (B220+ lymphocytes 
gated for CD19+ and CD25+) (B). BM cells from Eµ-myc mice with lymphadenopathy that had 
reached endpoint criteria were assessed for comparison (indicated by asterisk) (pathological 
findings: HG-NHL). Gated regions in dot plots indicate the B cell subsets of interest with 
frequency in percent. (C) Quantification of B lymphocytes (B220+) and (D) PreBII 
(B220+;CD19+; CD25+) subsets (figure A and B, 4 to 6 mice of each genotype). The graph 
represents the average percentage of with SEM. The statistical analysis was performed with the 
Student unpaired 2-tailed t test. Significant differences in means between genotypes are 
indicated, ** p < 0.01. N.S. for not statistically significant.  
 
Suppl.	Figure	10:	Ablation	both,	Hdac1	and	Hdac2	(Hdac1Δ/Δ;Hdac2Δ/Δ)	 is	 required	 to	
reduce	tumor	cell	load	
Experiments were performed in 8-week-old pre-lymphoma mice (unless mentioned otherwise). 
(A) Representative flow cytometry histograms showing the large lymphocyte subset in BM of 
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mice with indicated genotypes. Asterisks indicates end stage animals. (B) Analysis of B220low 
cells population in Eµ-myc Hdac1+/+;Hdac2+/+ mice compared to wild type Hdac1+/+;Hdac2+/+ 
control animals. Representative B220 and IgM immunophenotyping flow cytometry plots of 
lymphomas arising in SP, LN as well as BM and blood (BL) are depicted. (C) Quantification of 
the proportion of B220low flow cytometry analysis in the indicated organs (represented in D). 
Differences between all Eµ-myc tg mice with indicated genotypes were not statistically 
significant (N.S.). The graph represents the average percentage of B220low cells with SEM (n=4-
6 mice per genotype). The statistical analysis was performed with the Student unpaired 2-tailed t 
test. Significant differences in means between genotypes are indicated, *p < 0.05; **, P < 0.01. 
(D) Analysis of B220low cells population in Eµ-myc mice lacking Hdac1 (Hdac1Δ/Δ;Hdac2+/+), 
Hdac2 (Hdac1+/+;Hdac2Δ/Δ) or both enzymes (Hdac1Δ/Δ;Hdac2Δ/Δ) and control 
(Hdac1+/+;Hdac2+/+) mice. Representative flow cytometry dot plots of B220/IgM staining 
previously gated on total lymphocytes derived from BM, SP and LN and gated for B220low and 
B220high populations.  
 
Suppl.	Figure	11:	Hdac1Δ/Δ;Hdac2Δ/Δ	 induces	a	B	cell	developmental	block	 in	the	bone	
marrow	that	prevents	Eµ-myc	tumorigenesis	in	SP	and	LNs	
B cell specific double KO of Hdac1 and Hdac2 (Hdac1Δ/Δ;Hdac2Δ/Δ) impairs B cell development 
in both, non-transgenic and in Eµ-myc tg mice. All experiments were performed in 8-week-old 
lymphoma-free mice from indicated genotypes. BM, SP and LN cells were isolated and 
subjected to immunofluorescence staining with B cell surface marker-specific monoclonal 
antibodies (including B220, IgM, CD19, and CD25) followed by flow cytometry analysis. 
Representative BM flow cytometry dot pots with B220/IgM staining (A) and CD19/CD25 
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staining (B). Representative flow cytometry dot plots from SP cells (C) and LN cells (D) 
showing B220/IgM staining characteristic for B cell. All flow cytometry plots are representative 
of 3 independent experiments. (E) Quantification of flow cytometry analysis (A-D) (n=4 mice of 
each genotype). The graph represents the average percentage of B220+ B lymphocytes and 
percentage of PreBII cell subsets (B220+;CD19+; CD25+) with SEM. All the statistical analysis 
were performed with the Student unpaired 2-tailed t test. Significant differences in means 
between genotypes are indicated, *p < 0.05; **, P < 0.01. N.S. for not statistically significant.  
 
Suppl.	 Figure	12:	Rare	Hdac1F/F;Hdac2F/F	Mb1-Cre	 tg;	Eµ-myc	animals	are	not	KO	 for	
Hdac1	and	Hdac2	and	develop	tumors	
(A) Histopathological analysis revealed few Hdac1F/F;Hdac2F/F Mb1-Cre tg; Eµ-myc animal 
developed a malignant phenotype (granulocytic leukemia). SP, BM, and liver were stained with 
H&E. Hdac1F/F;Hdac2F/F Mb1-Cre tg; Eµ-myc SP have red pulp expanded with neoplastic cells. 
In the decalcified sternum of these mice the normal BM is replaced by neoplastic cells. Tumor 
(T), RBC (red blood cells), B (bone). Infiltration of neoplastic cells into the liver (arrow). (B) 
Rare Hdac1F/F;Hdac2F/F Mb1-cre tg Eµ-myc tg animals develop tumors but still express Hdac1 
and Hdac2. Immunohistochemistry (IHC) from serial splenic sections from Hdac1 and/or Hdac2 
KO animals with Eµ-myc tg stained for c-Myc, Hdac1, and Hdac2.  
 
Suppl.	Figure	13:	Rare	Hdac1Δ/Δ;Hdac2Δ/Δ	animals	developed	interstitial	pneumonia	
Rare Hdac1Δ/Δ;Hdac2Δ/Δ mice suffer from interstitial pneumonia due to abundant presence of 
fungal elements. Histopathological analysis of lung samples from Hdac1Δ/Δ;Hdac2Δ/Δ and control 
Hdac1+/+;Hdac2+/+ mice with and without Eµ-myc tg. (A) H&E staining revealed interstitial 
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pneumonia in Hdac1Δ/Δ;Hdac2Δ/Δ mice. Arrow indicates inflammation site with infiltration of 
macrophages (1x magnification). At 10x magnification, multifocal enlargement of alveolar 
septae due to infiltration of macrophages. Multifocally alveoli are filled with foamy exudate 
mixed with inflammatory cells (macrophages, lymphocytes and neutrophils) (arrow shows 
foamy exudate). (B) 20x magnification clearly shows multifocal alveolar inflammatory exudate 
(foamy exudate) infiltrated with protein and liquid (arrow) as well as massive infiltration of 
inflammatory cells including macrophages mainly (asterisk). (C) General staining for fungus 
with Grocott staining at 10X, 40X, and 60X magnification. Grocott staining shows fungal 
elements (black structures) and abundant fungal cysts present within the alveolar foamy exudate. 
Arrow indicates exudate, asterisk indicates macrophages. Images were taken and processed at 
Novartis NIBR. Scale bar are indicated.  
 
Suppl.	 Figure	 14:	 In	 vivo	 conditional	 ablation	 of	 Hdac1	 and	 Hdac2	 using	 the	 CreER-
LoxP	system	in	Eµ-myc	tumor	cells	
(A) Schematic representation of the experimental workflow for the transplantation experiment. 
(1) Syngeneic recipient mice that were previously sub lethally gamma-irradiated (350 cGy of 
whole-body γ-irradiation) were (2) injected with lymph node derived Eµ-myc tumor cells 
isolated from (Hdac1F/F;Hdac2F/F, Actin-cre tg, Eµ-myc tg) mice after development of overt 
malignancy (represented by red filled circles). (3) Conditional KO was induced in one group of 
mice by intraperitoneal (IP) injection of 4-OHT (tamoxifen). Control mice were injected with 
vehicle. (4) Mice were monitored for tumor onset and sacrificed when they reached termination 
criteria (see Material and Methods). Tumor weight and flow cytometry analysis were performed. 
(B) Conditional KO of Hdac1 and Hdac2 using the CreER-LoxP system. Recombination was not 
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100%, since Hdac1 (and Hdac2) floxed alleles did not disappear completely. PCR genotyping 
for Hdac1 and Hdac2 wild type (WT), floxed (FL) and knockout (KO) alleles are indicated to 
the right. Allele specification and molecular weights in base pairs (bp) of individual fragments 
are to the left of each gel.  
 
Suppl.	Figure	15:	Eµ-myc	tg	Hdac1Δ/Δ;Hdac2Δ/+	mice	have	less	circulating	leukemic	cells	
but	eventually	develop	HG-NHL	
(A) Hdac1Δ/Δ;Hdac2Δ/+ has no significant impact on spleen weight (n=10). Comparison of 
relative spleen weights (in % of body weight) of 8-week-old mice with indicated genotypes. (B-
C) Hdac1Δ/Δ;Hdac2Δ/+ mice reduces leukemia in Eµ-myc mice. Mice were bled at 4 and 8 week 
of age and blood was analyzed in an automated blood analyzer (Sysmex XT-2000). Shown are 
dot plots of number of total PBL count (B) and white blood cells (WBC) (C) from indicated 
genotypes (n=10). p-value calculated with the Wilcoxon Signed-Rank Test. **, P < 0.01. N.S. 
for not statistically significant. (D) Histopathological analysis of Eµ-myc Hdac1Δ/Δ;Hdac2Δ/+ 
mice with lymphoma compared to Hdac1+/+;Hdac2+/+ control mice. Eµ-myc Hdac1Δ/Δ;Hdac2Δ/+ 
mice develop HG-NHL. Representative sections of spleen, lymph nodes, liver, and thymus by 
H&E staining. All depicted peripheral organs are enlarged and have destroyed architecture du to 
diffuse infiltration by neoplastic lymphocytes. Original magnification of 4X and 20X are 
indicated (Nikon Eclipse E600).  
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Suppl.	Figure	16:	Hdac1Δ/Δ;Hdac2Δ/+	impacts	on	Eµ-myc	proliferation	at	the	G1	phase	of	
the	cell	cycle	(Preliminary	data)	
Experiments were performed in 8-week-old mice. Proliferation is decreased in 
Hdac1Δ/Δ;Hdac2Δ/+ Eµ-myc tg B cells compared to control Hdac1+/+;Hdac2+/+ Eµ-myc tg B cells. 
Cell cycle analysis, mice of indicated genotype were intraperitoneally injected with 1.5mg of 
BrdU. 24h after BrdU injection mice were sacrificed and BM cells were isolated and stained with 
anti-BrdU antibody for flow cytometry analysis. (A) Representative flow cytometry histograms 
showing count (%) of BrdU incorporation representing cells in S-phase from indicated 
genotypes. (B) Cell cycle analysis (n=3). Mean and standard error of BrdU-positive cells is 
shown. The percentages of cells in the G0/G1-, S-, and G2/M-phase, obtained by manual gating, 
are indicated in the plots.  
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2.3. Supplementary	figures	
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Results	Part	3:	Analysis	of	 the	 functional	 role	of	Hdac1	and	Hdac2	 in	B	
cell	development	
3.1. Results	
Analysis	of	Hdac1Δ/Δ;Hdac2Δ/+	mice	
Previous studies described that acetylation on histone lysine residues is positively correlated with 
gene transcription, and that histone H3 and H4 acetylation is enriched in actively transcribed 
euchromatin regions (Kurdistani et al., 2004; Vogelauer et al., 2000). Importantly, it was 
reported that Hdac1, but not Hdac2, deacetylates lysine residues on histone H3 and H4 (Dovey et 
al., 2010; Yamaguchi et al., 2010). This prompted us to examined the global acetylation levels on 
histones H3 (H3ac) and H4 (H4ac) in Hdac1Δ/Δ;Hdac2Δ/+ B cells. We first confirmed the 
genotypes by PCR (Suppl. Figure 1A). We then performed western blot analysis from 
Hdac1Δ/Δ;Hdac2Δ/+ and control Hdac1+/+;Hdac2+/+ splenic B cells (B220+; CD19+; CD3-) sorted 
by flow cytometry. Extracts were probed with antibodies recognizing Hdac1, Hdac2, H3Ac or 
H4Ac and against H3 and H4 to verify for equal protein loading. Consistent with previous 
reports, we observed a slight increase in global H3Ac levels, and an increase in global H4Ac 
levels in Hdac1Δ/Δ;Hdac2Δ/+ cells compared to control Hdac1+/+;Hdac2+/+ cells (Suppl. Figure 
1B). Thus, we conclude that in our Hdac1Δ/Δ;Hdac2Δ/+ B cells Hdac1 and/or Hdac2 deacetylate 
histone H3 and H4 as expected.  
 
Dissecting	the	impact	of	Hdac1Δ/Δ;Hdac2Δ/+	on	B	cell	development	
We previously showed that B cell development is normal in Hdac1Δ/+;Hdac2Δ/Δ mice but 
severely impacted in Hdac1Δ/Δ;Hdac2Δ/+ mice and completely blocked in Hdac1Δ/Δ;Hdac2Δ/Δ 
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mice (Pillonel et al., Figure 6A). Furthermore, we observed, that Hdac1Δ/Δ;Hdac2Δ/+, but not 
Hdac1Δ/+;Hdac2Δ/Δ mice, have higher number of pre-BI cells and a decrease in pre-BII cell 
numbers compared to control Hdac1+/+;Hdac2+/+ mice (Pillonel et al., Figure 6B). Thus, we 
concluded, that one allele of Hdac1 but not Hdac2 is sufficient to complete B cell development 
(Pillonel et al., Figure 6). We confirmed these previous findings by repeating flow cytometry 
analysis with Hdac1Δ/Δ;Hdac2Δ/+ and Hdac1Δ/+;Hdac2Δ/Δ mice to further determine the exact 
impact of Hdac1 and Hdac2 ablation on the different stages of B cell development. We 
confirmed that Hdac1Δ/Δ;Hdac2+/Δ is not sufficient to complete B cell development (Suppl. 
Figure 2A). We observed a significant decrease in B cell number and a massive decrease in 
PreBII cell number (Suppl. Figure 2B) as shown previously by Pillonel et al. In addition we 
observed a massive loss in immature B cell number (Suppl. Figure 2B). Interestingly, we also 
observed that Hdac1Δ/Δ;Hdac2+/Δ mice have more PreBI cells with high c-kit staining (Suppl. 
Figure 2B). This suggests that Hdac1Δ/Δ;Hdac2+/Δ PreBI cells remain in a less differentiated 
stage. Another interesting observation, was that Hdac1Δ/Δ;Hdac2+/Δ mice have normal amount of 
mature B cells in the spleen (Suppl. Figure 2B). We also observed that Hdac1+/Δ;Hdac2Δ/Δ mice 
have a normal B cell development (Suppl. Figure 2C), as previously shown by Pillonel et al. 
(Suppl. Figure 2C). These observations confirm previous observations (Pillonel et al., Figure 6), 
that Hdac1Δ/Δ;Hdac2+/Δ, but not Hdac1+/Δ;Hdac2Δ/Δ impact on B cell development. We further 
show that the few PreBII cells left in Hdac1+/Δ;Hdac2Δ/Δ mice are sufficient to eventually fill up 
the pool of mature B cells in the secondary lymphoid organs including the SP (Suppl. Figure 
2B).  
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Proliferation	 is	 increased	 in	Hdac1Δ/Δ;Hdac2Δ/+	 Pre-BI	 cells	 and	 decreased	 in	 Pre-BII	
cells		
Yamaguchi et al., previously showed that ablation of both, Hdac1 and Hdac2 
(Hdac1Δ/Δ;Hdac2Δ/Δ) induces cells cycle arrest and apoptosis in B cells (Yamaguchi et al., 2010). 
These finding prompted us to test proliferation and apoptosis in Hdac1Δ/Δ;Hdac2Δ/+ cells. We 
observed that Hdac1Δ/Δ;Hdac2Δ/+ induces a massive decrease in PreBII cell number (Suppl. 
Figure 2B). Hence, we first investigated the impact of Hdac1Δ/Δ;Hdac2Δ/+ on proliferation in 
PreBII and the preceding PreBI cell stage. To test this, we performed in vivo BrdU labelling of 
proliferating cells. We found that proliferation was slightly increased in Hdac1Δ/Δ;Hdac2Δ/+ Pre-
BI cells and decreased in Pre-BII cells (Figure 1A). Quantification of B220+;BrdU+ cells 
revealed a significant difference (Figure 1B). We measured the percentages of cells in the G0/G1-
, S-, and G2/M-phase of the cell cycle. Interestingly, we found that Hdac1Δ/Δ;Hdac2Δ/+ PreBII 
cells are blocked at G0/G1-phase (Figure 1A). Thus, we conclude that Hdac1Δ/Δ;Hdac2Δ/+ 
positively impacts on proliferation of Pre-BI and negatively impacts on proliferation of Pre-BII 
cells.  
 
Hdac1Δ/Δ;Hdac2Δ/+	Pre-BI	cells	have	reduced	apoptosis	
Yamaguchi et al. reported that Hdac1Δ/Δ;Hdac2Δ/Δ PreBII cells were arrested in the cell cycle and 
eventually underwent apoptosis (Yamaguchi et al., 2010). The foregoing indicates that 
proliferation is decreased in Pre-BII cells (Figure 1). We next measured whether apoptosis is also 
affected in Hdac1Δ/Δ;Hdac2+/Δ PreBII cells. Therefore, we investigated whether apoptosis was 
induced in Hdac1Δ/Δ;Hdac2Δ/+ PreBI and PreBII cells. We performed AnnexinV apoptosis assay 
by flow cytometry analysis. We first gated for PreBI or PreBII cell populations (Figure 2A left 
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panels) and measure apoptotic cells (AnnV+;DAPI-). Strikingly, we observed that 
Hdac1Δ/Δ;Hdac2Δ/+ PreBI cells underwent apoptosis at lower frequency, compared to control 
Hdac1+/+;Hdac2+/+ PreBI cells (Figure 2A, upper right panels). Quantification of these flow 
cytometry analysis revealed a significant decrease in apoptotic (AnnV+;DAPI-) cells (Figure 2B 
upper panel). In contrast, we did not detect any difference in apoptosis frequency in PreBII cells 
upon Hdac1Δ/Δ;Hdac2Δ/+ (Figure 2A, lower right panels). In summary, Hdac1Δ/Δ;Hdac2Δ/+ PreBI 
cells proliferate more (Figure 1) and undergo less frequently apoptosis (Figure 2), whereas 
Hdac1Δ/Δ;Hdac2Δ/+ PreBII cells proliferate less (Figure 1) and do undergo more frequently 
apoptosis (Figure 2).  
 
Hdac1Δ/Δ;Hdac2Δ/+	Pre-BI	cells	have	reduced	intracellular	IgM	
We observed that Hdac1Δ/Δ;Hdac2Δ/+ Pre-BI cells have reduced apoptosis (Figure 2). These 
findings prompted us to hypothesize, that Hdac1Δ/Δ;Hdac2Δ/+ PreBI cells might undergo less 
frequently apoptosis because they might have a problem with V(D)J recombination and therefore 
escape the selection process for differentiating to the next B cell stage involving apoptosis. 
Therefore these PreBI cells might not differentiate to PreBII cells. This would explain the 
massive decrease in PreBII cell number we observe in Hdac1Δ/Δ;Hdac2Δ/+ mice (Suppl. Figure 
2B). We therefore performed flow cytometry analysis of intra cellular IgM staining of 
Hdac1Δ/Δ;Hdac2Δ/+ and control Hdac1+/+;Hdac2+/+ PreBI cells. Our preliminary data show that 
Hdac1Δ/Δ;Hdac2Δ/+ decreased intra cellular IgM+ in PreBI cells (Figure 3A). Quantification 
revealed a decrease of intra cellular IgM+ PreBI cells in Hdac1Δ/Δ;Hdac2Δ/+ compared to 
Hdac1+/+;Hdac2+/+ mice (Figure 3B). These preliminary data suggests less IgM rearrangement in 
Hdac1Δ/Δ;Hdac2Δ/+ PreBI cells.  
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3.2. Figure	legends		
Figure	1:	Proliferation	is	increased	in	Hdac1Δ/Δ;Hdac2Δ/+	Pre-BI	cells	and	decreased	in	
Pre-BII	cells	
Experiments were performed in 8-week-old mice. (A) For cell cycle analysis, mice of indicated 
genotype were intraperitoneally injected with 1.5mg of BrdU. 24h after BrdU injection mice 
were sacrificed and bone marrow cells were isolated and stained with anti-BrdU antibody for 
flow cytometry analysis. The percentages of cells in the G0/G1-, S-, and G2/M-phase, obtained by 
manual gating, are indicated in the plots. Results are representative of 3 independent 
experiments. (B) BrdU-positive cells that represent cells in S-phase were quantified from (a) 
(n=2). Mean and standard error of BrdU-positive cells is shown.  
 
Figure	2:	Hdac1Δ/Δ;Hdac2Δ/+	Pre-BI	cells	have	reduced	apoptosis	
Experiments were performed in 8-week-old mice. (A) Bone marrow cells were isolated from 
Hdac1+/+;Hdac2+/+ and Hdac1Δ/Δ;Hdac2Δ/+ mice and stained with Annexin V, DAPI and B cell 
surface markers for flow cytometry analysis. PreBI (CD19+, c-kit+) and PreBII (CD19+, CD25+) 
cells were gated by flow cytometry (left dot plots). AnnexinV-positive (i.e., apoptotic) cells in 
PreBI and PreBII lymphocytes were quantified (right panels). (B) Mean percentages and 
standard deviations of apoptotic (annexinV+ DAPI-) cells are represented as bar plots (n=3 mice 
per genotype, representative from 3 independent experiments). All statistical analysis were 
performed with the Student unpaired 2-tailed t test. Significant differences in means between 
genotypes are indicated, *p < 0.05; **, p < 0.01. N.S. for not statistically significant.  
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Figure	3:	Hdac1Δ/Δ;Hdac2Δ/+	Pre-BI	cells	have	reduced	intracellular	IgM	(preliminary	
data)	
Experiments were performed in 8-week-old mice. (A) Flow cytometry analysis of 
Hdac1+/+;Hdac2+/+ and Hdac1Δ/Δ;Hdac2Δ/+ bone marrow cells by immunofluorescence cell 
surface staining with CD19 and c-kit followed by fixation, permeabilization and intra cellular 
IgM staining. (B) Quantification of intra IgM+ PreBI cells in percent are shown below (n=4 mice 
per genotype).  
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3.3. Figures		
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3.4. Supplementary	figure	legends		
Suppl.	Figure	1:	Analysis	of	Hdac1Δ/Δ;Hdac2Δ/+	mice	
Experiments were performed in 8-week-old mice. (A) PCR genotyping from splenic B cells 
(B220+; CD19+; CD3-) sorted by flow cytometry. Specific allele annotation are to the left of gel: 
Hdac1 and Hdac2 wild type (WT), floxed (FL), and knockout (KO) alleles and mb1-cre 
transgenes (tg). (B) Western blots were performed on lysates from flow cytometry sorted splenic 
B cells (B220+; CD19+; CD3-) from indicated genotypes. Hdac1+/+;Hdac2+/+ and 
Hdac1Δ/Δ;Hdac2Δ/+ cells were analyzed for the expression of Hdac1, Hdac2, and histone H3Ac, 
H4Ac. H3 and H4 expression was used as loading control.  
 
Suppl.	Figure	2:	Dissecting	the	impact	of	Hdac1Δ/Δ;Hdac2Δ/+	on	B	cell	development	
Experiments were performed in 8-week-old mice. (A) Representative flow cytometry dot plots of 
B220/IgM staining gated on total B220+ lymphocytes derived from the bone marrow (BM) of 
Hdac1Δ/Δ;Hdac2Δ/+ and control Hdac1+/+;Hdac2+/+ mice. Gated regions in dot plots indicate the 
B cell subsets of interest with Pro/preB (B220+; IgM-) and ImmatureB (B220low;IgM+) subsets 
highlighted. (B) Hdac1Δ/Δ;Hdac2+/Δ mice have less B cells and a huge decrease in pre-BII (and 
Immature B) cell number, but have normal amount of mature B cells in the spleen. 
Immunofluorescence staining with B cell surface marker-specific monoclonal antibodies (CD19, 
IgM, c-kit, and CD25) from Hdac1+/+;Hdac2+/+ and Hdac1Δ/Δ;Hdac2Δ/+ bone marrow cells 
followed by flow cytometry analysis. Gated regions in dot plots indicate the B cell subsets of 
interest with frequency in percent. Quantification of B cell numbers and B cell sub populations 
are shown below with SEM. The statistical analysis was performed with the Student unpaired 2-
tailed t test. Significant differences in means between genotypes are indicated, **, P < 0.01. N.S. 
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for not statistically significant. (C) Hdac1+/Δ;Hdac2Δ/Δ have a normal B cell development. 
Quantification of flow cytometry analysis from Hdac1+/+;Hdac2+/+ and Hdac1+/Δ;Hdac2Δ/Δ bone 
marrow B cell populations (same as (B)). N.S. for not statistically significant (Student unpaired 
2-tailed t test). 
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3.5. Supplementary	figures		
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Results	Part	4:	Dissecting	the	role	of	Hdac6	in	Eµ-myc	B	cell	lymphoma	
4.1. Results		
High	human	HDAC6	expression	predicts	poor	prognosis	in	DLBCL	patients	
We first explored the prognostic significance of human HDAC6 gene expression with 
DRUGSURV, a resource for repositioning of approved and experimental drugs in oncology 
based on patient survival information. We examined the prediction of survival in Diffuse Large 
B Cell Lymphoma (DLBCL), a B cell lymphoma with c-Myc deregulation. We compared the 
survival of DLBCL patients treated with chemotherapy plus rituximab (monoclonal antibody 
against pan-B-cell marker CD20) according to the HDAC6 gene expression level in DLBCL 
patient samples. Interestingly, we observed that high HDAC6 expression levels predict 
significant poorer survival than low HDAC6 expression levels (*p<0.01) (Figure 1). This clearly 
demonstrates, that molecular HDAC6 gene expression signature has a prognostic significance in 
patients treated with chemotherapy plus Rituximab.  
 
Hdac6	overexpression	(H6OE)	accelerates	lymphomagenesis	whereas	Hdac6	knockout	
in	the	germ	line	(H6KOGL)	may	delay	tumor	development	in	Eµ-myc	mice	
The finding that high human HDAC6 expression predicts poor prognosis in DLBCL patients 
(Figure 1), prompted us to investigate the role of mouse Hdac6 in the Eµ-myc mouse model of B 
cell lymphoma, a preclinical model with c-Myc deregulation. In order to test the B cell intrinsic 
and extrinsic effect of Hdac6 ablation, we used Hdac6 B cell specific conditional KO (H6KOBC), 
and Hdac6 germ line knockout (H6KOGL), respectively. These mice were generated in the lab by 
Dr. Yu Zhang (Zhang et al., 2008). In order to test the effect of Hdac6 overexpression, we used 
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mice overexpressing Hdac6 (H6OE), which were previously produced by Dr. Yu Zhang in our 
lab (unpublished). To generate these mice, the BAC clone (50M7) which contains the whole 
murine Hdac6 gene (Means et al., 2000) was used for microinjection into the pronucleus of 
fertilized mouse oocytes to generate Hdac6-BAC transgenic mice, which overexpress Hdac6 
(Suppl. Figure 1A). Quantitative Western Blotting in mouse testis, revealed that Hdac6-BAC tg 
mice have increased level of Hdac6 protein and hypoacetylation of α-tubulin (Suppl. Figure 1B). 
To investigate the role of Hdac6 in Eµ-myc tumorigenesis, we crossed Eµ-myc tg mice with 
H6OE mice, or mice with H6KOBC or H6KOGL (Figure 2A, Figure 2B). We then monitored mice 
for tumor development over a period of 300 days by Kaplan-Meyer (KPLM) analysis. Strikingly, 
H6OE significantly accelerated lymphomagenesis in Eµ-myc mice (Figure 2C). H6OE Eµ-myc 
mice developed tumors with a higher incidence (95% vs. 80%), shorter latency (42 days vs. 
47days), and shorter mean latency (103 days vs. 141days), compared with Eµ-myc mice (Figures 
2D). Interestingly, we observed, that H6KOGL may delay tumor development in Eµ-myc mice 
(Figure 2C). H6KOGL Eµ-myc mice developed tumors with a lower incidence (64 % vs. 80%), 
later latency (96 days vs. 47 days) and later mean latency (172 days vs. 140 days) compared with 
Eµ-myc (Figure 2D). However, statistical analysis revealed that the difference is not significant 
(p-value of 0.05504) (Figures 2D). Interestingly, we observed that H6KOBC had no effect in Eµ-
myc mice (Figure 2C). H6KOBC Eµ-myc mice developed tumors with similar latency and similar 
incidence compared with Eµ-myc mice (Figure 2D). This suggests that the assumed effect of 
H6KOGL is probably a B cell extrinsic effect. In summary, we show for the first time that Hdac6 
overexpression accelerates lymphomagenesis whereas Hdac6 knockout in the germ line may 
delay tumor development in Eµ-myc mice.  
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H6OE	increases,	and	H6KOGL	decreases	the	percentage	of	peripheral	blood	lymphocytes	
at	early	stages	of	Eμ-myc	tumorigenesis	
To determine how H6OE (and H6KOGL) impact on Eµ-myc tumorigenesis, we then measured 
the circulating peripheral blood lymphocytes (PBL) at 4 and 10 weeks using an automated blood 
cell counter (Figure 3). We observed, that H6KOBC had no effect on PBL at 4 and 10 weeks 
(Figure 3A). Interestingly, H6KOGL significantly reduced the percentage of PBL at 4 weeks, but 
this effect was not visible later at 10 weeks (Figure 3B). In contrast, H6OE significantly 
increased the percentage of PBL at 4 weeks, but also had no effect at 10 weeks. Hence, we 
conclude, that H6KOGL significantly reduced, whereas H6OE significantly increased the 
percentage of PBL at early but not at late stages of Eµ-myc tumorigenesis. These findings are 
consistent with our previously shown observations that H6OE accelerates lymphomagenesis 
whereas H6KOGL may delay tumor development in Eµ-myc mice (Figure2C).  
We also measured the spleen (SP) weight, since Eµ-myc tg mice have an enlarged spleen 
(splenomegaly). Surprisingly, we found that neither H6OE nor H6KO had any significant effect 
on SP enlargement in Eµ-myc mice (Supp. Figure 2A). In addition, we performed a 
histopathological analysis (Suppl. Figure 2B). As expected, some Eµ-myc mice displayed high 
grade Non-Hodgkin Lymphoma (HG-NHL) (corresponding to Burkitt’s lymphoma in men), as 
described previously (Adams et al., 1985; Morse et al., 2002). Preliminary analysis from H6KO 
Eµ-myc mice, revealed that H6KOGL Eµ-myc and H6KOBC Eµ-myc mice had HG-NHL 
incidence in SP and LNs at a similar frequency compared to control Eµ-myc mice (Suppl. Figure 
2B). Interestingly, histopathological analysis of old H6OE mice reveals unexpected fatty acid 
changes in liver (Suppl. Figure 2D). Five out of ten H6OE mice had these fatty acid changes 
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(Suppl. Figure 2C). We did not further investigate this phenomenon since it was not related to 
our research.  
H6OE	significantly	increases	tumor	cell	load	in	Eµ-myc	mice	
We next assessed the tumor cell load by quantifying the B220low population which are 
characteristically highly overrepresented in Eµ-myc mice (Croxford et al., 2013). We first 
measured by flow cytometry the B220low cells subsets in blood (BL), SP, LN, and bone marrow 
(BM) of 8-week-old pre-lymphoma Eµ-myc H6OE and control Eµ-myc mice. Consistently, with 
the results previously observed, we found that H6OE increases tumor cell load in BL, SP, LN of 
Eµ-myc mice (Figure 4A). Quantification of flow cytometry analysis revealed significant 
increase in frequency of B220low cells upon H6OE in BL, SP, and LN (Figure 4B). Interestingly, 
B220low cell numbers were not affected in the BM of H6OE mice (Figure 4B).  
In addition we performed further flow cytometry analysis from BM, SP, and LN of Eµ-myc 
H6OE and control Eµ-myc mice. We did immunofluorescence staining with B cell surface 
marker-specific antibodies including B220, IgM, CD19 and CD25 to identify the different B cell 
populations in the BM (Suppl. Figure 3A), SP (Suppl. Figure 3B), and LN (Suppl. Figure 3C). 
Eµ-myc mice displayed a blast at Pro/PreB cell stage that dominates the BM (Suppl. Figure 3A), 
as previously reported (Sidman et al., 1993). We did not observe any effect upon H6OE in the 
BM by B220/IgM flow cytometry analysis (Suppl. Figure 3A). Quantifications of flow 
cytometry analysis in BM, SP, and LN, revealed that the average percentage of B220+ B 
lymphocytes and the average percentage of large B220+ cell characteristic for the Eµ-myc 
phenotype was similar in H6OE Eµ-myc mice compared to control Eµ-myc mice (Suppl. Figure 
3D and Suppl. Figure 3E, respectively). Interestingly, and consistent with the previous 
observations (Figure 4), SP and LN analysis revealed that H6OE Eµ-myc had more cells which 
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express B220 at a low level (highlighted B220low populations) (Suppl. Figure 3B and Suppl. 
Figure 3C, respectively). Taken together, our data show that HOE significantly increases tumor 
cell load in Eµ-myc mice.  
H6KOGL	decreases	tumor	cell	load	in	Eµ-myc	mice	
We showed that H6OE increases tumor cell load (B220low populations) in BL, SP, and LN of 
Eµ-myc mice (Figure 4), and eventually accelerates lymphomagenesis (Figure 2). We also 
observed that H6KOGL may delay tumor development in Eµ-myc mice (Figure 2). Hence, we 
hypothesize that H6KOGL might also impact on B220low populations in these organs. We 
therefore assessed the tumor cell load in 8-week-old pre-lymphoma H6KOGL Eµ-myc mice, by 
quantifying the B220low population in BL, SP, LN, and BM (Figure 5). We observed, that 
H6KOGL mice reduces tumor cell load in Eµ-myc BL, SP, and LN (Figure 5A). Quantification of 
B220low cells population in BL, SP, LN, revealed a significant decrease upon H6KOGL (Figure 
5B). Similar to the previous observation in H6OE mice (Figure 4), we did not observe any effect 
on B220low cells population in the BM upon H6KOGL. In addition we performed further flow 
cytometry analysis from BM, SP, and LN of Eµ-myc H6OE and control Eµ-myc mice. 
Consistent with our previous observations, we did not observe any effect on Eµ-myc induced 
blast in the BM upon H6KOGL (Suppl. Figure 4A). Consistently, quantification of large B220+ 
cell in the BM, revealed no difference between Eµ-myc H6KOGL compared to control Eµ-myc 
mice (Suppl. Figure 4E). Further flow cytometry analysis of SP (Suppl. Figure 4B), and LN 
(Suppl. Figure 4C) did not reveal any significant impact of H6KOGL on the mature B cell 
populations (B220+;IgM+) (Suppl. Figure 4D).  
Our previous findings clearly show that ablation of Hdac6 only in B cells (H6KOBC) had no 
impact on Eµ-myc tumorigenesis (Figure 2). In addition, we performed flow cytometry analysis 
Results	 	 		
158 
 
of H6KOBC 8-weeks-old pre-lymphoma mice (Suppl. Figure 5). We found, that H6KOBC had no 
impact on B220+ (Suppl. Figure 5A), large B220+ (Suppl. Figure 5B), and B220low cell numbers 
(Suppl. Figure 5C) in Eµ-myc mice. Taken together, our data show that H6KOGL, but not 
H6KOBC, significantly decreases tumor cell load (B220low population) in the BL, SP, and LN of 
Eµ-myc mice.  
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4.2. Figure	legends	
Figure	 1:	 High	 human	HDAC6	 expression	 predicts	 poor	 prognosis	 in	 Diffuse	 Large	 B	
Cell	Lymphoma	(DLBCL)	patients	
(A) Molecular HDAC6 gene expression signature have a prognostic significance in patients 
treated with chemotherapy plus Rituximab. Prediction of survival in DLBCL patients treated 
with chemotherapy plus rituximab (monoclonal antibody against pan-B-cell marker CD20) 
according to the HDAC6 gene expression level in DLBCL patient samples: High HDAC6 
expression levels (red curve) predict significant poorer survival than low HDAC6 expression 
levels (green curve) (*p<0.01). Graph generated by DRUGSURV, a resource for repositioning of 
approved and experimental drugs in oncology based on patient survival information 
(www.bioprofiling.de/GEO/DRUGSURV). Gene expression Omnibus (GEO) dataset: 
GSE10846. 181 clinical samples from patients treated with a regimen of 4 drugs known as 
CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone), and 233 clinical samples 
from CHOP-treated patients, plus the monoclonal antibody rituximab.  
 
Figure	2:	Hdac6	overexpression	(H6OE)	accelerates	lymphomagenesis	whereas	Hdac6	
knockout	in	the	germ	line	(H6KOGL)	may	delay	tumor	development	in	Eµ-myc	mice	
(A) PCR genotyping for Hdac6 wild-type (WT), flox (FL), knockout (KO), and Bacterial 
Artificial Chromosome (BAC) alleles and mb1-cre transgene (tg). PCR was performed from 
CD19+ MACS sorted splenic B cells from 8-week-old mice with indicated genotypes: Hdac6 KO 
in the germ line (H6KOGL), Hdac6 KO in B cells (H6KOBC), Hdac6 overexpression (H6OE). 
Specific allele annotations are to the left of the gel. Loading marker (M) is indicated. (B) 
Western blot analysis of protein lysates from CD19+ MACS sorted splenic B cells derived from 
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8-week-old mice of indicated genotypes. Immunoblot of Hdac6 and Ac alpha tubulin. 
Hyperacetylated tubulin (Ac tubulin) was used as an additional readout for Hdac6 depletion. 
Tubulin serves as loading control. (C) H6OE accelerates whereas H6KO delays tumor onset in 
Eµ-myc mice. Kaplan-Meyer (KPLM) tumor-free survival plot of 21 age-matched H6KOGL, 
H6KOBC, H6OE and control WT mice with or without Eµ-myc tg. Mice were monitored over a 
period of 300 days for tumor onset and sacrificed when they reached termination criteria (see 
Material and Methods). The curves show the percentage of mice surviving without tumors at 
various days. The log-rank test was used to determine the level of significance between curves. 
**p < 0.01; N.S. for not statistically significant. (D) Statistical analysis from KPLM (C). 
Incidence (%), latency and mean latency (days) of tumor induced by the Eµ-myc tg in indicated 
genotypes.  
 
Figure	 3:	 H6OE	 increases,	 and	H6KOGL	 decreases	 the	 percentage	 of	 peripheral	 blood	
lymphocytes	at	early	stages	of	Eμ-myc	tumorigenesis	
Blood was analyzed in an automated blood analyzer (Sysmex XT-2000). Shown are detailed 
analysis of (A) H6KOBC, (B) H6KOGL and (C) H6OE animals with or without Eµ-myc tg at 4 
and 10 weeks (n≥10). Frequency (%) of Peripheral Blood Lymphocytes (PBL) is indicated. 
Boxplots with p-values calculated with the Wilcoxon Signed-Rank Test: *p < 0.05; **p < 0.01; 
N.S. for not statistically significant. 
 
Figure	4:	H6OE	increases	tumor	cell	load	in	Eµ-myc	mice	
We assessed the tumor cell load by quantifying the B220low population characteristic for Eµ-myc 
phenotype. Experiments were performed in 8-week-old pre-lymphoma mice. Quantification of 
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the proportion of malignant cells in Eµ-myc mice expressing B220 at a low level (% of B220low 
cells). Analysis of B220low cells population in blood (BL), spleen (SP), lymph node (LN), bone 
marrow (BM) from Eµ-myc Hdac6 overexpressing (H6OE) mice and control Eµ-myc mice. (A) 
Representative flow cytometry dotplots of B220/IgM staining and representative flow cytometry 
histograms of B220+ cells, gated on total lymphocytes and then gated for B220low and B220high 
populations. Percentages in the different gates are indicated. B220low populations of interest are 
highlighted with red gates. (B) H6OE increases tumor cell load in Eµ-myc mice. Quantification 
of flow cytometry analysis (n=3 mice per genotype). The graphs represents the average 
percentage of B220low cells with SEM. The statistical analysis was performed with the Student 
unpaired 2-tailed t test. Significant differences in means between genotypes are indicated, *p < 
0.05. N.S. for not statistically significant.  
 
Figure	5:	H6KOGL	decreases	tumor	cell	load	in	Eµ-myc	mice	
We assessed the tumor cell load by quantifying the B220low population characteristic for the Eµ-
myc phenotype. Experiments were performed in 8-week-old pre-lymphoma mice. Quantification 
of the proportion of malignant cells in Eµ-myc mice expressing B220 at a low level (% of 
B220low cells). (A) H6KOGL mice reduces tumor cell load in Eµ-myc mice. Cells were derived 
from blood (BL), spleen (SP), lymph node (LN) and bone marrow (BM) of Eµ-myc and Eµ-myc 
H6KOGL mice and analyzed by flow cytometry. Representative flow cytometry dot plots of 
B220/IgM staining and representative flow cytometry histograms of B220+ cells, gated on total 
lymphocytes and then gated for B220low and B220high populations. Percentages in the different 
gates are indicated. B220low populations of interest are highlighted with red gates. (B) 
Quantification of B220low cells population in SP, LN, BM, and BL from Eµ-myc Hdac6 germ 
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line KO (H6KOGL) (n=3) mice compared to control Eµ-myc animals. The graphs represents the 
average percentage of B220low cells with SEM. The statistical analysis was performed with the 
Student unpaired 2-tailed t test. Significant differences in means between genotypes are 
indicated, *p < 0.05; **, P < 0.01. N.S. for not statistically significant.  
  
Results	 	 		
163 
 
4.3. Figures	
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4.4. Supplementary	figure	legends	
Suppl.	Figure	1:	Generation	of	Hdac6	overexpressing	(H6OE)	mice	
(A) Schematic illustration of the BAC chromosome containing the Hdac6 locus. The BAC clone 
(50M7) which contains the whole murine Hdac6 gene (Means et al. 2000) was used for 
microinjection into the pronucleus of fertilized mouse oocytes to generate Hdac6-BAC 
transgenic mice, which overexpress Hdac6 (H6OE). The Hdac6 gene copy number was detected 
in the viable and fertile founder mice by real-time PCR using a pair of specific primers which 
recognize the region between exon 9 and 10 of Hdac6 (indicated with arrows). Performed 
previously in the lab (Yu Zhang et al., unpublished). (B) Hdac6-BAC mice have high levels of 
Hdac6 and hypoacetylation of α-tubulin. Quantitative Western Blotting (QWB) in mouse testis. 
Immunoblot analysis of Hdac6 expression, Ac α-tubulin, and α-tubulin as loading control. The 
Hdac6-BAC transgenic mice showed as expected, increased level of Hdac6 protein and 
hypoacetylation of α-tubulin. Performed previously in the lab (Yu Zhang et al., unpublished). 
Hdac6-BAC transgenic mice with 6 copies of Hdac6 were selected for all the subsequent 
experiments shown in this manuscript.  
 
Suppl.	 Figure	 2:	 Histopathological	 analysis	 reveals	 unexpected	 fatty	 acid	 changes	 in	
liver	of	H6OE	mice	but	no	changes	in	spleen	weight	
(A) H6OE or H6KO has no significant impact on spleen enlargement (splenomegaly) in Eµ-myc 
mice (n>10). Comparison of relative spleen weights (in % of body weight) of 8-week-old mice 
with indicated genotypes. Box plots with p-values generated using the Wilcoxon Signed-Rank 
test. Significant differences between genotypes are indicated, *p<0.05. N.S. for not statistically 
significant. (B) Histopathological analysis in 8-week-old mice with indicated genotypes. 
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Pathological finding of high grade Non-Hodgkin lymphoma (HG-NHL) were scored in spleen 
and lymph nodes and summarized in the table (n=10). (C) Fatty acid changes were observed in 
the liver of old H6OE mice. Histopathological analysis in 8- and 40-week-old WT, Hdac6 
germline knockout (H6KOGL) and Hdac6 overexpressing (H6OE) mice. 50% of H6OE mice (5 
out of 10) had fatty acid changes. No changes were observed in H6KOGL or control WT mice 
(n=10). (D) Histopathology analysis in 40-week-old WT and H6OE mice. Representative 
pictures from liver sections treated with hematoxylin and eosin (H&E). Original magnification of 
4X and 10X and 20X as indicated, (Nikon Eclipse E600). Pathological finding of fatty acid 
changes is clearly visible. Phenotype was scored in different samples and summarized in the 
table (C).  
 
Suppl	 Figure	 3:	Hdac6	 overexpression	 (H6OE)	might	 impact	 on	B	 cell	 populations	 in	
pre-lymphoma	Eµ-myc	mice	
Experiments were performed in 8-week-old pre-lymphoma mice. (A-C) Representative flow 
cytometry dot plots of B220/IgM staining gated on total lymphocytes derived from the bone 
marrow (BM), spleen (SP) and lymph nodes (LN) cells from WT, H6OE, Eµ-myc and Eµ-myc 
H6OE mice. Gated regions in dot plots indicate the B cell subsets of interest with frequency in 
percent. (A) H6OE has no impact on the B cell blasts (B220+, IgM-) which dominate the BM of 
Eµ-myc tg mice. In contrast, H6OE in Eµ-myc mice impacts on B220 B cell population in spleen 
(B) and lymph nodes (C). Some H6OE Eµ-myc mice have more cells which express B220 at a 
low level (highlighted B220low populations). (D-E) Quantifications of flow cytometry analysis 
from mice of indicated genotypes. The bar plots represents the average percentage of B220+ B 
lymphocytes (D) and the average percentage of large B220+ cell characteristic for the Eµ-myc 
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phenotype (E). SEM are indicated (n=3 mice per genotype). The statistical analysis was 
performed with the Student unpaired 2-tailed t test. Significant differences in means between 
genotypes are indicated, *p < 0.05. N.S. for not statistically significant.  
 
Suppl.	Figure	4:	Hdac6	germ	 line	knockout	has	no	 impact	on	B	 lymphocyte	 counts	 in	
pre-lymphoma	Eµ-myc	mice	
All experiments were performed in 8-week-old pre-lymphoma mice. (A-C) H6KOGL has neither 
an impact in WT nor in Eµ-myc mice in BM, SP and LN. Representative flow cytometry dot 
plots of B220/IgM staining gated on total lymphocytes derived from mice with indicated 
genotypes. Gated regions in dot plots indicate the B cell subsets of interest in percent. (A) 
H6KOGL has no impact on the B cell blasts (B220+, IgM-) which dominate the BM of Eµ-myc tg 
mice. H6KOGL has also no impact on the B220+/IgM+ B cell population in the SP (B) and LN 
(C) of WT or Eµ-myc mice. (D) Quantification of flow cytometry analysis from experiment (d-f) 
(n=3 mice per genotypes). The graph represents the average percentage of B220+ B lymphocytes 
with SEM. The statistical analysis was performed with the Student unpaired 2-tailed t test. (E) 
Representative flow cytometry histograms showing the large lymphocyte subset (FSC-H subset) 
in the BM of mice with indicated genotypes (left panels). The graph on the right represents the 
quantification of flow cytometry analysis with average percentage of large lymphocytes subsets 
with SEM (n=3 mice per genotype). N.S. for not statistically significant (Student unpaired 2-
tailed t test).  
 
Results	 	 		
170 
 
Suppl.	 Figure	 5:	 Hdac6	 B	 cell	 knockout	 has	 no	 impact	 on	 B	 cell	 populations	 in	 pre-
lymphoma	Eµ-myc	mice	
All experiments were performed in 8-week-old pre-lymphoma mice (unless otherwise indicated). 
Eµ-myc mice and Hdac6 B cell KO (H6KOBC) Eµ-myc mice have comparable B220+ and large 
B220+ and B220low cell numbers. (A-B) Quantification of flow cytometry analysis of BM B cells 
from mice of indicated genotypes Eµ-myc mice with a tumor are shown as control. The bar plots 
represents: (A) average percentage of B220+ B lymphocytes, and (B) average percentage of large 
B220+ cell characteristic for the Eµ-myc phenotype. (C) Quantification of flow cytometry 
analysis from SP, LN, and BM. Bar plots represents average percentage of B220low cells in Eµ-
myc and Eµ-myc H6KOBC mice. Experiments were performed with n=3 mice per genotype. SEM 
are indicated. The statistical analysis was performed with the Student unpaired 2-tailed t test. 
Significant differences in means between genotypes are indicated, *p < 0.05. N.S. for not 
statistically significant.  
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4.5. Supplementary	figures	
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Discussion		
1. Hdac1	and	Hdac2	in	Eµ-myc	B	cell	lymphoma	
In this study, using targeted conditional deletion of Hdac1 and Hdac2, we investigated the 
functional role of these enzymes in normal B cells and the Eµ-myc murine B cell lymphoma 
model. Our data reveal a predominant role of Hdac1 in both non-malignant B cells and Eµ-myc 
tg B cells. We demonstrate that Hdac1 and Hdac2 have a gene dose-dependent pro-oncogenic 
role in Eµ-myc tumorigenesis with a predominant role of Hdac1. Our results highlight the tumor 
promoting role of Hdac1 and Hdac2, in both Eµ-myc tumorigenesis and tumor maintenance.  
 
Hdac1	and	Hdac2	have	no	tumor	suppressor	functions	in	B	cells	
In accordance with previous studies (Yamaguchi et al., 2010), our results show that Hdac1 and 
Hdac2 do not have a tumor suppressor function in B lymphocytes (Figure 1). We found that 
ablation of Hdac1 and/or Hdac2 in non-malignant B cells did not lead to spontaneous tumor 
development, in contrast to T cells (Dovey et al., 2013; Heideman et al., 2013), and epidermal 
cells (Winter et al., 2013), in which Hdac1 and Hdac2 were reported to act as tumor suppressors. 
Consistently, we found that in B cells, Hdac1 and 2 do not regulate Jdp2 (Suppl. Figure 1B), a 
myc-collaborating gene which has been reported to be regulated by Hdac1 and Hdac2 in T cells 
to constrain myc-overexpressing cells from progressing into lymphomas (Heideman et al., 2013). 
One plausible interpretation of this apparent discrepancy between our data and these previous 
studies could be a cell type specific role of Hdac1 and Hdac2.  
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Hdac1	and	Hdac2	have	pro-oncogenic	roles	in	Eµ-myc	tumorigenesis		
We further investigated the function of Hdac1 and Hdac2 in the Eµ-myc murine B cell 
lymphoma model. In accordance with previous reports using HDACis in B lymphoid cancer 
models (Falkenberg and Johnstone, 2014; Haery et al., 2015; West and Johnstone, 2014), we 
could demonstrate that Hdac1 and Hdac2 have pro-oncogenic roles during Eµ-myc tumorigenesis 
(Figure 2). Interestingly, these findings differ from previous studies using a skin tumor model 
(Winter et al., 2013), or acute promyelocytic leukemia (APL) (Santoro et al., 2013), in which 
Hdac1 (but not Hdac2) was reported to act as tumor suppressor during tumorigenesis. 
Interestingly, and consistent with our findings, this was not observed in another Acute Myeloid 
leukemia (AML) subtype close to APL (Matthews et al., 2015). Importantly, Santoro et al., 
reported that pharmacological inhibition of Hdacs phenocopied the effect of Hdac1 short hairpin 
RNA (shRNA) knockdown (KD) only in APL, but not in Eµ-myc tumorigenesis (Santoro et al., 
2013). This divergence indicates that a tumor type or oncogene-specific effects may be at play. 
These different findings may also be due to off targets effects of shRNA used in these studies. 
shRNA induce a broad variety of sequence-non-specific effects, including the deregulation of 
cellular microRNAs (miRNAs) levels (Olejniczak et al., 2016). Interestingly, the deregulation of 
miRNA expression is a common event in cancer (Volinia et al., 2006). Furthermore, miRNAs 
have been shown to have a direct role in lymphomagenesis (Olejniczak et al., 2016). Hence, it is 
tempting to speculate that off targeted miRNAs may accelerate tumor development. Thus, the 
contradicting phenotypes between our study and these previous studies might be explained by 
the following facts: First, genetic deletion is permanent, RNAi (RNA interference) knockdown is 
transient. Second, knockout leads to complete inactivity, RNAi is incomplete. Third, off-target 
effects in RNAi might be at play. Fourth, mouse backgrounds are different. Fifth, different cell 
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systems and cancer models were used. Furthermore, we speculate that differences between these 
systems is likely due to cell type/tissue-specific differences in composition of Hdac1/2 
containing complexes and activities, resulting in different gene expression profiles. In agreement, 
it was previously observed that Hdac1 and Hdac2 have clear different target preferences 
(Yamaguchi et al., 2010) suggesting that they might regulate different set of genes in a cell type 
specific manner. The physiological activity of Hdac1 and Hdac2 enzymes is governed by 
incorporation into Sin3a, NuRD, CoREST and NODE multiprotein co-repressor complexes 
(Brunmeir et al., 2009; Yang and Seto, 2008). However, the molecular specificities of different 
isoforms of Hdac1 and 2 containing complexes are still undefined. Increasing body of evidence 
indicates a heterogeneity in their composition (Kelly and Cowley, 2013). Thus, it is difficult to 
determine which specific Hdac and/or complex is responsible for a specific effect. Importantly, 
some evidence suggests that the composition of these complexes might also be cell-type specific 
(Kelly and Cowley, 2013).  
 
Complete	 Hdac1	 and	 Hdac2	 ablation	 (Hdac1Δ/Δ;Hdac2Δ/Δ)	 prevents	 both,	 Eμ-myc	
tumorigenesis	and	tumor	maintenance	
We further show that complete deletion of both Hdac1 and Hdac2 (Hdac1Δ/Δ;Hdac2Δ/Δ) prevents 
Eµ-myc tumorigenesis (Figure 3). Consistently, we found that Hdac1Δ/Δ;Hdac2Δ/Δ prevents Eµ-
myc splenomegaly, HG-NHL occurrence, reduces leukemia, and prevents the B cell blasts which 
dominate the BM of Eµ-myc mice. These findings reveal that Hdac1Δ/Δ;Hdac2Δ/Δ prevents 
tumorigenesis already in the BM by preventing Eµ-myc induced blast at early B cell stages. This 
is in agreement with our previous report in non-transformed B cells, where Hdac1Δ/Δ;Hdac2Δ/Δ 
induced a cell cycle block at PreBII cell stage (Yamaguchi et al., 2010). We next investigated the 
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direct impact of Hdac1Δ/Δ;Hdac2Δ/Δ on existing Eµ-myc tumor cells using an in vivo 
transplantation approach. We found that conditional ablation of Hdac1 and Hdac2 in tumor cells 
also delays tumor appearance (Figure 4). These findings show that Hdac1Δ/Δ;Hdac2Δ/Δ has a 
direct impact on Eµ-myc tg B cells. Altogether, these results demonstrate a critical pro-oncogenic 
role of Hdac1 and Hdac2 not only in Eµ-myc tumorigenesis but also in tumor progression.  
 
Hdac1	and	Hdac2	are	not	completely	redundant;	Hdac1	has	a	redominant	role		
Interestingly, we observed that single ablation of either Hdac1 (Hdac1Δ/Δ;Hdac2+/+) or Hdac2 
(Hdac1+/+;Hdac2Δ/Δ) had no effect. Whereas Eµ-myc mice with a single allele of Hdac2 
(Hdac1Δ/Δ;Hdac2Δ/+), but not with a single allele of Hdac1 (Hdac1+/Δ;Hdac2Δ/Δ), presented a 
delayed tumor development (Figure 2). This clearly demonstrates that Eµ-myc tumorigenesis is 
Hdac1 and Hdac2 gene dose-dependent, with a predominant role of Hdac1. Hence, a critical 
level of Hdac1 and Hdac2 is required for Eµ-myc tumorigenesis. Several other studies reported a 
similar dosage-dependent effect of Hdac1 and Hdac2 in epidermis (Winter et al., 2013), T cells 
(Heideman et al., 2013), neural cells (Hagelkruys et al., 2014).  
Consistently, we observed that non-malignant B cell development is also Hdac1 and Hdac2 gene 
dose-dependent, with a predominant role of Hdac1 (Figure 6). We previously showed that in a 
non-malignant background B cell differentiation occurs normally in absence of either Hdac1 or 
Hdac2, but that ablation of both, resulted in a B cell developmental block. In this study, we 
further investigate the individual and redundant function of Hdac1 and Hdac2 in normal B cell 
development, by expressing single alleles of either Hdac1 or Hdac2 in the absence of the 
respective paralog in B cells. We show that mice with a single allele of Hdac2 in B cells 
(Hdac1Δ/Δ;Hdac2Δ/+) had significant impact on B cell development, and significant reduction in 
Discussion	 	 		
182 
 
total Hdac activity, indicating that one allele of Hdac2 is not sufficient to maintain proper B cell 
development (Figure 6). In contrast, mice with only one allele of Hdac1 (Hdac1+/Δ;Hdac2Δ/Δ) 
showed no significant changes in B cell development and Hdac activity. Thus, our data indicate 
that a critical level of Hdac1 and Hdac2 (at least one allele of Hdac1 or both alleles of Hdac2) is 
required for B cell development to occur normally. Interestingly, we observed that 
Hdac1Δ/Δ;Hdac2Δ/+ B cells had significantly reduced Hdac activity compared to 
Hdac1+/Δ;Hdac2Δ/Δ B cells. Altogether, these data demonstrate a predominant role of Hdac1, and 
suggest that a critical level of Hdac activity may be required for Eµ-myc tumorigenesis and 
proper B cell development.  
Here, we observe that one allele of Hdac1, but not Hdac2, can compensate for the loss of the 
other paralog in B cells (Figure 2 and Figure 6). Consistently, haploinsufficiency of Hdac2 in 
absence of Hdac1 has also been reported in epidermal cells (Winter et al., 2013) and T cells 
(Dovey et al., 2013). Interestingly, the opposite effect was observed in neural cells (Hagelkruys 
et al., 2014): They demonstrated a predominant effect of Hdac2 in neural progenitor cell during 
brain development. They found that one allele of Hdac2 but not Hdac1 is sufficient for normal 
brain development in absence of its paralog. Similarly, a predominant role of Hdac2 was also 
observed in oocytes (Ma and Schultz, 2013). This different phenotype might be explained by 
cell-type-specific expression pattern of Hdac1 and Hdac2 (Hagelkruys et al., 2014; MacDonald 
and Roskams, 2008). Taken together, these different observations indicate that Hdac1 and Hdac2 
have overlapping but specific functions during mouse development, which can differ between 
cell types and tissues. We therefore conclude that Hdac1 and Hdac2 have only partially 
redundant functions, with a predominant role of Hdac1 in B cells.  
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Our observations are also consistent with some previous studies reporting some enzyme 
specificities for Hdac1 and Hdac2. For example, Hdac1 and Hdac2 are not redundant during 
mouse embryogenesis, since the two paralogs cannot compensate for each other (Lagger et al., 
2002; Trivedi et al., 2007; Zupkovitz et al., 2010). Interestingly, Hdac1, but not Hdac2 was 
shown to be essential in this process: deletion of Hdac1 impairs cell cycle and results in 
embryonic lethality (Lagger et al., 2002), whereas deletion of Hdac2, leads to perinatal lethality, 
partial embryonic lethality or partial postnatal lethality, depending on the knockout strategy 
(Guan et al., 2009; Montgomery et al., 2007; Reichert et al., 2012; Trivedi et al., 2007; 
Zimmermann et al., 2007; Zupkovitz et al., 2010). Similarly, Hdac1, but not Hdac2, has been 
shown to control embryonic stem cell differentiation (Dovey et al., 2010).  
We observe that Hdac1 can compensate for the loss of the other paralog in B cells. We found 
that this compensation occurs at protein level (Figure 6E), but not at mRNA level (Suppl. Figure 
1B), indicating a posttranslational compensatory mechanism as previously reported (Winter et 
al., 2013). Interestingly, ablation of Hdac1 resulted in massive increase in Hdac2 protein levels. 
However, this increase of Hdac2 upon Hdac1 KO is not sufficient to compensate for the absence 
of Hdac1, highlighting the predominant role of Hdac1. Interestingly, Hdac1 may act 
independently of Hdac2, as shown by co-immunoprecipitation experiments revealing that 40% of 
Hdac1 exist independently of Hdac2 (Yamaguchi et al., 2010). This may explain specific non-
redundant functions of Hdac1. Consistently, several other studies reported that ablation of either 
Hdac1 or Hdac2 led to increased expression of the other paralog (Chen et al., 2011; Dovey et al., 
2010; Jurkin et al., 2011; Lagger et al., 2002; Lagger et al., 2010; Santoro et al., 2013; Wilting et 
al., 2010; Yamaguchi et al., 2010; Zupkovitz et al., 2006). 
 
Discussion	 	 		
184 
 
Hdac1Δ/Δ;Hdac2Δ/+	impacts	on	proliferation	and	apoptosis	of	Eμ-myc	B	cells	
Similar to Hdac1Δ/Δ;Hdac2Δ/Δ, we found that Hdac1Δ/Δ;Hdac2Δ/+ impacts on Eµ-myc 
tumorigenesis by reducing the Eµ-myc induced blast at early preBII cell stage in the BM, 
resulting in reduced circulating tumor cells (Figure5). We further investigated whether the 
impact of Hdac1Δ/Δ;Hdac2Δ/+ in Eµ-myc B cells could be due to proliferation defects and/or 
apoptosis. Strikingly, we found that Hdac1Δ/Δ;Hdac2Δ/+ decreased proliferation and increased 
apoptosis in Eµ-myc B cells (Figure 7). These findings are consistent with earlier studies 
reporting that complete loss of Hdac1 and Hdac2 induces cell death in proliferating cells, 
including B and T cells (Dovey et al., 2013; Heideman et al., 2013; Reichert et al., 2012; 
Yamaguchi et al., 2010). Interestingly, combined deletion of both, Hdac1 and 2, has been shown 
to induce a cell cycle block only in proliferating cells, whereas their deletion in postmitotic, 
(resting) cells had no effect (Haberland et al., 2009a; Yamaguchi et al., 2010). Hence, this clearly 
shows, that dual loss of Hdac1/2 is not compatible with proliferation. Several labs including ours 
reported that Hdac1 and Hdac2 regulate G1-S-phase transition of the cell cycle by increasing the 
levels of cyclin-dependent kinase inhibitors (CKI) including p21WAF/CIP1, p27KIP1, and p57KIP2 
preventing cell cycle progression in different cellular systems including primary and transformed 
cells (Lagger et al., 2002; Senese et al., 2007; Yamaguchi et al., 2010; Zupkovitz et al., 2010). In 
this study we observe that Hdac1Δ/Δ;Hdac2Δ/+ reduces proliferation of Eµ-myc tg B cells. 
Although the mechanism underlying this proliferation defect remains elusive, it is tempting to 
speculate that similar pathways could be activated upon loss of these enzymes in Eµ-myc tg B 
cells. In contrast, loss of Hdac1 was linked to enhanced proliferation in T cells (Dovey et al., 
2013; Grausenburger et al., 2010; Heideman et al., 2013) and epithelial cells (Lagger et al., 2010; 
Winter et al., 2013). The reason for this discrepancy is still unclear, but it suggests that the 
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impact of Hdac1 (and Hdac2) on proliferation is dependent on the cell type and possibly on its 
corresponding target genes.  
We observed, that Hdac1Δ/Δ;Hdac2Δ/+ increases apoptosis in Eµ-myc tg B cells. Consistently, 
apoptosis has been shown to be increased upon combined loss of Hdac1 and Hdac2 in many 
different cell types, including B cells (Yamaguchi et al., 2010), T cells (Heideman et al., 2013), 
fibroblasts (Haberland et al., 2009a), keratinocytes (Winter et al., 2013), and others (Hagelkruys 
et al., 2014; Jacob et al., 2011; Ma et al., 2012; Montgomery et al., 2007). Interestingly, Eµ-myc 
driven tumorigenesis requires inactivation of apoptosis for malignant transformation to occur 
(Eischen et al., 1999). Resistance to apoptosis in tumors arising in Eµ–myc transgenic mice is 
frequently acquired through spontaneous inactivation of the ARF–Mdm2–p53 tumor-suppressor 
pathway (Eischen et al., 1999). Interestingly, Hdac1 was shown to deacetylate p53, which is then 
destabilized and degraded, and thereby represses p53-dependent transcription (Ito et al., 2002; 
Luo et al., 2000; Tang et al., 2008). In line with this, Hdac1 and Hdac2 were shown to be the 
major targets for HDACi-mediated apoptosis induction (Inoue et al., 2006). Altogether, these 
findings demonstrate that Hdac1Δ/Δ;Hdac2Δ/+ reduces Eµ-myc induced blast in the BM and 
delays tumorigenesis by decreasing proliferation and inducing apoptosis.  
 
Future	medical	impact	
Our results provide an insight into the important pro-oncogenic roles of Hdac1 and Hdac2 in Eµ-
myc tumorigenesis. Our study is fully consistent with the use of HDACis in clinics: Currently, 
four pan-HDACis, targeting classI and/or classII HDACs (Bantscheff et al., 2011), varinostat, 
romidepsin, belinostat, and panobinostat, are Food and Drug Administration (FDA)-approved for 
the following hematological malignancies: Cutaneous T cell lymphoma (CTCL), Peripheral T 
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cell lymphoma (PTCL) and multiple myeloma (Ghobrial et al., 2013; Rasheed et al., 2008; 
Richardson et al., 2013; San-Miguel et al., 2013), and several others are in clinical trials for 
various cancers, including B cell malignancies (Haery et al., 2015). Previous studies already 
demonstrated that pan-HDACis have therapeutic efficacy in Eµ-myc lymphoma (Ellis et al., 
2009b; Lindemann et al., 2007; Newbold et al., 2008; Newbold et al., 2013; Newbold et al., 
2014). However, until recently, it was still not known whether single HDAC1 or HDAC2 
isoform-selective inhibitors would impact on cell growth and/or survival. Our findings 
demonstrate that HDAC1 and HDAC2 can be considered as important players in Eµ-myc 
tumorigenesis suggesting that selective HDAC1 and HDAC2 inhibitors could be effective for the 
treatment of BL, modeled by our preclinical Eµ-myc system, and possibly other hematological 
malignancies including DLBCL. This provides a rational for the development of Hdac1 and/or 
Hdac2 isoform-selective inhibitors. However, there are currently no available HDAC1-specific 
and only few HDAC2-specific inhibitors (Wagner et al., 2015), but there are several compounds 
capable of inhibiting both HDAC1 and HDAC2. For example, two novel HDAC1 and Hdac2 
isoform selective inhibitors, RGFP233 (Matthews et al., 2015) and MRLB-223 (Newbold et al., 
2013), were shown to induce apoptosis in Eµ-myc lymphoma cells in vitro and in vivo, 
respectively. Two other Hdac1 and Hdac2 isoform specific HDACis; K560 (Choong et al., 2016) 
and Cpd60 (Methot et al., 2008; Schroeder et al., 2013; Stubbs et al., 2015) were recently tested 
in other disease models but not in Eµ-myc model. Although several of these agents were shown 
to have an in vitro and/or in vivo therapeutic efficacy in pre-clinical models like Eµ-myc, it is 
possible that different drugs may have different mechanistic, biological, and therapeutic 
activities. Furthermore, it is still unclear whether selective HDAC1 and HDAC2 inhibition might 
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have comparable therapeutic benefit and limit toxicity observed with these broad-spectrum 
inhibitors (Dawson and Kouzarides, 2012; Ononye et al., 2012).  
Interestingly, we found human HDAC1 but not human HDAC2 mRNA expression is increased 
in some Burkitt’s lymphoma (BL) and diffuse large B cell lymphoma (DLBCL) cancer cell lines 
and human lymphoma samples compared to other cancer cell types and other human cancer 
samples, respectively (Suppl. Figure 3). Hence, these data are consistent with our findings 
outlined above, revealing a predominant role of Hdac1. Comprehensive knowledge about the 
different expression profiles as well as their specific involvement in the different disease settings 
is crucial for future use in personalized therapies. The current aim in HDAC cancer drug 
discovery is to find predictive biomarkers that can predict responsiveness to HDACi therapy 
(Stimson and La Thangue, 2009). Further work is required to determine whether tumor cells with 
low HDAC activity are more responsive to HDAC inhibition. If this is the case, decreased 
HDAC-activity might be used as a predictive marker for HDACi sensitivity. Hence, in a clinical 
setting, patients having tumors with low HDAC activity level could benefit more from HDACis, 
whereas patients having tumors with high levels of HDAC activity would need higher doses of 
the inhibitor.  
 
General	conclusion	-	Hdac1	and	Hdac2	
In conclusion, our results demonstrate that Hdac1 and Hdac2 promote tumor initiation and tumor 
progression in Eµ-myc mice by regulating proliferation and apoptosis. This is the first study 
showing a gene dose-dependent pro-oncogenic role of Hdac1 and Hdac2 in tumorigenesis.  
Despite improved knowledge about the function of these Hdacs, many aspects remain 
unexplored. Future research will focus on identifying which Hdac isoforms are relevant in the 
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different cancer types. Future studies may use knockin mice with catalytically inactive Hdac1 
and Hdac2 and mutant forms of Hdac1 and Hdac2 which bind only to specific co-repressor 
complexes. Most importantly, future research will focus on elucidating the underlying molecular 
mechanism, by which Hdac1 and Hdac2 regulate proliferation and apoptosis in malignant and 
non-malignant cells. The comprehension of these and other mechanisms will help to design 
selective HDACis with possibly less side effects than pan-HDACis. The predominant role of 
Hdac1 that we unravel in this study, raises the prospect of using selective HDAC1 inhibitor in 
clinics for the treatment of BL and other B cell lymphomas with Myc deregulation.  
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2. Hdac1	and	Hdac2	in	B	cell	development	
In collaboration with R.M. Heideman, I investigated the role of Hdac1 and Hdac2 in B cell 
development. We could confirm our previous findings (Pillonel et al., Accepted for publication 
in Scientific Reports) that Hdac1Δ/Δ;Hdac2Δ/+, but not Hdac1+/Δ;Hdac2Δ/Δ leads to severely 
affected B cell development with a partial developmental block at the PreBI cell stage, and 
significantly reduced number of PreBII (Suppl. Figure 2). In addition, we demonstrate that 
Hdac1Δ/Δ;Hdac2Δ/+ mice have significantly reduced immature B cells. Importantly, we also 
observe, that Hdac1Δ/Δ;Hdac2Δ/+ mice have normal numbers of splenic B cells (Suppl. Figure 2). 
This indicates that the few PreBII cells left in Hdac1Δ/Δ;Hdac2Δ/+ mice are sufficient to 
eventually fill up the pool of mature B cells in the secondary lymphoid organs, including SP.  
We further investigated whether the observed impact of Hdac1Δ/Δ;Hdac2Δ/+ on PreBI and PreBII 
cells could be due to proliferation defects or apoptosis. Interestingly, we show that upon 
Hdac1Δ/Δ;Hdac2Δ/+, PreBII cells proliferate less (Figure 2). These findings are fully consistent 
with earlier studies reporting that complete loss of Hdac1 and Hdac2 (Hdac1Δ/Δ;Hdac2Δ/Δ) 
induces a cell cycle block at PreBII cell stage (Yamaguchi et al., 2010). Consistently, we observe 
that upon Hdac1Δ/Δ;Hdac2Δ/+, PreBII are also arrested in G0/G1-phase of the cell cycle (Figure 
1A). Furthermore, apoptosis has been shown to be increased upon Hdac1Δ/Δ;Hdac2Δ/Δ in B cells 
(Yamaguchi et al., 2010). In contrast, our preliminary data did not show any increase in 
apoptosis in PreBII cells upon Hdac1Δ/Δ;Hdac2Δ/+ (Figure 2). Further experiments will be needed 
to confirm this.  
Interestingly, we observed that in Hdac1Δ/Δ;Hdac2Δ/+ mice, PreBI cells express highly the stem 
cell marker c-kit, which suggests, that these PreBI cells remain probably in a less differentiated 
state (Suppl. Figure 2B). Consistently, we also found that Sca-1 is highly expressed at the surface 
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of Hdac1Δ/Δ;Hdac2Δ/+ PreBI cells (R.M.Heideman., data not shown). Interestingly, we observed 
that upon Hdac1Δ/Δ;Hdac2Δ/+, PreBI cell proliferate more and undergo less frequently apoptosis 
(Figure 2). These findings could suggest that Hdac1Δ/Δ;Hdac2Δ/+ PreBI cells might undergo less 
frequently apoptosis because they might have a problem with V(D)J recombination, and hence, 
could not differentiate to PreBII cells. This would explain the massive decrease in PreBII cell 
number we observe in Hdac1Δ/Δ;Hdac2Δ/+ mice (Suppl. Figure 2B). We therefore performed flow 
cytometry analysis of intra cellular IgM staining. Our preliminary results demonstrate, that 
Hdac1Δ/Δ;Hdac2Δ/+ decreases intra cellular IgM+ in PreBI cells (Figure 3A). Our preliminary 
findings could suggest that less IgM rearrangement is occurring in Hdac1Δ/Δ;Hdac2Δ/+ PreBI 
cells. The IL7 receptor alpha (IL7Ra), is crucial for V(D)J rearrangement of heavy chain in 
PreBI cells, and light chain in PreBII cells, by (Corcoran et al., 1998; Hamel et al., 2014). 
Interestingly, and consistent with the findings outlined above, we also found that IL7Ra 
expression is slightly reduced in PreBI cells and in large PreBII cells of Hdac1Δ/Δ;Hdac2Δ/+ mice 
(R.M. Heideman, data not shown).  
Our preliminary results provide an insight into the role of Hdac1 and Hdac2 in B cell 
development. Future research directions will focus on investigating the role of these enzymes in 
V(D)J recombination and IgH and IgL allelic exclusion. We hypothesize that PreBI cells cannot 
differentiate to PreBII because they have less intra IgM due to a problem with V(D)J 
recombination. Future experiments will be needed to test this hypothesis. This could be done for 
example by trying to rescue phenotype in vivo with a V(D)J knock in mouse. If our hypothesis is 
correct, one then could test for the recombination activation genes 1 (RAG1) and 2 (RAG2), 
V(D)J locus contraction by PCR or by FISH, as well as locus acetylation upon 
Hdac1Δ/Δ;Hdac2Δ/+.  
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We observed that Hdac1Δ/Δ;Hdac2Δ/+ mice have increased H3-acetylation (Suppl. Figure 2), and 
normal number of B cells (R.M. Heideman, data not shown). Future research will investigate the 
impact of altered acetylation (upon Hdac1Δ/Δ;Hdac2Δ/+) on class switch recombination (CSR) 
and somatic hyper mutation (SHM) in the SP. We hypothesize that in Hdac1Δ/Δ;Hdac2Δ/+ B cell 
with high H3-Ac H4-Ac, the Ig locus would be more open, and this could have an impact on 
CSR. To test this, one could challenge cells with IL-4 and CD40, which activates the activation 
induced cytidine deaminase (AID), the initiator of both CSR and SHM, and measure CSR by 
flow cytometry and test SHM by sequencing.  
In conclusion, our result demonstrate that Hdac1Δ/Δ;Hdac2Δ/+ mice have abnormal early B cell 
development and suggests possible defects in V(D)J recombination. Despite improved 
knowledge about the function of Hdac1 and Hdac2, many aspects still remain unexplored. Future 
research will be needed to dissect the exact functional role of Hdac1 and Hdac2 in B cell 
development, and to characterize the underlying molecular and regulatory mechanisms. We 
already performed an RNA-seq analysis in PreBI cells from Hdac1Δ/Δ;Hdac2Δ/+ vs control 
Hdac1+/+;Hdac2+/+ mice, and found several up- and downregulated genes, and are currently 
validating these hits (R.M. Heideman, data not shown).  
In the case that V(D)J recombination, CSR or SHM are affected in Hdac1Δ/Δ;Hdac2Δ/+ B cells, it 
would be interesting to test whether these processes are also affected during Eµ-myc 
tumorigenesis upon Hdac1Δ/Δ;Hdac2Δ/+. This could help to uncover mechanisms by which 
Hdac1Δ/Δ;Hdac2Δ/+ delays Eµ-myc tumorigenesis (Pillonel et al., Accepted for publication in 
Scientific Reports), and ultimately, will help to better understand the function of the two pro-
oncogenic proteins Hdac1 and Hdac2 in B lymphoid malignancies.  
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3. Hdac6	in	Eµ-myc	B	cell	lymphoma	
In this side project, we investigated the functional role of Hdac6 in the Eµ-myc murine B cell 
lymphoma model. We used mice with Hdac6 OE (H6OE), Hdac6 B cell specific conditional KO 
(H6KOBC), and Hdac6 germ line knockout (H6KOGL). Three main findings arise from this study. 
First, we show that H6OE accelerates lymphomagenesis, whereas H6KOGL may delay tumor 
development in Eµ-myc mice (Figure 2). Second, H6OE increases, and H6KOGL decreases the 
percentage of PBL at early stages of Eµ-myc tumorigenesis (Figure 3). Third, H6OE increases 
(Figure 4) and H6KOGL decreases tumor cell load in Eµ-myc mice (Figure 5). Our data show that 
Hdac6 plays a pro-oncogenic role during Eµ-myc tumorigenesis. 
We observe that high human HDAC6 expression predicts poor prognosis in DLBCL patients 
(online available datasets on DRUGSURV). This observation is consistent with previous studies 
reporting that HDAC6 is overexpressed in several lymphoid malignancies including ALL 
(Bradbury et al., 2005; Moreno et al., 2010; Van Damme et al., 2012), AML (Bradbury et al., 
2005), CLL (Van Damme et al., 2012; Wang et al., 2011) and CTCL (Marquard et al., 2008), 
and DLBCL (Marquard et al., 2009; Zhang et al., 2004). In accordance, HDAC6 was shown to 
have oncogenic roles in AML (Bradbury et al., 2005), and was also found to be overexpressed in 
advanced stage of ALL (Bradbury et al., 2005). However, HDAC6 may also play a role as tumor 
suppressor (Seidel et al., 2015). OE of HDAC6 correlates with a good prognosis in DLBCL 
(Marquard et al., 2009), CLL (Van Damme et al., 2012) and CTCL (Marquard et al., 2008) and 
HDAC6 underexpression was found to be correlated with a poor prognosis in CLL (Van Damme 
et al., 2012). Hence, the exact role of HDAC6 in the different cancer types remains elusive.  
Interestingly, we found that only H6KOGL, but not H6KOBC, had an impact on tumor cell load. 
The cause of this difference is presently unclear. It is tempting to speculate that tumor cell 
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extrinsic effects in the tumor microenvironment might be at play. In this context, targeting all 
cell using Hdac6 isoform-selective HDACis, like tubacin, might be useful. Our data suggest that 
such Hdac6 specific HDACis may provide some antitumor effects, and may be effective for the 
treatment of hematolological malignancies modeled by our preclinical Eu-myc system.  
Further work is required to elucidate the molecular mechanism by which Hdac6 impacts on Eµ-
myc tumorigenesis. It would be interesting to investigate the impact of HOE and H6KO on 
HSP90 client oncoproteins, which have been proposed to be degraded upon HDACi treatment 
(Bolden et al., 2006). Such proteins were shown to be involved in invasion and metastasis (Yang 
et al., 2008). Besides this, it would be interesting to test other pathways which could be affected 
in this context. Hdac6 has been shown to be implicated not only in cell motility, and EMT (Shan 
et al., 2008), but also in proliferation of cancer cells (Hagelkruys et al., 2011; Lee et al., 2008),  
In conclusion, our findings highlight the tumor promoting role of Hdac6 in Eµ-myc 
tumorigenesis, and opens new avenues of research for the future. 
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Material	and	methods		
Experimental	mice		
The Hdac1F/F;Hdac2F/F conditional knockout (cKO) mice were as described in the manuscript 
Pillonel et al. (Result Part1). Hdac6 germ line knockout (H6KOGL), and Hdac6 conditional KO 
mice were generated in the lab by Dr. Yu Zhang (Zhang et al., 2008). Hdac6 overexpressing 
(H6OE) mice were generated previously by Dr. Yu Zhang in the lab (unpublished). To generate 
these mice, a Bacterial Artificial Chromosome (BAC) clone (50M7) which contains the murine 
Hdac6 gene (Means et al., 2000) was injected into the pronucleus of fertilized mouse oocytes. 
Founders were screened by PCR and Southern blot. Overexpression of HDAC6 protein was 
confirmed by Western blot. BAC tg mice overexpressiong Hdac6 (H6OE) were crossbred with 
Eµ-myc tg mice. B lymphocyte specific deletion of Hdac6 (H6KOBC) was obtained using 
heterozygote Mb1-cre transgenic (tg) mice (Hobeika et al., 2006) in combination with Hdac6 
cKO (floxed) alleles. All these mice were interbred to heterozygote Eµ-myc tg mice as described 
in the manuscript Pillonel et al. (Result Part1). All experiments were done with mice in pure 
C57BL/6 (Ly5.2+) genetic background (backcrossing at least 11 generations). Mice were bred 
and housed as described in the manuscript Pillonel et al. (Result Part1). All animal experiments 
were approved and carried out according to regulations effective in the Kanton of Basel-Stadt, 
Switzerland.  
 
Genotyping	PCR		
Polymerase chain reaction (PCR)–based genotyping was performed on tail-derived DNA. Mice 
were genotyped for Hdac1 and Hdac2 conditional alleles, Eµ-myc tg, Mb1-Cre tg and Actin-Cre 
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tg, as described in the manuscript Pillonel et al. (Result Part1). Genotyping for Hdac6 germline 
KO (H6KOGL) and Hdac6 B cell specific KO (H6KOBC) was determined by PCR, with primers 
spanning the deleted Exons of the HDAC6 gene (Zhang et al., 2008). Primers P1 (Forward; 5’-
GTA CAA TGT GGC TCA CAG AA) and P45 (Reverse; 5’-CAG GCA CAG GAA TAT GAG 
TT) were used to detect the wild type (WT) and floxed (FL) alleles, and P1 and P42 (Reverse; 
5’-CAA CTC TGC CTC TCC TGG AT) to detect the knockout (KO). For detecting the HDAC6 
overexpressing BAC construct (H6OE), we used: Forward; 5’-CCG TCG ACC AAT TCT CAT 
GT, and Reverse; 5’-CGC AAG ATG TGG CGT GTT AC. PCRs were performed using the 
GoTaq Flexi DNA Polymerase Kit (Promega, Cat.M8306) and MJ Mini Thermal Cyclers 
(BioRad).  
 
RNA	isolation	and	Quantitative	Real-Time	PCR	(RT–qPCR)	
Quantitative real-time PCR (RT-qPCR) analysis was performed as described in the manuscript 
Pillonel et al. (Result Part1). The following primers were used: Hdac1 (forward; 5’-ACG GCA 
TTG ACG ACG AAT C; and reverse; 5’-TAA GAC CAC TGC ACT AGG CTG G); for Hdac2 
(forward; 5’-CCA GAG GAT GCT GTT CAT GA; and reverse; 5’-GCT ATC CGT TTG TCT 
GAT GCT); Jdp2 (forward; 5’-CGC TGA CAT CCG CAA CAT TG; and reverse; 5’-CAT CTG 
GCT GCA GCG ACT TT).  
 
Histopathological	analysis	and	Immunohistochemistry	(IHC)	
Tumor sections from LN, SP, thymus, (lung, heart, liver) were fixed in formalin (Shandon 
Formal-Fixx, Thermo Scientific, Cat.9990244) for 24h. Tissues were transferred in embedding 
cassettes and kept in 70% ethanol for 30 min before dehydration in the medite tissue processor 
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(TPC15) and subsequent embedding in paraffin. Paraffin-embedded tissue were cut in 3-µm-
thick sections with an automatic microtome (Microm HM355S, Thermo Scientific). Sections 
were subjected to classical hematoxylin and eosin (H&E) staining. Histopathological evaluation 
was performed by Prof. Dr. Alexandar Tzankov, an experienced hematopathologist and head of 
the histopathology & autopsy at the university hospital Basel. Examinations were first performed 
in blind by the pathologist to determine any pathological findings, and subsequently joint 
reviewed with the student V.P. using a multiheaded microscope. Pathological finding of high 
grade Non-Hodgkin Lymphoma (HG-NHL) (corresponding to Burkitt’s lymphoma in men) were 
scored in these organ sections according to the Bethesda proposals for classification of lymphoid 
neoplasms in mice (Morse et al., 2002). Histopathological evaluation of sick Hdac1Δ/Δ;Hdac2Δ/Δ 
mice was performed in collaboration with the pathologist Dr. Annabelle Heier (NIBR, Novartis 
Pharma, Basel).  
Immunohistochemistry experiments were performed on Ventana DiscoveryUltra instrument 
(Roche Diagnostics, Manheim) with the procedure RUO Discovery Universal. CC1 (Roche 
Diagnostics, Manheim) pre-treatment was used for anti-HDAC1, -HDAC2, -c-Myc and -CD45 
antibodies with the following incubation times: 16, 24, 72 and 32 min respectively. Antibodies 
were incubated for one hour at 37°C except for anti-c-Myc and –CD45 which were incubated for 
16 and 32 min respectively. In addition, a blocking step (Innovex Background Buster NB306, 
Innovex, 12 min incubation) was added for anti-HDAC1 and -HDAC2 antibodies. Detection of 
bound anti-HDAC1, -HDAC2 and -c-Myc antibodies was achieved by using anti-rabbit HQ 
followed by anti-HQ horseradish peroxidase (Roche Diagnostics, Manheim) incubated for 32 
min at 37°C. To detect anti-CD45 a rabbit anti-rat linker was applied for 20 min at 37°C. Finally, 
bound anti-p53 and anti-B220 were detected by using a secondary antibody (ImmPRESS reagent 
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kit peroxidase anti-rabbit Ig MP-7401, Vector) applied manually (200 microliters) and incubated 
for 32 min at 37°C. ChromoMap DAB kit (Roche Diagnostics, Manheim) was used for the 
detection and slides were counterstained with Hematoxylin II and Bluing Reagent (Roche 
Diagnostics, Manheim) for 8 min. Hdac1 and Hdac2 staining were used to confirm the genotype 
of the lymphoma. Scoring for p53 staining intensity in Eµ-myc tumors was performed by using a 
wild-type spleen as a negative control.  
 
Immunofluorescent	staining,	flow	cytometric	analysis,	and	cell	sorting	
Flow cytometry analysis was performed as described in the manuscript Pillonel et al. (Result 
Part1). Intra cellular IgM staining was performed with anti-IgM conjugated to APC (clone II/41) 
using the cytofix/cytoperm method according to the manufacturer’s instruction (BD 
Biosciences). Sorting was performed on the basis of forward (FSC) and side light scatter (SSC), 
by exclusion of doublets and by staining with the indicated B cell subset surface markers. 
Absolute cell numbers of B lymphoid subpopulations were determined by counting cells 
excluding Trypan Blue Dye and multiplying cell numbers by the percentage of cell subsets as 
determined by flow cytometry.  
 
Oncomine,	Cancer	Cell	Line	Encyclopedia	and	DRUGSURV	database	analysis	
Oncomine and Cancer Cell Line Encyclopedia database analysis was performed as described in 
the manuscript Pillonel et al. (Result Part1). The free online computational tool DRUGSURV 
was used to examine whether there is any correlation of HDAC1, HDAC2 and HDAC6 gene 
expression with survival outcome in patients with cancer (http://www.bioprofiling.de/PPISURV) 
(Amelio et al., 2014; Antonov et al., 2014). 
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Additional	material	and	methods	
The following methods were performed as described in the manuscript Pillonel et al. (Result 
Part1): KPLM analysis, Eµ-myc lymphoma transplantation, blood sampling and analysis, 
cell preparation, B cell isolation by MACS, In vivo cell cycle analysis by BrdU 
incorporation, Apoptosis assay, Protein extracts and Western blot analysis, In vitro Hdac-
activity assay, Affymetrix expression analysis, Statistical analysis.  
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Abstract
We have identified expression of the gene encoding the transcriptional coactivator FOG-1 (Friend of GATA-1; Zfpm1, Zinc
finger protein multitype 1) in B lymphocytes. We found that FOG-1 expression is directly or indirectly dependent on the B
cell-specific coactivator OBF-1 and that it is modulated during B cell development: expression is observed in early but not in
late stages of B cell development. To directly test in vivo the role of FOG-1 in B lymphocytes, we developed a novel
embryonic stem cell recombination system. For this, we combined homologous recombination with the FLP recombinase
activity to rapidly generate embryonic stem cell lines carrying a Cre-inducible transgene at the Rosa26 locus. Using this
system, we successfully generated transgenic mice where FOG-1 is conditionally overexpressed in mature B-cells or in the
entire hematopoietic system. While overexpression of FOG-1 in B cells did not significantly affect B cell development or
function, we found that enforced expression of FOG-1 throughout all hematopoietic lineages led to a reduction in the
number of circulating eosinophils, confirming and extending to mammals the known function of FOG-1 in this lineage.
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Introduction
The development of specialized hematopoietic cells from self-
renewing hematopoietic stem cells proceeds through a number of
precursor stages with progressively restricted differentiation
potential and requires a complex interplay of transcription factors
and epigenetic modifiers. These regulators are responsible for
orchestrating the establishment of lineage-specific gene expression
patterns that underlie cellular differentiation (reviewed in [1,2]).
While many factors involved in this process are already known, a
complete molecular understanding is still missing. Friend of
GATA-1 (FOG-1), which is encoded by the Zfpm1 (Zinc finger protein
multitype 1) gene, was previously thought to be expressed primarily
in cells of the erythroid and megakaryocytic lineages, where it is
essential for differentiation [3,4]. FOG-1 is a zinc finger protein
initially identified as an interacting partner of GATA factors which
contributes to activation or repression of their target genes [3,5,6].
FOG-1 also interacts with the C-terminal binding protein (CtBP),
mainly described as a corepressor and the nucleosome remodelling
and histone deacetylase repressive (NuRD) complex and thus
makes a link between transcription factors and chromatin
modifiers. FOG-1 also activates or represses gene transcription
by facilitating binding of GATA factors to DNA [7], recruiting
chromatin remodelling complexes [5,8], or by stabilizing tissue-
specific chromatin loops [9]. FOG-1 is expressed at high level in
multipotent progenitors, erythroid and megakaryocytic cells, low
level in lymphoid and haematopoietic stem cells; it is absent in
myeloid lineages [3]. Zfpm1-deficient mice lack megakaryocytes
and show severe defects in erythropoiesis, leading to embryonic
lethality [4]. FOG-1 also plays a role in the T-lineage by repressing
GATA-3-dependent induction of Th2 development [10,11].
Interestingly, overexpression of FOG-1 in avian eosinophils,
which do not normally express FOG-1, reprograms these
differentiated cells into multipotent cells [12], reminiscent of the
reprogramming of B-cells into macrophages following ectopic
expression of C/EBPalpha and C/EBPbeta [13,14]. Thus, FOG-1
is essential for specific branches of the haematopoietic system, and
its inappropriate expression leads to abnormal cell differentiation.
Strikingly, we have identified relatively high FOG-1 expression
in early B-lymphocytes, and low or lack of expression in late
developmental stages such as mature B-cells and plasma cells. In
analogy to some of the systems mentioned above, we were
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intrigued by the regulated expression of FOG-1 during B cell
development and hypothesized that the downregulation of FOG-1
might be a necessary step for proper differentiation and function of
mature B cells. We therefore set out to test this hypothesis and for
this made use of a novel transgenic mouse model strategy based on
recombination mediated cassette exchange (RMCE, [15,16])
which we had designed to generate mice with conditional
overexpression of any cDNA. Using this system, we generated
transgenic mice in which FOG-1 expression was enforced at a
physiologically relevant level in mature B-cells or in the entire
hematopoietic system. We found that sustained FOG-1 expression
in mature and late B cells did not affect their development or
function, contrary to our hypothesis. In contrast, overexpressing
FOG-1 in the whole hematopoietic system led to a reduction in the
number of circulating eosinophils, confirming and extending to
mammals the previously reported role of FOG-1 in repressing
avian eosinophil development.
Materials and Methods
Ethics statement
Animal experimentation was carried out according to regula-
tions effective in the canton of Basel-Stadt, Switzerland. All
experimental procedures were approved by the Animal Commit-
tee of the Friedrich Miescher Institute for Biomedical Research
and the Veterinary office of the Kanton Basel Stadt.
Generation of the targeting pR26-SA-FRT-Hygror vector
The backbone of a pre-existing targeting vector pR26-STOP-
FRT-Hygro [17] was adapted to allow transcription from the
endogenous Rosa26 promoter. After removal of the unwanted
sequences, the backbone vector contained two homology arms and
the hygromycin B resistance gene flanked by an FRT3 and an
FRTwt sites in 59 and 39, respectively. The 59 and 39 homology
arms correspond to Chr6: 113 024 284–113 026 000 and to
Chr6: 113 021 493–113 024 090 using the mm9 assembly on the
UCSC genome browser. The integration site maps about 2 kb
downstream of the insertion point obtained with the targeting
vector pROSA26-1 [18]. The splice acceptor sequence (SA) of the
STOP-eGFP-Rosa26TV vector (Adgene plasmid 11739) was PCR
amplified and cloned upstream of the FRT3 site [19]. The STOP
sequence from Adgene plasmid 11739 is based on SV40 polyA
sites.
Generation of the control and FOG-1 donor vectors
The backbone of the donor vector, containing the FRT3 site, a
polyA sequence and the FRTwt site, was derived from the FRT3-
CAG-lox-stop-lox-Enpp1-tkNeo-FRTwt [17] vector and was
further modified as follows. The loxP-Neo-STOP-loxP cassette
was PCR amplified from the STOP-eGFP-Rosa26TV vector
(Adgene plasmid 11739) with 59-tagccctaggcttcgcggtctttccagtggt-39
and 39-atgcaccggtcttcggtaccgaattgatcg-59 containing an AvrII and
an AgeI site, respectively. This fragment was cloned downstream
of the FRT3 site using SpeI and AgeI sites. The IRES-hCD2t
fragment was obtained from the pBS-IRES-hCD2t vector (kindly
provided by M. Busslinger, Vienna, [20]) and cloned downstream
of the loxP-Neo-STOP-loxP cassette. The resulting control donor
vector FRT3-loxP-Neo-STOP-loxP-IRES-hCD2t-FRTwt harbors
a unique NotI site in between the second loxP site and the IRES
sequence. The FlagFOG-1 cDNA which is encoded by the Zfpm1
gene was obtained from a pcDNA3-FlagFOG-1 vector (kindly
provided by M. Crossley, Sydney) and cloned in the NotI site of
the control donor vector, resulting in the 10.9 kb FOG-1 donor
vector: FRT3-loxP-Neo-STOP-loxP-FlagFOG-1-IRES-hCD2t-
FRTwt.
Targeting of ES cells
The SacI-linearized targeting pR26-SA-FRT-Hygror vector was
electroporated into 129 sv jae ES cells. Electroporated ES cells
were then selected with 0.1 mg/ml hygromycin B. 480 hygro-
mycin-resistant clones were collected, and five potentially success-
fully recombined clones were identified by PCR screening using
the following primer pair (0F: ctactggaaagaccgcgaag, 0R:
tacctttctgggagttctctgc, 2 kb product).
Southern blot analysis
Verification of ES cell targeting: 10 mg of genomic DNA was
analyzed by standard Southern blotting. Genomic DNA was
restricted with BamHI, PstI or PvuII to confirm the 59, 39 and
single integration of the targeting vector, respectively. The 59 and
39 probes were PCR amplified from genomic DNA with the
following primers: 59 fwd: cgcctaaagaagaggctgtg and 59 rev:
gactggagttgcagatcacg; 39 fwd: agccatctgggccttttaac and 39 rev:
aagggcacagacaatccttc. The 59 probe highlighted a 5.8 kb wild-type
and a 4.9 kb targeted bands. The 39 probe detected a 6.5 kb wild-
type and a 7.5 kb targeted bands. The internal hygromycin probe
was obtained from the targeting vector and highlighted an 8 kb
band.
Verification of the RMCE targeting: 20 mg of genomic DNA
was analyzed by standard Southern blotting. Genomic DNA was
digested with PvuII or BglI to confirm the 59, internal and 39 single
integration of the donor vector, respectively. The 59 and 39 probes
were PCR amplified from genomic DNA with the following
primers: 59 fwd: cgcctaaagaagaggctgtg and 59 rev: gactggagttgca-
gatcacg and 39 fwd: ggacaggacagtgcttgtttaagg and 39 rev:
acaccacaaatgaacagtgccaag. The 59 probe highlighted a 5.8 kb
wild-type and a 6.3 kb targeted bands. The 39 probe detected a
6.5 kb wild-type and a 6.2 kb targeted bands. The internal
neomycin probe was obtained by PCR from the control donor
vector using the following primers: Neo fwd: gaactcgtcaagaaggc-
gatagaag and Neo rev: gaacaagatggattgcacgcagg. It highlighted a
3.2 kb and a 2.4 kb bands in the control clone and FOG-1 clone,
respectively in addition to a 6.3 kb targeted band detected in both
clones.
Recombinase-mediated cassette exchange: FLP-
mediated recombination of the control and FOG-1 donor
vectors into the pre-targeted ES cells
The pre-targeted R26Hygro ES cells were thawed and cultured
for 2 days on feeders in ES cell culture medium without
hygromycin. 0.86106 cells in a 6 cm dish were then transfected
with a FLP-expressing vector together with the FOG-1 donor
vector (FRT3-loxP-Neo-STOP-loxP-FlagFOG-1-IRES-hCD2t-
FRTwt), or the control donor vector (FRT3-loxP-Neo-STOP-
loxP-IRES-hCD2t-FRTwt) using Effectene reagent according to
the manufacturer’s instructions. One day later, the medium was
replaced by ES cell medium containing 0.2 mg/ml geneticin. Ten
days later, 48 or 94 colonies were picked and single-cell
suspensions made by trypsin treatment. Each colony was then
plated in medium containing geneticin only or geneticin and
hygromycin (0.1 mg/ml). Five days later, colonies that were
geneticin resistant and hygromycin sensitive were picked and
seeded in 35 mm dishes for further expansion.
Clones of interest were checked by PCR for correct insertion
(see Figure S2A for a scheme of the strategy). The 59 insertion was
verified by primer pair 1 (1F: 59-aactcttcgcggtctttcc-39 and 1R: 39-
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tctggattcatcgactgtgg-59) and the 39 insertion by primer pair 2 (2F:
59-gccttcttgacgagttcttctgag-39 and 2R: 39-gaaggacggtacaccaga-
gaac-59). A primer pair 3 (3F: 59-aactcttcgcggtctttcc-39 and 3R:
39-gactttccacacctggttgc-59) and a primer pair 4 (4F: 59-
agagcttggcgtaatcatgg-39 and 4R: 39-cgtaagggattactcggtga-59) am-
plifying only products in the unrecombined allele were used as
Figure 1. FOG-1 is expressed in a regulated manner during B-cell development. (A) Gene expression level of FOG-1 determined by
Affymetrix microarray in wild-type or OBF-12/2 Abl Pro-B-cells [25]. (B) Reverse transcriptase (RT)-PCR analysis of FOG-1 mRNA level in wild-type or
OBF-12/2 Abl Pro-B-cells. GAPDH mRNA amount was used as a control. +, 2 refer to cDNA synthesis reactions performed in the presence or absence
of reverse transcriptase (RT), respectively. (C) mRNA expression level of FOG-1 in bone marrow B-cells (B220+) and in red blood cells (TER 119+)
determined by semi-quantitative RT-PCR. Actin mRNA amount was used as a reference. (D) mRNA expression level of FOG-1 during B-cell
development determined by semi-quantitative RT-PCR. The analysis was performed on primary Pro-B, large Pre-B, small Pre-B, immature-B and
splenic mature-B cells. Actin mRNA amount was used as a reference. (E) mRNA expression level of FOG-1 measured by real-time RT-PCR during the B-
cell development. The analysis was performed on primary B-cells as in (D). RNA Polymerase II mRNA was used as a reference. (F) mRNA expression
level of FOG-1 in B-cell lines representing different stages of B-cell development, determined by RT-PCR. From early to late stages, the analysis was
performed on the five following cell lines: wild-type Abelson (Abl+/+), B3, A20J, X63 and J558. GAPDH mRNA was used as a control.
doi:10.1371/journal.pone.0092836.g001
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negative controls. For checking the integration of the neomycin
cassette by PCR, the same primers than those used for the
synthesis of the internal neomycin probe and specified above were
used. The integration of the hCD2t sequence was checked by PCR
with the following primers: fwd: tctgaagaccgatgatcagg and rev:
tcattacctcacaggtcagg. The primer pair 29 (2F9: 59-aacagatggtccc-
cagatgc-39 and 2R9: 39-agtggctcattagggaatgc-59) was used for
genotyping the R26FOG-1 mice.
Cre-expression in the recombined ES cells
106 R26FOG-1 ES cells were electroporated with a Cre-
expressing vector (pCAGS-nlsCre-PGK-Puro, kindly provided by
D. Schu¨beler, Basel). Neomycin-selection was performed at a
concentration of 0.2 mg/ml geneticin for 48 hrs in absence of
feeders.
Mouse work
The mice were housed in groups of one to six animals at 25uC
with a 12-h light-dark cycle (12 h light, 12 h dark) and were fed a
standard laboratory diet containing 0.8% phosphorus and 1.1%
calcium (NAFAG 890; Kliba, Basel, Switzerland). Food and water
were provided ad libitum.
R26FOG-1 ES cells were used to generate chimeric mice which
were then crossed with C57BL/6J mice to generate transgenic
animals. The R26FOG-1 mice were subsequently crossed with
different Cre-expressing mouse lines to obtain overexpression of
FOG-1 in specific B cell subpopulations or throughout hematopoi-
etic lineages. In particular, they were crossed with Cd23-Cre [20],
Vav-iCre [21] or mb1-Cre mice [22] to obtain R26FOG-1:Cd23-
Cre, R26FOG-1:Vav-iCre or R26FOG-1:mb1-Cre mice, respectively.
Mice or targeted ES cells will be made available upon request.
Cell culture and RT-PCR analysis
Cells were cultured in a humidified tissue culture incubator set
up at 5% CO2 and 37uC. Abelson lines (OBF-1 wt or OBF-1
2/2),
B3, A20J, X63Ag8 and J558L cell lines were cultured in RPMI
1640 completed with 10% heat-inactivated FCS, 1% penicillin-
streptomycin and 4 mM L-glutamine. Total cellular RNA was
extracted using RNeasy Mini Kit (Qiagen), DNaseI treated and
reverse transcribed using oligo(dT) and SuperScript II RT
(Invitrogen) kit according to standard procedures. Subsequent
quantitative real-time PCRs were performed with the MESA
GREEN qPCR MasterMix Plus for SYBR (Eurogentec) on an
ABI prism 7000 instrument. The FOG-1 primers were 59-
ccaactgtgaacgccatctc-39 and 39-gatctcacccttggagcctg-59. The prim-
ers specific for transgene-derived FOG-1 (FlagFOG-1) were 59-
atggactacaaggacgacg-39 and 59-tccatggccttggcttcttc-39. The RNA
polymerase II (RPII) primers were 59-aggagcgccaaatgccgataa-39
and 59-aggagcgccaaatgccgataa-39. The GAPDH primers were 59-
TGCACCACCAACTGCTTAG-39 and 59-TGGAAGAGTGG-
GAGTTGCTG-39. The moue beta actin primers were: 59-
ctaaggccaaccgtgaaag-39 and 59-accagaggcatacagggaca-39.
Western blot analysis
Proteins were separated on a 7–8% SDS–PAGE, transferred to
a PROTRAN Nitrocellulose Transfer Membrane (Whatman) or
to an Immobilon-P Membrane PVDF (Millipore) and immuno-
blotted with the appropriate primary and secondary antibodies.
The following antibodies were used: anti-FOG-1 (Santa Cruz, sc-
9362), anti-b-tubulin (Sigma, T4026), anti-actin (NeoMarkers,
MS-1295-P1), anti-goat IgG, HRP (Abcam, ab7125), anti-mouse
IgG, HRP (GE Healthcare, NA931V), anti-goat 680 and anti-
mouse 680 (Molecular Probes). Signals were detected either with
Amersham HyperFilm ECL (GE Healthcare) or quantified using a
Figure 2. Strategy for the rapid generation of conditionally overexpressing ES cells. Schematic representation of the wild-type Rosa26
(R26) locus, the pre-targeted R26Hygro and the recombined R26 alleles. The Rosa26 locus was first pre-targeted by homologous recombination with a
cassette containing a splice acceptor and a hygromycin B resistance gene flanked by a FRT3 site in 59 and a FRTwt site in 39 to generate the pre-
targeted R26Hygro allele (step 1). The hygromycin B cassette is then replaced by the cassette of interest via the FRT sites using transient expression of
the FLP recombinase (step 2). Our cassette of interest contains a loxP-Neo-STOP-loxP cassette for neomycin selection of ES cells and conditional
expression of the transgene, and an IRES-hCD2t sequence to monitor expressing cells. Notably, Cre-mediated recombination will excise the neomycin
gene from the targeted allele in the transgenic mice. Neo: neomycin resistance gene. R26 pro: promoter of the R26 gene.
doi:10.1371/journal.pone.0092836.g002
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LI-COR Odissey instrument and the Odissey 2.1 software
(Biosciences).
Flow cytometry analysis
Cells were stained in PBS-3%FCS for 30 min on ice with the
following antibodies: anti-B220 (BD 553092), anti-CD25 (BD
553050), anti-IgM (Southern biotechnology 1140-02), anti-
TER119 (BD 557915), anti-CD71 (BD 553267), anti-CD4 (BD
553729), anti-CD8 (BD 553032), and anti-hCD2t (R&D FAB
18561P). For cell sorting, the following antibody combinations
were used: ProB cells, B220+, cKit+, CD252, IgM2; large or
small Pre B, B220+, cKit2, CD25+, IgM2; immature B, B220+,
IgMlow; splenic mature B, B220+, IgMhigh. Cells were analyzed on
a Becton Dickinson FACSCalibur or sorted on a Cytomation
MoFlo instrument
Mature B-cell activation
106 splenic mature B-cells purified using CD43-magnetic beads
(Miltenyi Biotec) were cultured for 4 days in the presence of IL4
(10 ng/ml) and/or LPS (5 mg/ml) and/or anti-CD40 antibody
(1 mg/ml; BD 553721).
Figure 3. Correct recombination at the pre-targeted R26Hygro allele by RMCE. A. Schematic representation of the wild-type R26, pre-
targeted R26Hygro and recombined R26FOG-1 alleles. In the FOG-1 cassette, the neomycin resistance gene (Neo, black) and the STOP sequence (red) are
flanked by LoxP sites (white triangles) to allow conditional expression. The cDNA encoding FlagFOG-1 (pink) followed by an IRES sequence and the
sequence coding for hCD2t (pale blue) were inserted downstream. A polyA signal was placed at the 39 end of the hCD2t coding sequence (blue oval).
The probes (green bars) used for Southern blot analysis are shown. B. Correct insertion of the vectors was confirmed by Southern blotting. To test the
59 boundary, PvuII-digested ES cell genomic DNA was hybridized with the radioactively labeled 59 probe to detect the wild-type (5.8 kb) and the
targeted (6.3 kb) bands (Left panel). To verify single-copy insertion, PvuII-digested DNA was hybridized with a radioactively labeled internal probe to
detect the 3.2 kb or 2.4 kb targeted bands in control or FOG-1 clones, respectively, in addition to the 6.3 kb targeted band (Middle panel). To test the
39 boundary, BglI-digested DNA was hybridized with the radioactively labeled 39 probe to detect the 6.5 kb wild-type and the 6.2 kb targeted bands
(Right panel).
doi:10.1371/journal.pone.0092836.g003
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ELISA assay
IgM or IgG1 antibody titers in the mature B-cell activation
cultures were determined by standard ELISA protocol.
Full blood analysis
Tail blood samples were collected in EDTA-coated tubes and
analyzed with a Sysmex XT-2000iV blood analyzer.
Statistical analysis
Where appropriate, standard error of the mean is presented.
Statistical significance (p value,0.05) was determined by per-
forming t-test analysis.
Results
Identification of FOG-1 expression in B cells
In previous studies from our laboratory microarray analysis had
been used to determine expression profiles of Pre-B-cells lacking
the transcriptional coactivator OBF-1 [23,24] and transgenic
thymocytes overexpressing OBF-1; these experiments identified
several genes that were downregulated in null cells [25] or
upregulated in overexpressing cells [25,26]. Among these genes,
we identified Zfpm1, which encodes the developmental regulator
FOG-1 (Fig. 1A, 1B and data not shown). Zfpm1 had also been
identified as a gene consistently activated or repressed in Ebf1
(early B-cell factor-1) gain- and loss-of-function experiments,
respectively and ChIP-Seq data demonstrated that Ebf1 binds to
the promoter of Zfpm1 within 10 kb of the transcription start site
[27].
In agreement with previous results [3], we detected a lower
expression level of FOG-1 in total bone marrow B-cells than in red
blood cells (Fig. 1C). Microarray and quantitative RT-PCR
analysis demonstrated that FOG-1 was expressed from Pro-B-cell
to immature B-cell stages at a relatively high level and was
downregulated in mature B-cells and plasma cells. This specific
expression pattern was observed in primary cells and also in
cultured cell lines representative of different B-cell developmental
stages (Fig. 1D, 1E and 1F).
Together these results show that FOG-1 is expressed in a
regulated manner during B cell development and suggest that this
factor may play a role not previously appreciated in this lineage.
To examine this in greater detail, we wished to test the effect of
overexpressing FOG-1 in B cells, in particular in late stages,
hypothesizing that this might affect their differentiation or
function. For this, we made use of a system that we had designed
to generate mice overexpressing a gene of interest in a conditional
manner.
Pre-targeting of the Rosa26 locus
Our strategy has been to generate ES cells pre-targeted at the
Rosa26 (R26) locus, so that appropriate expression constructs can
rapidly be inserted by recombination mediated cassette exchange
(RMCE, see Figure 2). We chose to use the Rosa26 locus, which
was first described in a gene trap experiment and was shown to be
expressed in the whole mouse [28]. This locus is believed to
encode two non-coding transcripts and an antisense transcript of
unknown function and can be used to drive the expression of any
cDNA [28]. In the original gene trap experiment, the insertion of a
splice acceptor and a promoter-less cDNA in intron 1 of the gene
led to expression of this cDNA from the endogenous Rosa26
promoter. For these reasons, we decided to target the Rosa26 locus
and we used 59 and 39 homology arms located in intron 1. The
targeting vector containing a splice acceptor sequence to allow
expression from the endogenous Rosa26 promoter and an
hygromycin B resistance gene flanked by FRT3 and FRTwt sites
was linearized and introduced by electroporation into 129svjae ES
cells to generate the pre-targeted R26Hygro allele (Figure 2, step 1
and Figure S1A). 480 hygromycin-resistant ES cell clones were
first screened by PCR using a forward primer located upstream of
the 59 homology arm and a reverse primer located in the
hygromycin cassette. Four clones (1–4, Figure S1B) showed the
expected 2 kb band for successful homologous recombination, as
compared to the aberrant product obtained for clone 5. To further
confirm the correct homologous recombination, we performed
Southern blot analysis using 59 and 39 probes with BamHI or PstI-
digested genomic DNA blots. Clones 1–4 showed the expected
4.9 kb band for correct integration of the selection cassette in 59
(Figure S1C), as well as the 7.5 kb band for correct integration at
the 39 end (Figure S1D). As a control, clone 5 only showed the
wild-type bands. To ensure that a single copy was integrated in the
genome, an additional Southern blot analysis was performed with
a hygromycin probe and PvuII-digested genomic DNA blots.
Clones 2–4 showed a single band at the expected size, whilst clone
1 showed an additional smaller band, suggesting multiple
insertions of the transgene (Figure S1E). Thus, our targeting
vector was successfully homologously recombined into the Rosa26
locus to generate the pre-targeted R26Hygro allele. Clone 4 was
selected as our R26Hygro ES cell clone for further use.
Efficient recombination of the FOG-1 cassette in the pre-
targeted R26Hygro locus
The combined use of the heterospecific FRT3/FRTwt sites
allows replacement of a target DNA by an incoming plasmid
donor cassette upon transient FLP expression [29]. Hence, any
cassette of interest flanked by FRT3/FRTwt sites can readily be
introduced into pre-targeted R26Hygro ES cells upon transient
Figure 4. Cre-dependent expression of hCD2t and FOG-1 in recombined ES cells. R26FOG-1 ES cells were electroporated with a Cre
expressing vector. Cre-induced expression of hCD2t and FOG-1 was detected by flow cytometry (A) and western blot analysis (B), respectively.
doi:10.1371/journal.pone.0092836.g004
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Figure 5. Overexpression of FOG-1 in mature B-cells. A. In R26FOG-1:Cd23-Cre mice, hCD2t expression is restricted to mature B-cells. Cell
surface expression of hCD2t was analyzed by flow cytometry in Pre-B-cells (B220+, CD25+) and in mature B-cells (B220+, IgMhigh) of control (R26FOG-1)
and R26FOG-1:Cd23-Cre mice. Representative results of at least 3 independent experiments are shown. B. FOG-1 mRNA is increased 3-fold in
R26FOG-1:Cd23-Cre mature B-cells. RNA extracted from 3 control (R26FOG-1) and 3 R26FOG-1:Cd23-Cre mice was reverse transcribed and subjected to
quantitative PCR to detect FOG-1 and RNA Polymerase II (RPII, for normalization) transcripts. Standard error of the mean is shown. C. FOG-1 protein is
up-regulated ca. 6-fold in mature B-cells derived from R26FOG-1:Cd23-Cre mice. FOG-1 and actin proteins were detected by western blotting in mature
B-cells derived from 3 control (R26FOG-1) and 3 R26FOG-1:Cd23-Cre mice (upper panel). The band intensities were quantified by LiCor Odyssey scanning
and normalized to expression of actin (lower panel). Standard error of the mean is shown. D. FOG-1-overexpressing mature B-cells respond normally
to in vitro stimulation. Splenic resting mature B-cells isolated from 3 to 6 control (R26FOG-1, black dots) or R26FOG-1:Cd23-Cre mice (grey dots) were
activated in vitro by LPS, LPS+IL4 or anti-CD40+IL4 for 4 days. Titers of IgM (left panel) or IgG1 (right panel) in the culture supernatants were
determined by ELISA; means are shown (red bar) as well as the corresponding p values at the bottom.
doi:10.1371/journal.pone.0092836.g005
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expression of the FLP recombinase (Figure 2, step 2). Inducible
expression cassettes contain a loxP-Neo-STOP-loxP sequence
upstream of the cDNA of interest to allow neomycin selection of
the recombined clones and Cre-dependent expression of the
transgene from the endogenous Rosa26 promoter. The cassettes
also contain an internal ribosome entry site (IRES) sequence
derived from the Encephalomyocarditis virus placed downstream
of the cDNA of interest to allow the concomitant expression of a
‘‘reporter’’ gene (here a truncated version of the human cell
surface marker CD2, hCD2t), and selective monitoring of the
recombined cells. In order to study the effect of enforced
expression of FOG-1 in transgenic mice, two donor vectors were
generated: (i) a control donor vector with loxP-Neo-STOP-loxP
and the IRES-hCD2t sequences, but no cDNA (Figure S2A), (ii)
the FOG-1 donor vector which contained a cDNA encoding Flag-
tagged FOG-1 downstream of the loxP-Neo-STOP-loxP sequence
and upstream of the IRES-hCD2t sequence (Figure 3A and Figure
S2A).
To test the efficiency of our system, RMCE experiments were
performed in R26Hygro ES cells: cells were transfected with either
the FOG-1 donor vector or the control donor vector, together with
an expression vector encoding the FLP recombinase. The
R26Hygro ES cells are resistant to hygromycin B and, upon
successful RMCE, become sensitive to this antibiotic, while
acquiring neomycin-resistance (see Figure 2). In two independent
RMCE experiments, a total of 142 NeoR colonies were picked for
each vector and were tested for hygromycin B resistance, as
described in the Materials and Methods section. We found that at
this step 48.5% of the FOG-1 colonies and 62.5% of the control
colonies were both neomycin-resistant and hygromycin-sensitive,
indicative of successful RMCE. We next selected 12 NeoR/HygroS
clones of each kind (control or FOG-1 vector) for an extensive
PCR analysis which demonstrated that all the clones analyzed
were properly recombined (Figure S2A–B). Successful integration
of the neomycine cassette and of the hCD2t cassette in the genome
of these ES cell clones was also tested and all clones were positive
for these PCRs as well (Figure S2C–D). Thus, using the system
described here, we efficiently recombined a large cassette of 5.0 kb
or 8.0 kb at the R26Hygro allele of the pre-targeted ES cells to
generate ES cell clones carrying the R26Control allele or R26FOG-1
Figure 6. hCD2t is expressed in all hematopoietic cells of R26FOG-1:Vav-iCre mice. A–F. Flow cytometry analysis of hCD2t expression in
R26FOG-1:Vav-iCre (red line) and control (R26FOG-1, blue line) mice. A. Bone marrow B-lymphocytes (B220+ cells). B. Bone marrow granular cells (based
on Forward and Side Scatters). C. Bone marrow erythrocytes (TER119+ cells). D. Thymocytes (CD4+, CD8+ cells). E. Splenic B-lymphocytes (B220+
cells). F. Splenic erythrocytes (TER119+ cells). Data for one representative animal of each genotype are shown (n= 5).
doi:10.1371/journal.pone.0092836.g006
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allele, respectively. Based on the extensive PCR analysis presented
here, 100% of the NeoR/HygroS clones appear to be correctly
recombined upon RMCE. We next chose one control clone and
one FOG-1 clone for verifying the successful RMCE by Southern
blot analysis and used genomic digests and probes allowing us to
interrogate the 59 and the 39 boundaries, as well as the copy
number. This analysis also confirmed the correct recombination of
the targeting vectors into the Rosa26 locus (Figure 3A–B).
Before generating mice, we tested the Cre-inducible expression
of FOG-1 and hCD2t in our recombined FOG-1 clone. To this
end, a Cre-expressing vector was transiently transfected in the
targeted ES cells and expression of hCD2t and FOG-1 was tested
two days later by flow cytometry and western blot analysis,
Figure 7. Normal B-cell, T-cell and granular cell populations in R26FOG-1:Vav-iCre mice. A. Cells of the bone marrow (BM), spleen (Spl)
and thymus (Thy) of R26FOG-1 (black bars) and R26FOG-1:Vav-iCre (grey bars) mice were enumerated. Standard error of the mean is shown. B. Bone
marrow cells were stained with anti-B220 and anti-IgM antibodies to analyze B-cell development. C. Splenocytes were stained with anti-B220 and
anti-IgM antibodies to identify B-cells. D. Thymocytes were stained with anti-CD4 and anti-CD8 antibodies to analyze T-cell development. E.
Splenocytes were stained with anti-CD4 and anti-CD8 antibodies to identify mature T-cells. F. Bone marrow cells were stained with anti-TER119 and
anti-CD71 antibodies to analyze erythropoiesis. G. Bone marrow cells were stained with anti-Gr1 and anti-CD11b antibodies to identify Gr1+ CD11b+
myeloid cells. H. Splenocytes were stained with anti-TER119 and anti-CD71 antibodies to analyze splenic erythropoiesis. Cells were analyzed by flow
cytometry in R26FOG-1 (control) and R26FOG-1:Vav-iCre animals; data for one representative animal are shown (n= 5 for each genotype). Percentages of
the populations are shown next to the gates. A diagram representing the developmental pathway of the different lineages from pale (progenitors) to
dark grey (differentiated cells) is shown next to the pseudo-dotplots B, D, F and H.
doi:10.1371/journal.pone.0092836.g007
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respectively. As expected, the recombined R26FOG-1 ES cells
expressed hCD2t and FOG-1 only when Cre was expressed
(Figure 4A and 4B). The partial expression of hCD2t observed by
flow cytometry is due to the experimental settings: here,
transfected ES cells were only selected for a short period of time
to avoid FOG-1-induced cell cycle arrest in ES cells [30]. As a
result of this, not all ES cells were expressing Cre, leading to a
heterogeneous cell population.
In conclusion, we efficiently recombined our FOG-1 donor
vector in the pre-targeted R26Hygro locus to generate R26FOG-1 ES
cells and demonstrated that, upon Cre expression, both FOG-1
and hCD2t were expressed in these ES cells. We therefore used the
R26FOG-1 ES cell clone to generate transgenic R26FOG-1 mice.
Enforced expression of FOG-1 does not affect B-cell
differentiation or function
To investigate the potential effect of sustained level of FOG-1 in
mature B-cells, we first crossed the R26FOG-1 mice with Cd23-Cre
mice which express Cre specifically in mature B-cells [20]. Flow
cytometry analysis of hCD2t expression in B-cells derived from
R26FOG-1:Cd23-Cre mice showed that in the early developmental
stages (Pre-B-cells), no hCD2t could be detected, as expected
(Figure 5A, second panel). In contrast, more than 85% of the
mature B-cells derived from these animals were found to express
hCD2t (Figure 5A, fourth panel). Importantly, the expression of
hCD2t was never detected in control animals which carry the
R26FOG-1 allele but do not express Cre. Next, quantitative RT-
PCR and western blot analysis were performed to estimate the
level of FOG-1 overexpression in mature B-cells derived from
R26FOG-1:Cd23-Cre animals and compared to that of R26FOG-1
animals. As shown in Figure 5B, FOG-1 mRNA was upregulated
slightly more than three fold in the overexpressing cells, as
compared to the control cells. At the protein level, the increase was
even larger: careful quantification of the FOG-1 signal in relation
to the expression of actin showed that the protein was upregulated
about 6-fold (Figure 5C). Overall this analysis demonstrated that
our system allows reliable overexpression of FOG-1 in vivo.
To investigate the potential biological effect of this elevated level
of FOG-1 on plasma cell development, mature B-cells derived
from R26FOG-1:Cd23-Cre mice were activated in vitro with
different stimuli and the antibody titers in the culture supernatants
were determined by ELISA. Irrespective of the stimulus used, no
difference in the level of IgM or IgG1 was observed between
overexpressing and control cultures, indicating that enforced
expression of FOG-1 in mature B-cells did not impair or alter their
ability to differentiate into antibody-secreting cells in vitro
(Figure 5D). In addition, we also performed immunization
experiments to test whether FOG-1 overexpression in mature B
cells might have an impact on the immune response in vivo. For
this, R26FOG-1:Cd23-Cre and control mice were immunized with
DNP-KLH and the serum titers of antigen-specific immunoglob-
ulins were measured by ELISA 8 and 15 days later. However, also
in this case no significant difference was found (data not shown).
Thus, although the expression of FOG-1 is normally downregu-
lated during B cell development, enforcing expression of this factor
at late B cell stages did not reveal any detrimental effect, contrary
to our hypothesis. Finally, R26FOG-1 mice were also crossed with
mb1-Cre mice, to induce FOG-1 overexpression from the earliest
stages of B cell development onwards. However, this did not
impact B cell development as examined by flow cytometric
analysis (data not shown).
Reduction of eosinophil numbers upon enforced
expression of FOG-1
To further analyze the consequences of an elevated level of FOG-
1 in the hematopoietic system, we next crossed the R26FOG-1 mice
with Vav-iCre mice [21] to overexpress FOG-1 in all hematopoietic
lineages. Remarkably, all B-lymphocytes, myeloid cells, and
erythrocytes derived from the bone marrow of R26FOG-1:Vav-iCre
animals expressed hCD2t (Figure 6A, 6B and 6C). Similarly, all
thymocytes and splenic B-lymphocytes as well as all splenic
erythrocytes expressed hCD2t (Figure 6D, 6E and 6F), thus
demonstrating the usefulness of our reporter system. Expression of
transgene-derived FOG-1 mRNA was analyzed by quantitative
RT-PCR and showed that FlagFOG-1 mRNA is produced at a
similar level in bone marrow, spleen, and thymus of R26FOG-1:Vav-
iCre mice (Figure S3). Altogether these data indicated that in
R26FOG-1:Vav-iCre animals virtually all hematopoietic cells express
the transgene at a roughly similar level.
The total numbers of bone marrow cells, splenocytes, and
thymocytes in overexpressing mice were comparable to the
numbers obtained in control animals (Figure 7A). Using a panel
of antibodies against lineage-specific surface markers we analyzed
by flow cytometry the major hematopoietic cell populations.
R26FOG-1:Vav-iCre mice showed normal B-cell development
(Figure 7B and 7C), normal T-cell development (Figure 7D and
7E), as well as a normal myeloid population (Figure 7G).
Developing erythrocytes can be subdivided into early and late
erythroblasts based on the expression of the cell surface markers
TER119 and CD71 [31]. Using this method, we found a largely
normal erythroid development, although a slight but significant
increase of the early erythroblast population (CD71+ TER119+)
was seen in the spleen of some (#50%) of the R26FOG-1:Vav-iCre
animals (exemplified in Figure 7H). However, no difference was
observed in the bone marrow (Figure 7F). More detailed analysis
will be required to understand this phenotype. Statistical analysis
of the flow cytometry data showed that, except for the increase in
the early splenic erythroblast population (Figure 7H), expression of
FOG1 did not have any significant impact on the cell populations
examined (see Figure S4). Full blood count analysis of R26FOG-
1:Vav-iCre females and males revealed no major difference in red
blood cell count, hemoglobin content, hematocrit and platelet
counts (Table 1). Similarly, no significant changes were observed
in the total numbers of white blood cells, lymphocytes, monocytes,
neutrophils and basophils in the blood of these mice (Table 1). In
contrast, a consistent decrease in the total number of circulating
eosinophils was observed for R26FOG-1:Vav-iCre females and
males (Table 1). A highly reproducible and significant difference of
more than 3-fold was found when comparing the average numbers
of circulating eosinophils in control and R26FOG-1:Vav-iCre
animals (Figure 8, p= 0.00758). To ascertain that the phenotypes
observed were not due to Cre expression, which can have effects
on its own in some cases [32], we also performed a flow cytometric
and full blood count analysis of Vav-iCre mice in comparison with
control animals lacking the Cre transgene (C57BL/6J). As can be
seen in Figure S5, the flow cytometry profile of the different
populations analyzed showed no difference between mice carrying
the Vav-iCre transgene and control mice. Statistical analysis of the
flow cytometry data demonstrated that there was indeed no
significant difference between these mice (Figure S6). Further-
more, full blood count analysis also failed to show any statistically
significant difference (Table S1). Finally, FOG1 mRNA expression
in mature B cells was identical in C57BL/6J and Vav-iCre mice
(Figure S7). Thus, the phenotypes described for the FOG1
overexpressing mice are not due to an artefact of cre expression,
but are indeed FOG1-dependent.
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Discussion
We have shown here that FOG-1 expression is regulated during
B cell development, being high in early stages (e.g. pre-B cells) and
low or absent in late stages such as mature B cells and plasma cells.
Based on these observations, we hypothesized that this downreg-
ulation is important for effective B cell development and that
artificially maintaining FOG-1 expression at late stages might have
an impact on normal B cell development or function. However, we
did not observe any major phenotypes when FOG-1 was
selectively overexpressed in mature B-cells. Flow cytometric
analysis of the major B cell populations failed to reveal alterations
in R26FOG-1:Cd23-Cre mice, demonstrating no obvious develop-
mental impact. Furthermore, in vivo immune response to a T cell-
dependent antigen or antibody secretion following in vitro
stimulation were also not affected, thus suggesting that B cell
function was not impaired. In addition, mice overexpressing FOG-
1 from the pre-B cell stage onwards also did not show any
remarkable phenotype. Nevertheless, it remains possible that
FOG-1 affects a B cell subset that was not examined here and
additional experiments will be required to determine this.
Furthermore, since B cells do not express GATA factors (our
unpublished data), other B cell ancillary factors must be postulated
for a role for FOG-1 in these and potentially other cells (Versavel
et al., in preparation).
In contrast, R26FOG-1:Vav-iCre mice with enforced expression
of FOG-1 in the entire hematopoietic system showed two main
phenotypes. First, consistent with the known role of FOG-1 in red
blood cell development [4,6,33,34], we observed a moderately
altered erythropoiesis in the spleen of some (#50%) R26FOG-
1:Vav-iCre animals. The reason for the partial penetrance of this
phenotype is unclear and additional work will be required.
Second, we found a striking and highly significant reduction of the
total number of circulating eosinophils. This is of great interest,
since a previous study concluded that FOG-1 is a repressor of the
eosinophil lineage in avian cells [12]. Our results, therefore, extend
this finding to mammals. In the future, the R26FOG-1:Vav-iCre
mice will be analyzed further to draw a more complete view of
FOG-1 functions in hematopoiesis.
The Recombinase-Mediated Cassette Exchange technology
relies on the exquisite selectivity of recombinases such as cre or
flp and has been developed to facilitate the generation of
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Figure 8. Altered eosinophil numbers in R26FOG-1:Vav-iCre
mice. Reduction of circulating eosinophils. The numbers of eosinophils
obtained in full blood count analysis of 8 control (R26FOG-1) and 8
R26FOG-1:Vav-iCre including those presented in Table 1 mice were
averaged. Standard error of the mean is shown.
doi:10.1371/journal.pone.0092836.g008
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transgenic ES cell lines [29,35] [35–41] [15,16]. To allow
inducible or lineage-specific expression, the RMCE technology
has been combined with tetracycline-inducible systems [42–44], or
with the Cre recombinase activity [45,46]. Recent studies made
use of a pre-targeted locus to generate shRNA-expressing mice
[47,48] and Hitz et al. combined the C31 integrase-mediated
recombination at a pre-targeted locus with Cre-dependent
expression to establish shRNA-expressing mice [49]. Other
systems that allow RMCE into pre-modified ES cells [50,51] or
in human ES cells pre-targeted at the HPRT locus [52] have also
been developed.
To alter the expression pattern of FOG-1 in vivo, we developed a
novel and rapid transgenic system that is also based on the RMCE
technology and that allows rapid insertion of expression cassettes
into the Rosa 26 locus. In this system, expression of the transgene
from the endogenous Rosa26 promoter is dependent on Cre
recombinase-mediated excision of a STOP sequence, allowing
cell- or temporal-specific control of expression. A hCD2t cDNA is
also included as a reporter to track transgene-expressing cells in
vitro and in vivo.
Our strategy is broadly similar to the one described by Hitz and
colleagues, where C31 integrase-mediated recombination is used
instead of FLP-mediated recombination to insert a transgene at a
modified Rosa26 locus and where the loxP/Cre system is used for
conditional expression of shRNAs [49]; the RMCE efficiency of
the two systems is also comparable. A particularly useful feature of
our system is the concomitant expression of a ‘‘marker’’ gene,
hCD2t, together with our transgene (i.e. FOG-1); this allows to
monitor Cre-recombined cells ex vivo or in vivo. This is especially
useful in situations where Cre expression, and therefore transgene
expression, is only partial or mosaic and leads to a mixture of
recombined and non-recombined cells; having a marker gene such
as hCD2t then allows to selectively examine –and potentially
isolate- the transgene-expressing cells. Expression of hCD2t can
conveniently be detected by flow cytometry and is therefore
particularly well suited for analyses in the hematopoietic system.
Furthermore, since the antibodies recognizing hCD2t are species-
specific, expression of the endogenous mouse protein (e.g. by T
cells) does not interfere. Finally, hCD2t can also be detected by
immunohistochemistry, further extending the range of cells that
can be selectively examined.
Using this system we generated mice with moderate overexpres-
sion of FOG-1 either in mature B cells (R26FOG-1:Cd23-Cre mice),
throughout B cell development (R26FOG-1:mb1-Cre), or in all
hematopoietic lineages (R26FOG-1:Vav-iCre mice). Remarkably,
flow cytometry analysis of bone marrows and spleens derived from
R26FOG-1:Vav-iCre mice revealed that all hematopoietic cells
expressed hCD2t. In contrast and as expected, in R26FOG-1:Cd23-
Cre mice, where Cre starts being expressed just before the mature
B-cell stage, hCD2t was only detected in mature B-cells. Impor-
tantly, cells derived from control R26FOG-1 mice lacking Cre
expression did not express any hCD2t. These results demonstrate
that conditional expression of a transgene using our system is tightly
regulated and underscore the utility of having a marker gene.
We found that the Rosa26 promoter drives moderate FOG-1
expression in the hematopoietic system. Interestingly, this expres-
sion level was sufficient to marginally alter splenic erythropoiesis
and to significantly reduce the number of circulating eosinophils in
R26FOG-1:Vav-iCre mice, demonstrating its physiological rele-
vance. Such moderate expression level is an advantage to unravel
the roles of proteins in physiologic and pathologic situations, as it
avoids aberrant phenotypes that may be partly caused by too
strong overexpression. Since targeted Rosa26 homozygous mice
are viable and appear normal, the expression level of the transgene
could be doubled by generating R26FOG-1/R26FOG-1 homozygous
mice [18] or by inserting additional regulatory elements in the
expression cassette. Following this idea, Tchorz et al. generated a
modified RMCE-compatible Rosa26 locus for the expression of
transgenes and characterized several promoters with different
strengths [17].
In conclusion, despite our finding that the expression of FOG-1
is tightly regulated throughout B-cell differentiation and is
dependent on the B-cell specific coactivator OBF1, we could not
demonstrate a role for FOG-1 in B-cell differentiation or function.
However, we could confirm the finding that FOG-1 is a negative
regulator of eosinophil development and extend it to mammals.
Further work will be required to better understand this important
function of FOG-1 in the mouse.
Supporting Information
Figure S1 Pre-targeting of ES cells with the pR26-SA-FRT-
HygroR vector. A. Schematic representation of the wild-type and
pre-targeted R26Hygro alleles. The splice acceptor (yellow dot) and
the hygromycin B resistance cassette (Hygro, orange) flanked by
FRT sites were inserted using the homology arms (thick grey)
between exons 1 and 2 (blue). The PCR primers (0F, 0R; arrows)
as well as the restriction sites and probes (green bars) used for
Southern blotting are shown. For clarity, only the relevant PstI
sites are shown. B. PCR screening of the putative R26Hygro ES cell
clones. Clones 1–4 are positive, clone 5 shows an aberrant
product. C–E. Correct insertion of the transgene confirmed by
Southern blotting. Clone 5 was included as a negative control. To
test the 59 insertion, BamHI-digested ES cell genomic DNA was
hybridized with the radioactively labeled 59 probe to detect the
wild-type (WT, 5.8 kb) and the targeted (Targ, 4.9 kb) bands (C).
To test the 39 insertion, PstI-digested DNA was hybridized with
the radioactively labeled 39 probe to detect the 6.5 kb WT and the
7.5 kb targeted bands (D). To verify single-copy insertion, PvuII-
digested DNA was hybridized with a radioactively labeled internal
probe to detect the 8 kb targeted band (arrow). Note that clone 1
shows an aberrant extra band, indicating multiple insertions in this
clone (E).
(EPS)
Figure S2 Efficiency of RMCE at the pre-targeted R26Hygro
allele. A. Schematic representation of the different alleles, from top
to bottom: wild-type R26 locus, R26Hygro, R26Control and
R26FOG-1. The different primer pairs used for PCR analysis of
the ES clones are depicted by arrows. B. PCR analysis of NeoR/
HygroS ES cell clones for testing RMCE recombination at the 59
(FRT3) and at the 39 (FRTwt) sites. Lanes 1–12: control clones,
cells derived from RMCE with the control donor vector; lanes 19–
129: FOG-1 clones, cells derived from RMCE with the FOG-1
donor vector; + Ctl, positive control. From top to bottom: PCR
screening with primer pairs 1F/1R and 3F/3R at the 59 end
junction of the recombined cassette. PCR screening with primer
pairs 2F/2R and 4F/4R at the 39 end junction of the recombined
cassette. Appropriate positive controls were chosen for each PCR
set up. Note that on the presented gel control clone 9 shows a faint
band with primer pair 3F/3R. Upon reanalysis of the DNA it was
however found to be positive only with primers 1F/1R, as would
be expected from a correctly recombined clone. C. PCR analysis
of NeoR/HygroS ES cell clones for presence of the Neomycin
resistance gene; -Ctl, negative control. D. PCR analysis of NeoR/
HygroS ES cell clones for presence of the human CD2t gene.
Lanes labeling as in (B) above. As shown, all clones analyzed are
positive for both the Neomycin and the hCD2t gene.
(EPS)
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Figure S3 Expression of transgene-derived FOG-1 in R26FOG-
1:Vav-iCre animals. Total RNA from bone marrow (BM), spleen
(Spl), and thymus (Thy) of 3 R26FOG-1:Vav-iCre animals was
extracted, reverse transcribed and subjected to quantitative PCR
to specifically detect transgene-derived FlagFOG-1 mRNA.
Values are relative to RNA Polymerase II (RPII) expression.
Standard error of the mean is shown. FlagFOG-1/RPII relative
expression in bone marrow was arbitrarily set to 1.
(EPS)
Figure S4 Statistical analysis of the flow cytometry data.The
flow cytometric data of R26FOG-1 (blue bars) and R26FOG-1:Vav-
iCre (red bars) animals (including the mice presented in Figure 7)
were used for statistical analysis applying Student’s two-tailed t-
test. A. Bone marrow B-cells. B. Bone marrow myeloid cells. C.
Bone marrow erythroid cells. D. Splenic B-cells. E. Splenic mature
T-cells. F. Splenic erythropoiesis. G. Thymocytes.
(EPS)
Figure S5 Normal B-cell and granular cell populations in Vav-
iCre mice. A. Cells of the bone marrow (BM), spleen (Spl) and
thymus (Thy) of control (C57BL/6J, blue bars) and Vav-iCre (red
bars) mice were enumerated. Standard error of the mean is shown.
B. Bone marrow cells were stained with anti-B220 and anti-IgM
antibodies to analyze B-cell development. C. Splenocytes were
stained with anti-B220 and anti-IgM antibodies to identify B-cells.
D. Bone marrow cells were stained with anti-TER119 and anti-
CD71 antibodies to analyze erythropoiesis. E. Bone marrow cells
were stained with anti-Gr1 and anti-CD11b antibodies to identify
Gr1+ CD11b+ myeloid cells. F. Splenocytes were stained with
anti-TER119 and anti-CD71 antibodies to analyze splenic
erythropoiesis. Cells were analyzed by flow cytometry; data for
one representative animal are shown (n= 4 for each genotype).
Percentages of the populations are shown next to the gates. The
statistical analysis (two-tailed Student’s t-test) of the data is
presented.
(EPS)
Figure S6 Statistical analysis of the flow cytometry data in Vav-
iCre mice. The flow cytometric data presented in Figure S5 of
control (C57BL/6, blue bars) and Vav-iCre animals (red bars)
were used for statistical analysis applying Student’s two-tailed t-
test. A. Bone marrow B-cells. B. Bone marrow erythroid cells. C.
Bone marrow myeloid cells. D. Splenic B-cells. E. Splenic
erythropoiesis.
(EPS)
Figure S7 Unchanged FOG1 expression in Vav-iCre mice.
RNA from mature B cells from C57BL/6J (WT) or Vav-iCre mice
(n = 4 per genotype) was used to measure FOG1 mRNA
expression by RT-qPCR. Statistical analysis was done using
Student’s two-tailed t-test.
(EPS)
Table S1 Blood samples from 4 control (C57BL/6J) and 4 Vav-
iCre mice were examined with a mouse blood analyzer. Individual
values are shown, as well as the corresponding averages (in red)
and the p values of the comparison between the 4 control and 4
Cre expressing mice. Note the absence of significant variation.
RBC: red blood cells; HGB: hemoglobin; HCT: hematocrit; PLT:
platelets; WBC: white blood cells; LYMPH: lymphocytes;
MONO: monocytes; NEUT: neutrophils; BASO: basophils; EO:
eosinophils.
(DOCX)
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Abstract	
We showed previously that B cell development strictly requires the presence of either HDAC1 or 
2, as ablation of both proteins leads to a strong developmental block at the pre-BII cell stage.  
Using microarrays, we identified novel putative HDAC target genes in the remaining early pre-
BI cells. In particular, two interesting target genes have been analyzed: Flt3 (fms-like tyrosine 
kinase 3), which is critical for early hematopoetic differentiation and Ptprf (protein tyrosine 
phosphatase, receptor type, F), which encodes a T cell lineage-specific phosphatase. Both genes 
are strongly expressed in HDAC double-deficient cells, and the failure to down-regulate these 
genes in multipotent progenitors has been reported to impair B cell development. We found that 
in committed B cells, the transcription factor Pax5, in addition to recruiting the Groucho family 
member Grg4, also co-recruits HDAC1 and 2, thereby leading to hypoacetylation and repression 
of the Flt3 and Ptprf promoters. Thus, HDAC1 and 2 play a critical role in B cell differentiation 
by promoting cell cycle progression at the pre-BII stage and by repressing important 
developmental regulators antagonistic of the B cell lineage at the pre-BI stage. 
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